[
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "BCR-ABL1 Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000318560", 
                    "curatedRefSeq": "NM_005157.4", 
                    "entrezGeneId": 25, 
                    "geneAliases": [
                        "v-abl", 
                        "bcr/abl", 
                        "JTK7", 
                        "c-ABL1", 
                        "c-ABL", 
                        "ABL", 
                        "p150"
                    ], 
                    "hugoSymbol": "ABL1", 
                    "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "BCR-ABL1 Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Druker BJ et al", 
                "elocationId": "", 
                "issue": "14", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1031-7", 
                "pmid": "11287972", 
                "pubDate": "2001 Apr 5", 
                "reference": "Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1031-7.", 
                "title": "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.", 
                "volume": "344"
            }, 
            {
                "abstract": null, 
                "authors": "O'Brien SG et al", 
                "elocationId": "", 
                "issue": "11", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "994-1004", 
                "pmid": "12637609", 
                "pubDate": "2003 Mar 13", 
                "reference": "O'Brien SG et al. The New England journal of medicine. 2003 Mar 13;348(11)994-1004.", 
                "title": "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.", 
                "volume": "348"
            }, 
            {
                "abstract": null, 
                "authors": "Druker BJ et al", 
                "elocationId": "", 
                "issue": "14", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1038-42", 
                "pmid": "11287973", 
                "pubDate": "2001 Apr 5", 
                "reference": "Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1038-42.", 
                "title": "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.", 
                "volume": "344"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000318560", 
            "curatedRefSeq": "NM_005157.4", 
            "entrezGeneId": 25, 
            "geneAliases": [
                "v-abl", 
                "bcr/abl", 
                "JTK7", 
                "c-ABL1", 
                "c-ABL", 
                "ABL", 
                "p150"
            ], 
            "hugoSymbol": "ABL1", 
            "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8420, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1490392211000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [
                "C3172"
            ], 
            "UMLS": [
                "C0023470"
            ], 
            "children": null, 
            "code": "CML", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Chronic Myelogenous Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "CML", 
        "treatments": [
            {
                "approvedIndications": [
                    "1) Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase. 2) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. 3) Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "BCR-ABL1 Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000318560", 
                    "curatedRefSeq": "NM_005157.4", 
                    "entrezGeneId": 25, 
                    "geneAliases": [
                        "v-abl", 
                        "bcr/abl", 
                        "JTK7", 
                        "c-ABL1", 
                        "c-ABL", 
                        "ABL", 
                        "p150"
                    ], 
                    "hugoSymbol": "ABL1", 
                    "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "BCR-ABL1 Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Hochhaus A et al", 
                "elocationId": "doi: 10.1182/blood-2012-04-423418", 
                "issue": "18", 
                "journal": "Blood", 
                "link": null, 
                "pages": "3703-8", 
                "pmid": "23502220", 
                "pubDate": "2013 May 2", 
                "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.", 
                "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.", 
                "volume": "121"
            }, 
            {
                "abstract": null, 
                "authors": "Saglio G et al", 
                "elocationId": "doi: 10.1056/NEJMoa0912614", 
                "issue": "24", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2251-9", 
                "pmid": "20525993", 
                "pubDate": "2010 Jun 17", 
                "reference": "Saglio G et al. The New England journal of medicine. 2010 Jun 17;362(24)2251-9.", 
                "title": "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.", 
                "volume": "362"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000318560", 
            "curatedRefSeq": "NM_005157.4", 
            "entrezGeneId": 25, 
            "geneAliases": [
                "v-abl", 
                "bcr/abl", 
                "JTK7", 
                "c-ABL1", 
                "c-ABL", 
                "ABL", 
                "p150"
            ], 
            "hugoSymbol": "ABL1", 
            "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8421, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1491851200000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [
                "C3172"
            ], 
            "UMLS": [
                "C0023470"
            ], 
            "children": null, 
            "code": "CML", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Chronic Myelogenous Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "CML", 
        "treatments": [
            {
                "approvedIndications": [
                    " 2)For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP-CML)", 
                    "1) For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy, including imatinib"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Nilotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "BCR-ABL1 Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000318560", 
                    "curatedRefSeq": "NM_005157.4", 
                    "entrezGeneId": 25, 
                    "geneAliases": [
                        "v-abl", 
                        "bcr/abl", 
                        "JTK7", 
                        "c-ABL1", 
                        "c-ABL", 
                        "ABL", 
                        "p150"
                    ], 
                    "hugoSymbol": "ABL1", 
                    "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "BCR-ABL1 Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kantarjian H et al", 
                "elocationId": "doi: 10.1056/NEJMoa1002315", 
                "issue": "24", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2260-70", 
                "pmid": "20525995", 
                "pubDate": "2010 Jun 17", 
                "reference": "Kantarjian H et al. The New England journal of medicine. 2010 Jun 17;362(24)2260-70.", 
                "title": "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.", 
                "volume": "362"
            }, 
            {
                "abstract": null, 
                "authors": "Kantarjian HM et al", 
                "elocationId": "doi: 10.1182/blood-2011-08-376087", 
                "issue": "5", 
                "journal": "Blood", 
                "link": null, 
                "pages": "1123-9", 
                "pmid": "22160483", 
                "pubDate": "2012 Feb 2", 
                "reference": "Kantarjian HM et al. Blood. 2012 Feb 2;119(5)1123-9.", 
                "title": "Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).", 
                "volume": "119"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000318560", 
            "curatedRefSeq": "NM_005157.4", 
            "entrezGeneId": 25, 
            "geneAliases": [
                "v-abl", 
                "bcr/abl", 
                "JTK7", 
                "c-ABL1", 
                "c-ABL", 
                "ABL", 
                "p150"
            ], 
            "hugoSymbol": "ABL1", 
            "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8422, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1506001040000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [
                "C3172"
            ], 
            "UMLS": [
                "C0023470"
            ], 
            "children": null, 
            "code": "CML", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Chronic Myelogenous Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "CML", 
        "treatments": [
            {
                "approvedIndications": [
                    "For the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in chronic phase (CP-CML)."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Dasatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000257290", 
                    "curatedRefSeq": "NM_006206.4", 
                    "entrezGeneId": 5156, 
                    "geneAliases": [
                        "PDGFR2", 
                        "RHEPDGFRA", 
                        "GAS9", 
                        "PDGFR-2", 
                        "CD140A"
                    ], 
                    "hugoSymbol": "PDGFRA", 
                    "name": "platelet derived growth factor receptor alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Curtis CE et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "British journal of haematology", 
                "link": null, 
                "pages": "77-81", 
                "pmid": "17555450", 
                "pubDate": "2007 Jul", 
                "reference": "Curtis CE et al. British journal of haematology. 2007 Jul;138(1)77-81.", 
                "title": "Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.", 
                "volume": "138"
            }, 
            {
                "abstract": null, 
                "authors": "Safley AM et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Genes, chromosomes &amp; cancer", 
                "link": null, 
                "pages": "44-50", 
                "pmid": "15034867", 
                "pubDate": "2004 May", 
                "reference": "Safley AM et al. Genes, chromosomes &amp; cancer. 2004 May;40(1)44-50.", 
                "title": "Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.", 
                "volume": "40"
            }, 
            {
                "abstract": null, 
                "authors": "Klion AD et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Blood", 
                "link": null, 
                "pages": "473-8", 
                "pmid": "14504092", 
                "pubDate": "2004 Jan 15", 
                "reference": "Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.", 
                "title": "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Cools J et al", 
                "elocationId": "", 
                "issue": "13", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1201-14", 
                "pmid": "12660384", 
                "pubDate": "2003 Mar 27", 
                "reference": "Cools J et al. The New England journal of medicine. 2003 Mar 27;348(13)1201-14.", 
                "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.", 
                "volume": "348"
            }, 
            {
                "abstract": null, 
                "authors": "Walz C et al", 
                "elocationId": "", 
                "issue": "10", 
                "journal": "Genes, chromosomes &amp; cancer", 
                "link": null, 
                "pages": "950-6", 
                "pmid": "16845659", 
                "pubDate": "2006 Oct", 
                "reference": "Walz C et al. Genes, chromosomes &amp; cancer. 2006 Oct;45(10)950-6.", 
                "title": "Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.", 
                "volume": "45"
            }, 
            {
                "abstract": null, 
                "authors": "Trempat P et al", 
                "elocationId": "", 
                "issue": "36", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "5702-6", 
                "pmid": "12944919", 
                "pubDate": "2003 Aug 28", 
                "reference": "Trempat P et al. Oncogene. 2003 Aug 28;22(36)5702-6.", 
                "title": "Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec.", 
                "volume": "22"
            }, 
            {
                "abstract": null, 
                "authors": "Score J et al", 
                "elocationId": "", 
                "issue": "5", 
                "journal": "Leukemia", 
                "link": null, 
                "pages": "827-32", 
                "pmid": "16498388", 
                "pubDate": "2006 May", 
                "reference": "Score J et al. Leukemia. 2006 May;20(5)827-32.", 
                "title": "Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.", 
                "volume": "20"
            }
        ], 
        "cancerType": "Myelodysplasia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000257290", 
            "curatedRefSeq": "NM_006206.4", 
            "entrezGeneId": 5156, 
            "geneAliases": [
                "PDGFR2", 
                "RHEPDGFRA", 
                "GAS9", 
                "PDGFR-2", 
                "CD140A"
            ], 
            "hugoSymbol": "PDGFRA", 
            "name": "platelet derived growth factor receptor alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 15334, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493063804000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Myelodysplasia"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "BCR-ABL1 Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000318560", 
                    "curatedRefSeq": "NM_005157.4", 
                    "entrezGeneId": 25, 
                    "geneAliases": [
                        "v-abl", 
                        "bcr/abl", 
                        "JTK7", 
                        "c-ABL1", 
                        "c-ABL", 
                        "ABL", 
                        "p150"
                    ], 
                    "hugoSymbol": "ABL1", 
                    "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "BCR-ABL1 Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Druker BJ et al", 
                "elocationId": "", 
                "issue": "14", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1038-42", 
                "pmid": "11287973", 
                "pubDate": "2001 Apr 5", 
                "reference": "Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1038-42.", 
                "title": "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.", 
                "volume": "344"
            }, 
            {
                "abstract": null, 
                "authors": "Ottmann OG et al", 
                "elocationId": "", 
                "issue": "6", 
                "journal": "Blood", 
                "link": null, 
                "pages": "1965-71", 
                "pmid": "12200353", 
                "pubDate": "2002 Sep 15", 
                "reference": "Ottmann OG et al. Blood. 2002 Sep 15;100(6)1965-71.", 
                "title": "A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.", 
                "volume": "100"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000318560", 
            "curatedRefSeq": "NM_005157.4", 
            "entrezGeneId": 25, 
            "geneAliases": [
                "v-abl", 
                "bcr/abl", 
                "JTK7", 
                "c-ABL1", 
                "c-ABL", 
                "ABL", 
                "p150"
            ], 
            "hugoSymbol": "ABL1", 
            "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8424, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1491851200000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [
                "C3167"
            ], 
            "UMLS": [
                "C0023449"
            ], 
            "children": null, 
            "code": "ALL", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Acute Lymphoid Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "ALL", 
        "treatments": [
            {
                "approvedIndications": [
                    "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000257290", 
                    "curatedRefSeq": "NM_006206.4", 
                    "entrezGeneId": 5156, 
                    "geneAliases": [
                        "PDGFR2", 
                        "RHEPDGFRA", 
                        "GAS9", 
                        "PDGFR-2", 
                        "CD140A"
                    ], 
                    "hugoSymbol": "PDGFRA", 
                    "name": "platelet derived growth factor receptor alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Curtis CE et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "British journal of haematology", 
                "link": null, 
                "pages": "77-81", 
                "pmid": "17555450", 
                "pubDate": "2007 Jul", 
                "reference": "Curtis CE et al. British journal of haematology. 2007 Jul;138(1)77-81.", 
                "title": "Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.", 
                "volume": "138"
            }, 
            {
                "abstract": null, 
                "authors": "Safley AM et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Genes, chromosomes &amp; cancer", 
                "link": null, 
                "pages": "44-50", 
                "pmid": "15034867", 
                "pubDate": "2004 May", 
                "reference": "Safley AM et al. Genes, chromosomes &amp; cancer. 2004 May;40(1)44-50.", 
                "title": "Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.", 
                "volume": "40"
            }, 
            {
                "abstract": null, 
                "authors": "Klion AD et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Blood", 
                "link": null, 
                "pages": "473-8", 
                "pmid": "14504092", 
                "pubDate": "2004 Jan 15", 
                "reference": "Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.", 
                "title": "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Cools J et al", 
                "elocationId": "", 
                "issue": "13", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1201-14", 
                "pmid": "12660384", 
                "pubDate": "2003 Mar 27", 
                "reference": "Cools J et al. The New England journal of medicine. 2003 Mar 27;348(13)1201-14.", 
                "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.", 
                "volume": "348"
            }, 
            {
                "abstract": null, 
                "authors": "Walz C et al", 
                "elocationId": "", 
                "issue": "10", 
                "journal": "Genes, chromosomes &amp; cancer", 
                "link": null, 
                "pages": "950-6", 
                "pmid": "16845659", 
                "pubDate": "2006 Oct", 
                "reference": "Walz C et al. Genes, chromosomes &amp; cancer. 2006 Oct;45(10)950-6.", 
                "title": "Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.", 
                "volume": "45"
            }, 
            {
                "abstract": null, 
                "authors": "Trempat P et al", 
                "elocationId": "", 
                "issue": "36", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "5702-6", 
                "pmid": "12944919", 
                "pubDate": "2003 Aug 28", 
                "reference": "Trempat P et al. Oncogene. 2003 Aug 28;22(36)5702-6.", 
                "title": "Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec.", 
                "volume": "22"
            }, 
            {
                "abstract": null, 
                "authors": "Score J et al", 
                "elocationId": "", 
                "issue": "5", 
                "journal": "Leukemia", 
                "link": null, 
                "pages": "827-32", 
                "pmid": "16498388", 
                "pubDate": "2006 May", 
                "reference": "Score J et al. Leukemia. 2006 May;20(5)827-32.", 
                "title": "Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.", 
                "volume": "20"
            }
        ], 
        "cancerType": "Myeloproliferative Neoplasm", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000257290", 
            "curatedRefSeq": "NM_006206.4", 
            "entrezGeneId": 5156, 
            "geneAliases": [
                "PDGFR2", 
                "RHEPDGFRA", 
                "GAS9", 
                "PDGFR-2", 
                "CD140A"
            ], 
            "hugoSymbol": "PDGFRA", 
            "name": "platelet derived growth factor receptor alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 15336, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493063804000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Myeloproliferative Neoplasm"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Imatinib is FDA-approved for the treatment of adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "BCR-ABL1 Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000318560", 
                    "curatedRefSeq": "NM_005157.4", 
                    "entrezGeneId": 25, 
                    "geneAliases": [
                        "v-abl", 
                        "bcr/abl", 
                        "JTK7", 
                        "c-ABL1", 
                        "c-ABL", 
                        "ABL", 
                        "p150"
                    ], 
                    "hugoSymbol": "ABL1", 
                    "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "BCR-ABL1 Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Lilly MB et al", 
                "elocationId": "doi: 10.1002/ajh.21615", 
                "issue": "3", 
                "journal": "American journal of hematology", 
                "link": null, 
                "pages": "164-70", 
                "pmid": "20131302", 
                "pubDate": "2010 Mar", 
                "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.", 
                "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.", 
                "volume": "85"
            }, 
            {
                "abstract": null, 
                "authors": "Ottmann O et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "Blood", 
                "link": null, 
                "pages": "2309-15", 
                "pmid": "17496201", 
                "pubDate": "2007 Oct 1", 
                "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.", 
                "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.", 
                "volume": "110"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000318560", 
            "curatedRefSeq": "NM_005157.4", 
            "entrezGeneId": 25, 
            "geneAliases": [
                "v-abl", 
                "bcr/abl", 
                "JTK7", 
                "c-ABL1", 
                "c-ABL", 
                "ABL", 
                "p150"
            ], 
            "hugoSymbol": "ABL1", 
            "name": "ABL proto-oncogene 1, non-receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8425, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1491851200000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [
                "C3167"
            ], 
            "UMLS": [
                "C0023449"
            ], 
            "children": null, 
            "code": "ALL", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Acute Lymphoid Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "ALL", 
        "treatments": [
            {
                "approvedIndications": [
                    "Adults with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL) with resistance or intolerance to prior therapy."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Dasatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Wildtype", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000256078", 
                    "curatedRefSeq": "NM_033360.2", 
                    "entrezGeneId": 3845, 
                    "geneAliases": [
                        "KI-RAS", 
                        "RALD", 
                        "NS", 
                        "RASK2", 
                        "CFC2", 
                        "K-RAS2B", 
                        "K-RAS2A", 
                        "K-RAS4B", 
                        "NS3", 
                        "K-RAS4A", 
                        "C-K-RAS", 
                        "KRAS2", 
                        "KRAS1"
                    ], 
                    "hugoSymbol": "KRAS", 
                    "name": "KRAS proto-oncogene, GTPase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Wildtype", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Cunningham D et al", 
                "elocationId": "", 
                "issue": "4", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "337-45", 
                "pmid": "15269313", 
                "pubDate": "2004 Jul 22", 
                "reference": "Cunningham D et al. The New England journal of medicine. 2004 Jul 22;351(4)337-45.", 
                "title": "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.", 
                "volume": "351"
            }, 
            {
                "abstract": null, 
                "authors": "Chung KY et al", 
                "elocationId": "", 
                "issue": "9", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "1803-10", 
                "pmid": "15677699", 
                "pubDate": "2005 Mar 20", 
                "reference": "Chung KY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20;23(9)1803-10.", 
                "title": "Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.", 
                "volume": "23"
            }, 
            {
                "abstract": null, 
                "authors": "Van Cutsem E et al", 
                "elocationId": "doi: 10.1056/NEJMoa0805019", 
                "issue": "14", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1408-17", 
                "pmid": "19339720", 
                "pubDate": "2009 Apr 2", 
                "reference": "Van Cutsem E et al. The New England journal of medicine. 2009 Apr 2;360(14)1408-17.", 
                "title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.", 
                "volume": "360"
            }, 
            {
                "abstract": null, 
                "authors": "Price TJ et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)70118-4", 
                "issue": "6", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "569-79", 
                "pmid": "24739896", 
                "pubDate": "2014 May", 
                "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.", 
                "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.", 
                "volume": "15"
            }
        ], 
        "cancerType": "Colorectal Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000256078", 
            "curatedRefSeq": "NM_033360.2", 
            "entrezGeneId": 3845, 
            "geneAliases": [
                "KI-RAS", 
                "RALD", 
                "NS", 
                "RASK2", 
                "CFC2", 
                "K-RAS2B", 
                "K-RAS2A", 
                "K-RAS4B", 
                "NS3", 
                "K-RAS4A", 
                "C-K-RAS", 
                "KRAS2", 
                "KRAS1"
            ], 
            "hugoSymbol": "KRAS", 
            "name": "KRAS proto-oncogene, GTPase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8564, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493056148000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Colorectal Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Cetuximab is FDA-approved for treatment of KRAS wildtype, EGFR-expressing, metastatic colorectal cancer (mCRC): 1) In combination with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) as first-line treatment 2) In combination with irinotecan (for patients unresponsive to irinotecan-based chemotherapy) 3) As monotherapy for patients who have failed oxaliplatin- and irinotecan-based chemotherapy or are intolerant to irinotecan."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cetuximab", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Wildtype", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000256078", 
                    "curatedRefSeq": "NM_033360.2", 
                    "entrezGeneId": 3845, 
                    "geneAliases": [
                        "KI-RAS", 
                        "RALD", 
                        "NS", 
                        "RASK2", 
                        "CFC2", 
                        "K-RAS2B", 
                        "K-RAS2A", 
                        "K-RAS4B", 
                        "NS3", 
                        "K-RAS4A", 
                        "C-K-RAS", 
                        "KRAS2", 
                        "KRAS1"
                    ], 
                    "hugoSymbol": "KRAS", 
                    "name": "KRAS proto-oncogene, GTPase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Wildtype", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Van Cutsem E et al", 
                "elocationId": "", 
                "issue": "13", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "1658-64", 
                "pmid": "17470858", 
                "pubDate": "2007 May 1", 
                "reference": "Van Cutsem E et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 May 1;25(13)1658-64.", 
                "title": "Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.", 
                "volume": "25"
            }, 
            {
                "abstract": null, 
                "authors": "Peeters M et al", 
                "elocationId": "doi: 10.1200/JCO.2009.27.6055", 
                "issue": "31", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4706-13", 
                "pmid": "20921462", 
                "pubDate": "2010 Nov 1", 
                "reference": "Peeters M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4706-13.", 
                "title": "Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.", 
                "volume": "28"
            }, 
            {
                "abstract": null, 
                "authors": "Price TJ et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)70118-4", 
                "issue": "6", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "569-79", 
                "pmid": "24739896", 
                "pubDate": "2014 May", 
                "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.", 
                "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.", 
                "volume": "15"
            }, 
            {
                "abstract": null, 
                "authors": "Douillard JY et al", 
                "elocationId": "doi: 10.1200/JCO.2009.27.4860", 
                "issue": "31", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4697-705", 
                "pmid": "20921465", 
                "pubDate": "2010 Nov 1", 
                "reference": "Douillard JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4697-705.", 
                "title": "Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.", 
                "volume": "28"
            }
        ], 
        "cancerType": "Colorectal Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000256078", 
            "curatedRefSeq": "NM_033360.2", 
            "entrezGeneId": 3845, 
            "geneAliases": [
                "KI-RAS", 
                "RALD", 
                "NS", 
                "RASK2", 
                "CFC2", 
                "K-RAS2B", 
                "K-RAS2A", 
                "K-RAS4B", 
                "NS3", 
                "K-RAS4A", 
                "C-K-RAS", 
                "KRAS2", 
                "KRAS1"
            ], 
            "hugoSymbol": "KRAS", 
            "name": "KRAS proto-oncogene, GTPase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8565, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493056148000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Colorectal Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Panitumumab is FDA-approved for KRAS wildtype, EGFR-expressing metastatic colorectal cancer, either in combination with FOLFOX (first-line) or as monotherapy following disease progression after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Panitumumab", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Wildtype", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000256078", 
                    "curatedRefSeq": "NM_033360.2", 
                    "entrezGeneId": 3845, 
                    "geneAliases": [
                        "KI-RAS", 
                        "RALD", 
                        "NS", 
                        "RASK2", 
                        "CFC2", 
                        "K-RAS2B", 
                        "K-RAS2A", 
                        "K-RAS4B", 
                        "NS3", 
                        "K-RAS4A", 
                        "C-K-RAS", 
                        "KRAS2", 
                        "KRAS1"
                    ], 
                    "hugoSymbol": "KRAS", 
                    "name": "KRAS proto-oncogene, GTPase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Wildtype", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Grothey A et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)61900-X", 
                "issue": "9863", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "303-12", 
                "pmid": "23177514", 
                "pubDate": "2013 Jan 26", 
                "reference": "Grothey A et al. Lancet (London, England). 2013 Jan 26;381(9863)303-12.", 
                "title": "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.", 
                "volume": "381"
            }
        ], 
        "cancerType": "Colorectal Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000256078", 
            "curatedRefSeq": "NM_033360.2", 
            "entrezGeneId": 3845, 
            "geneAliases": [
                "KI-RAS", 
                "RALD", 
                "NS", 
                "RASK2", 
                "CFC2", 
                "K-RAS2B", 
                "K-RAS2A", 
                "K-RAS4B", 
                "NS3", 
                "K-RAS4A", 
                "C-K-RAS", 
                "KRAS2", 
                "KRAS1"
            ], 
            "hugoSymbol": "KRAS", 
            "name": "KRAS proto-oncogene, GTPase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8566, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493056148000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Colorectal Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Regorafenib is FDA-approved for patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, or anti-VEGF therapy. Patients who are KRAS wild type also have to have had prior anti-EGFR therapy."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Regorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "A750P", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "A750P", 
                "proteinEnd": 750, 
                "proteinStart": 750, 
                "refResidues": "A", 
                "variantResidues": "P"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Chang JW et al", 
                "elocationId": "doi: 10.4103/2319-4170.138320", 
                "issue": "3", 
                "journal": "Biomedical journal", 
                "link": null, 
                "pages": "221-8", 
                "pmid": "25179728", 
                "pubDate": "2015 May-Jun", 
                "reference": "Chang JW et al. Biomedical journal. 2015 May-Jun;38(3)221-8.", 
                "title": "Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.", 
                "volume": "38"
            }, 
            {
                "abstract": null, 
                "authors": "Pao W et al", 
                "elocationId": "", 
                "issue": "3", 
                "journal": "PLoS medicine", 
                "link": null, 
                "pages": "e73", 
                "pmid": "15737014", 
                "pubDate": "2005 Mar", 
                "reference": "Pao W et al. PLoS medicine. 2005 Mar;2(3)e73.", 
                "title": "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.", 
                "volume": "2"
            }, 
            {
                "abstract": null, 
                "authors": "Sun QM et al", 
                "elocationId": "", 
                "issue": "17", 
                "journal": "Cancer biology &amp; therapy", 
                "link": null, 
                "pages": "1640-7", 
                "pmid": "19625781", 
                "pubDate": "2009 Sep", 
                "reference": "Sun QM et al. Cancer biology &amp; therapy. 2009 Sep;8(17)1640-7.", 
                "title": "BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities.", 
                "volume": "8"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12408, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "G719C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G719C", 
                "proteinEnd": 719, 
                "proteinStart": 719, 
                "refResidues": "G", 
                "variantResidues": "C"
            }, 
            {
                "alteration": "G719S", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G719S", 
                "proteinEnd": 719, 
                "proteinStart": 719, 
                "refResidues": "G", 
                "variantResidues": "S"
            }, 
            {
                "alteration": "G719D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G719D", 
                "proteinEnd": 719, 
                "proteinStart": 719, 
                "refResidues": "G", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "G719A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G719A", 
                "proteinEnd": 719, 
                "proteinStart": 719, 
                "refResidues": "G", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kris MG et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2149-58", 
                "pmid": "14570950", 
                "pubDate": "2003 Oct 22", 
                "reference": "Kris MG et al. JAMA. 2003 Oct 22;290(16)2149-58.", 
                "title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.", 
                "volume": "290"
            }, 
            {
                "abstract": null, 
                "authors": "Li D et al", 
                "elocationId": "doi: 10.1038/onc.2008.109", 
                "issue": "34", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "4702-11", 
                "pmid": "18408761", 
                "pubDate": "2008 Aug 7", 
                "reference": "Li D et al. Oncogene. 2008 Aug 7;27(34)4702-11.", 
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Lynch TJ et al", 
                "elocationId": "", 
                "issue": "21", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2129-39", 
                "pmid": "15118073", 
                "pubDate": "2004 May 20", 
                "reference": "Lynch TJ et al. The New England journal of medicine. 2004 May 20;350(21)2129-39.", 
                "title": "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.", 
                "volume": "350"
            }, 
            {
                "abstract": null, 
                "authors": "Fukuoka M et al", 
                "elocationId": "doi: 10.1200/JCO.2010.33.4235", 
                "issue": "21", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2866-74", 
                "pmid": "21670455", 
                "pubDate": "2011 Jul 20", 
                "reference": "Fukuoka M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jul 20;29(21)2866-74.", 
                "title": "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).", 
                "volume": "29"
            }, 
            {
                "abstract": null, 
                "authors": "Perez-Soler R", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "S20-3", 
                "pmid": "15638953", 
                "pubDate": "2004 Dec", 
                "reference": "Perez-Soler R. Clinical lung cancer. 2004 Dec;6 Suppl 1()S20-3.", 
                "title": "Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": null, 
                "authors": "Yang JC et al", 
                "elocationId": "doi: 10.1016/S1470-2045(15)00026-1", 
                "issue": "7", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "830-8", 
                "pmid": "26051236", 
                "pubDate": "2015 Jul", 
                "reference": "Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.", 
                "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.", 
                "volume": "16"
            }, 
            {
                "abstract": null, 
                "authors": "Beau-Faller M et al", 
                "elocationId": "doi: 10.1093/annonc/mdt418", 
                "issue": "1", 
                "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", 
                "link": null, 
                "pages": "126-31", 
                "pmid": "24285021", 
                "pubDate": "2014 Jan", 
                "reference": "Beau-Faller M et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)126-31.", 
                "title": "Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.", 
                "volume": "25"
            }, 
            {
                "abstract": null, 
                "authors": "Rosell R et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Lung cancer (Amsterdam, Netherlands)", 
                "link": null, 
                "pages": "25-33", 
                "pmid": "16011858", 
                "pubDate": "2005 Oct", 
                "reference": "Rosell R et al. Lung cancer (Amsterdam, Netherlands). 2005 Oct;50(1)25-33.", 
                "title": "Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.", 
                "volume": "50"
            }, 
            {
                "abstract": null, 
                "authors": "Greulich H et al", 
                "elocationId": "", 
                "issue": "11", 
                "journal": "PLoS medicine", 
                "link": null, 
                "pages": "e313", 
                "pmid": "16187797", 
                "pubDate": "2005 Nov", 
                "reference": "Greulich H et al. PLoS medicine. 2005 Nov;2(11)e313.", 
                "title": "Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.", 
                "volume": "2"
            }, 
            {
                "abstract": null, 
                "authors": "Wu JY et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-10-3408", 
                "issue": "11", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "3812-21", 
                "pmid": "21531810", 
                "pubDate": "2011 Jun 1", 
                "reference": "Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jun 1;17(11)3812-21.", 
                "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.", 
                "volume": "17"
            }, 
            {
                "abstract": null, 
                "authors": "Maemondo M et al", 
                "elocationId": "doi: 10.1056/NEJMoa0909530", 
                "issue": "25", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2380-8", 
                "pmid": "20573926", 
                "pubDate": "2010 Jun 24", 
                "reference": "Maemondo M et al. The New England journal of medicine. 2010 Jun 24;362(25)2380-8.", 
                "title": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.", 
                "volume": "362"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12154, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "L858R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L858R", 
                "proteinEnd": 858, 
                "proteinStart": 858, 
                "refResidues": "L", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "729_761del", 
                "consequence": {
                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_deletion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 19 deletion", 
                "proteinEnd": 761, 
                "proteinStart": 729, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "729_761indel", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 19 deletion/insertion", 
                "proteinEnd": 761, 
                "proteinStart": 729, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Perez-Soler R", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "S20-3", 
                "pmid": "15638953", 
                "pubDate": "2004 Dec", 
                "reference": "Perez-Soler R. Clinical lung cancer. 2004 Dec;6 Suppl 1()S20-3.", 
                "title": "Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": null, 
                "authors": "Rosell R et al", 
                "elocationId": "doi: 10.1016/S1470-2045(11)70393-X", 
                "issue": "3", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "239-46", 
                "pmid": "22285168", 
                "pubDate": "2012 Mar", 
                "reference": "Rosell R et al. The Lancet. Oncology. 2012 Mar;13(3)239-46.", 
                "title": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.", 
                "volume": "13"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12156, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Erlotinib is FDA-approved for (1) First-line treatment of metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test", 
                    " (3) locally advanced or metastatic NSCLC after failure of chemotherapy", 
                    " (2) maintenance treatment of non small cell lung cancer (NSCLC) that has stabilized after platinum-based chemotherapy"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "L858R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L858R", 
                "proteinEnd": 858, 
                "proteinStart": 858, 
                "refResidues": "L", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "729_761del", 
                "consequence": {
                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_deletion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 19 deletion", 
                "proteinEnd": 761, 
                "proteinStart": 729, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "729_761indel", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 19 deletion/insertion", 
                "proteinEnd": 761, 
                "proteinStart": 729, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Li D et al", 
                "elocationId": "doi: 10.1038/onc.2008.109", 
                "issue": "34", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "4702-11", 
                "pmid": "18408761", 
                "pubDate": "2008 Aug 7", 
                "reference": "Li D et al. Oncogene. 2008 Aug 7;27(34)4702-11.", 
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Yang JC et al", 
                "elocationId": "doi: 10.1016/S1470-2045(12)70086-4", 
                "issue": "5", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "539-48", 
                "pmid": "22452895", 
                "pubDate": "2012 May", 
                "reference": "Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.", 
                "title": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.", 
                "volume": "13"
            }, 
            {
                "abstract": null, 
                "authors": "Yang JC et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)71173-8", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "141-51", 
                "pmid": "25589191", 
                "pubDate": "2015 Feb", 
                "reference": "Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.", 
                "title": "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.", 
                "volume": "16"
            }, 
            {
                "abstract": null, 
                "authors": "Sequist LV et al", 
                "elocationId": "doi: 10.1200/JCO.2012.44.2806", 
                "issue": "27", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3327-34", 
                "pmid": "23816960", 
                "pubDate": "2013 Sep 20", 
                "reference": "Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.", 
                "title": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.", 
                "volume": "31"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12157, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    " (2) Treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy", 
                    "Afatinib is FDA-approved for (1) First-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "L858R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L858R", 
                "proteinEnd": 858, 
                "proteinStart": 858, 
                "refResidues": "L", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "729_761del", 
                "consequence": {
                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_deletion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 19 deletion", 
                "proteinEnd": 761, 
                "proteinStart": 729, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "729_761indel", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 19 deletion/insertion", 
                "proteinEnd": 761, 
                "proteinStart": 729, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Mok TS et al", 
                "elocationId": "doi: 10.1056/NEJMoa0810699", 
                "issue": "10", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "947-57", 
                "pmid": "19692680", 
                "pubDate": "2009 Sep 3", 
                "reference": "Mok TS et al. The New England journal of medicine. 2009 Sep 3;361(10)947-57.", 
                "title": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.", 
                "volume": "361"
            }, 
            {
                "abstract": null, 
                "authors": "Kris MG et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2149-58", 
                "pmid": "14570950", 
                "pubDate": "2003 Oct 22", 
                "reference": "Kris MG et al. JAMA. 2003 Oct 22;290(16)2149-58.", 
                "title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.", 
                "volume": "290"
            }, 
            {
                "abstract": null, 
                "authors": "Mitsudomi T et al", 
                "elocationId": "doi: 10.1016/S1470-2045(09)70364-X", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "121-8", 
                "pmid": "20022809", 
                "pubDate": "2010 Feb", 
                "reference": "Mitsudomi T et al. The Lancet. Oncology. 2010 Feb;11(2)121-8.", 
                "title": "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.", 
                "volume": "11"
            }, 
            {
                "abstract": null, 
                "authors": "Fukuoka M et al", 
                "elocationId": "doi: 10.1200/JCO.2010.33.4235", 
                "issue": "21", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2866-74", 
                "pmid": "21670455", 
                "pubDate": "2011 Jul 20", 
                "reference": "Fukuoka M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jul 20;29(21)2866-74.", 
                "title": "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).", 
                "volume": "29"
            }, 
            {
                "abstract": null, 
                "authors": "Han JY et al", 
                "elocationId": "doi: 10.1200/JCO.2011.36.8456", 
                "issue": "10", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "1122-8", 
                "pmid": "22370314", 
                "pubDate": "2012 Apr 1", 
                "reference": "Han JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Apr 1;30(10)1122-8.", 
                "title": "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.", 
                "volume": "30"
            }, 
            {
                "abstract": null, 
                "authors": "Maemondo M et al", 
                "elocationId": "doi: 10.1056/NEJMoa0909530", 
                "issue": "25", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2380-8", 
                "pmid": "20573926", 
                "pubDate": "2010 Jun 24", 
                "reference": "Maemondo M et al. The New England journal of medicine. 2010 Jun 24;362(25)2380-8.", 
                "title": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.", 
                "volume": "362"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12158, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Gefitinib is FDA-approved for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Flaherty KT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1210093", 
                "issue": "18", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1694-703", 
                "pmid": "23020132", 
                "pubDate": "2012 Nov 1", 
                "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.", 
                "title": "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.", 
                "volume": "367"
            }, 
            {
                "abstract": null, 
                "authors": "Johnson DB et al", 
                "elocationId": "doi: 10.1200/JCO.2014.57.3535", 
                "issue": "33", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3697-704", 
                "pmid": "25287827", 
                "pubDate": "2014 Nov 20", 
                "reference": "Johnson DB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Nov 20;32(33)3697-704.", 
                "title": "Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.", 
                "volume": "32"
            }, 
            {
                "abstract": null, 
                "authors": "McGettigan S", 
                "elocationId": "", 
                "issue": "3", 
                "journal": "Journal of the advanced practitioner in oncology", 
                "link": null, 
                "pages": "211-5", 
                "pmid": "25089220", 
                "pubDate": "2014 May", 
                "reference": "McGettigan S. Journal of the advanced practitioner in oncology. 2014 May;5(3)211-5.", 
                "title": "Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Flaherty KT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1203421", 
                "issue": "2", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "107-14", 
                "pmid": "22663011", 
                "pubDate": "2012 Jul 12", 
                "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Jul 12;367(2)107-14.", 
                "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.", 
                "volume": "367"
            }, 
            {
                "abstract": null, 
                "authors": "Robert C et al", 
                "elocationId": "doi: 10.1056/NEJMoa1412690", 
                "issue": "1", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "30-9", 
                "pmid": "25399551", 
                "pubDate": "2015 Jan 1", 
                "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.", 
                "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.", 
                "volume": "372"
            }, 
            {
                "abstract": null, 
                "authors": "Long GV et al", 
                "elocationId": "doi: 10.1056/NEJMoa1406037", 
                "issue": "20", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1877-88", 
                "pmid": "25265492", 
                "pubDate": "2014 Nov 13", 
                "reference": "Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.", 
                "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.", 
                "volume": "371"
            }, 
            {
                "abstract": null, 
                "authors": "Wright CJ et al", 
                "elocationId": "doi: 10.1007/s40265-013-0096-1", 
                "issue": "11", 
                "journal": "Drugs", 
                "link": null, 
                "pages": "1245-54", 
                "pmid": "23846731", 
                "pubDate": "2013 Jul", 
                "reference": "Wright CJ et al. Drugs. 2013 Jul;73(11)1245-54.", 
                "title": "Trametinib: first global approval.", 
                "volume": "73"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4608, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493057315000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Dabrafenib + Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Dabrafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Larkin J et al", 
                "elocationId": "doi: 10.1056/NEJMoa1408868", 
                "issue": "20", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1867-76", 
                "pmid": "25265494", 
                "pubDate": "2014 Nov 13", 
                "reference": "Larkin J et al. The New England journal of medicine. 2014 Nov 13;371(20)1867-76.", 
                "title": "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.", 
                "volume": "371"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4609, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493057315000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Cobimetinib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cobimetinib", 
                        "priority": 2, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Vemurafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Long GV et al", 
                "elocationId": "doi: 10.1016/S1470-2045(12)70431-X", 
                "issue": "11", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "1087-95", 
                "pmid": "23051966", 
                "pubDate": "2012 Nov", 
                "reference": "Long GV et al. The Lancet. Oncology. 2012 Nov;13(11)1087-95.", 
                "title": "Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.", 
                "volume": "13"
            }, 
            {
                "abstract": null, 
                "authors": "Falchook GS et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)60398-5", 
                "issue": "9829", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1893-901", 
                "pmid": "22608338", 
                "pubDate": "2012 May 19", 
                "reference": "Falchook GS et al. Lancet (London, England). 2012 May 19;379(9829)1893-901.", 
                "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.", 
                "volume": "379"
            }, 
            {
                "abstract": null, 
                "authors": "McGettigan S", 
                "elocationId": "", 
                "issue": "3", 
                "journal": "Journal of the advanced practitioner in oncology", 
                "link": null, 
                "pages": "211-5", 
                "pmid": "25089220", 
                "pubDate": "2014 May", 
                "reference": "McGettigan S. Journal of the advanced practitioner in oncology. 2014 May;5(3)211-5.", 
                "title": "Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Ascierto PA et al", 
                "elocationId": "doi: 10.1200/JCO.2013.49.8691", 
                "issue": "26", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3205-11", 
                "pmid": "23918947", 
                "pubDate": "2013 Sep 10", 
                "reference": "Ascierto PA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3205-11.", 
                "title": "Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Hauschild A et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)60868-X", 
                "issue": "9839", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "358-65", 
                "pmid": "22735384", 
                "pubDate": "2012 Jul 28", 
                "reference": "Hauschild A et al. Lancet (London, England). 2012 Jul 28;380(9839)358-65.", 
                "title": "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.", 
                "volume": "380"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4610, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493057315000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Dabrafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Dabrafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "McArthur GA et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)70012-9", 
                "issue": "3", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "323-32", 
                "pmid": "24508103", 
                "pubDate": "2014 Mar", 
                "reference": "McArthur GA et al. The Lancet. Oncology. 2014 Mar;15(3)323-32.", 
                "title": "Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.", 
                "volume": "15"
            }, 
            {
                "abstract": null, 
                "authors": "Robert C et al", 
                "elocationId": "doi: 10.1056/NEJMoa1412690", 
                "issue": "1", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "30-9", 
                "pmid": "25399551", 
                "pubDate": "2015 Jan 1", 
                "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.", 
                "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.", 
                "volume": "372"
            }, 
            {
                "abstract": null, 
                "authors": "Flaherty KT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1002011", 
                "issue": "9", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "809-19", 
                "pmid": "20818844", 
                "pubDate": "2010 Aug 26", 
                "reference": "Flaherty KT et al. The New England journal of medicine. 2010 Aug 26;363(9)809-19.", 
                "title": "Inhibition of mutated, activated BRAF in metastatic melanoma.", 
                "volume": "363"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4611, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493057315000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Vemurafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Vemurafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Flaherty KT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1203421", 
                "issue": "2", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "107-14", 
                "pmid": "22663011", 
                "pubDate": "2012 Jul 12", 
                "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Jul 12;367(2)107-14.", 
                "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.", 
                "volume": "367"
            }, 
            {
                "abstract": null, 
                "authors": "Robert C et al", 
                "elocationId": "doi: 10.1056/NEJMoa1412690", 
                "issue": "1", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "30-9", 
                "pmid": "25399551", 
                "pubDate": "2015 Jan 1", 
                "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.", 
                "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.", 
                "volume": "372"
            }, 
            {
                "abstract": null, 
                "authors": "Long GV et al", 
                "elocationId": "doi: 10.1056/NEJMoa1406037", 
                "issue": "20", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1877-88", 
                "pmid": "25265492", 
                "pubDate": "2014 Nov 13", 
                "reference": "Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.", 
                "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.", 
                "volume": "371"
            }, 
            {
                "abstract": null, 
                "authors": "Wright CJ et al", 
                "elocationId": "doi: 10.1007/s40265-013-0096-1", 
                "issue": "11", 
                "journal": "Drugs", 
                "link": null, 
                "pages": "1245-54", 
                "pmid": "23846731", 
                "pubDate": "2013 Jul", 
                "reference": "Wright CJ et al. Drugs. 2013 Jul;73(11)1245-54.", 
                "title": "Trametinib: first global approval.", 
                "volume": "73"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4612, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1502474214000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 5
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "McGettigan S", 
                "elocationId": "", 
                "issue": "3", 
                "journal": "Journal of the advanced practitioner in oncology", 
                "link": null, 
                "pages": "211-5", 
                "pmid": "25089220", 
                "pubDate": "2014 May", 
                "reference": "McGettigan S. Journal of the advanced practitioner in oncology. 2014 May;5(3)211-5.", 
                "title": "Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Flaherty KT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1203421", 
                "issue": "2", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "107-14", 
                "pmid": "22663011", 
                "pubDate": "2012 Jul 12", 
                "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Jul 12;367(2)107-14.", 
                "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.", 
                "volume": "367"
            }, 
            {
                "abstract": null, 
                "authors": "Planchard D et al", 
                "elocationId": "doi: 10.1016/S1470-2045(16)30146-2", 
                "issue": "7", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "984-993", 
                "pmid": "27283860", 
                "pubDate": "2016 Jul", 
                "reference": "Planchard D et al. The Lancet. Oncology. 2016 Jul;17(7)984-993.", 
                "title": "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4614, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1502479212000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Dabrafenib and trametinib are FDA-approved for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Dabrafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "729_761ins", 
                "consequence": {
                    "description": "An inframe non synonymous variant that inserts bases into in the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_insertion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 19 insertion", 
                "proteinEnd": 761, 
                "proteinStart": 729, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "He M et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-11-2361", 
                "issue": "6", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1790-7", 
                "pmid": "22190593", 
                "pubDate": "2012 Mar 15", 
                "reference": "He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.", 
                "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.", 
                "volume": "18"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12166, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Diamond EL et al", 
                "elocationId": "doi: 10.1001/jamaoncol.2017.5029", 
                "issue": "", 
                "journal": "JAMA oncology", 
                "link": null, 
                "pages": "", 
                "pmid": "29188284", 
                "pubDate": "2017 Nov 29", 
                "reference": "Diamond EL et al. JAMA oncology. 2017 Nov 29;().", 
                "title": "Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.", 
                "volume": ""
            }, 
            {
                "abstract": null, 
                "authors": "Hyman DM et al", 
                "elocationId": "doi: 10.1056/NEJMoa1502309", 
                "issue": "8", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "726-36", 
                "pmid": "26287849", 
                "pubDate": "2015 Aug 20", 
                "reference": "Hyman DM et al. The New England journal of medicine. 2015 Aug 20;373(8)726-36.", 
                "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.", 
                "volume": "373"
            }
        ], 
        "cancerType": "Histiocytosis", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4617, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1513804137000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Histiocytosis"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Vemurafenib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Vemurafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "T790M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "T790M", 
                "proteinEnd": 790, 
                "proteinStart": 790, 
                "refResidues": "T", 
                "variantResidues": "M"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Jnne PA et al", 
                "elocationId": "doi: 10.1056/NEJMoa1411817", 
                "issue": "18", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1689-99", 
                "pmid": "25923549", 
                "pubDate": "2015 Apr 30", 
                "reference": "Jnne PA et al. The New England journal of medicine. 2015 Apr 30;372(18)1689-99.", 
                "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.", 
                "volume": "372"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12170, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "FDA granted accelerated approval to osimertinib once daily tablets for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Osimertinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "L747P", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L747P", 
                "proteinEnd": 747, 
                "proteinStart": 747, 
                "refResidues": "L", 
                "variantResidues": "P"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "He M et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-11-2361", 
                "issue": "6", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1790-7", 
                "pmid": "22190593", 
                "pubDate": "2012 Mar 15", 
                "reference": "He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.", 
                "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.", 
                "volume": "18"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12177, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "MSI-H", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": null, 
                    "curatedRefSeq": null, 
                    "entrezGeneId": -2, 
                    "geneAliases": [], 
                    "hugoSymbol": "Other Biomarkers", 
                    "name": "Other Biomarkers", 
                    "oncogene": false, 
                    "tsg": false
                }, 
                "name": "Microsatellite Instability-High", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Lipson EJ et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-12-2625", 
                "issue": "2", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "462-8", 
                "pmid": "23169436", 
                "pubDate": "2013 Jan 15", 
                "reference": "Lipson EJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Jan 15;19(2)462-8.", 
                "title": "Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.", 
                "volume": "19"
            }, 
            {
                "abstract": "Overman et al. Abstract# 3501, ASCO 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/166455-176, PMID: 28223062", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Morris VK et al", 
                "elocationId": "doi: 10.1016/S1470-2045(17)30104-3", 
                "issue": "4", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "446-453", 
                "pmid": "28223062", 
                "pubDate": "2017 Apr", 
                "reference": "Morris VK et al. The Lancet. Oncology. 2017 Apr;18(4)446-453.", 
                "title": "Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.", 
                "volume": "18"
            }
        ], 
        "cancerType": "Colorectal Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": null, 
            "curatedRefSeq": null, 
            "entrezGeneId": -2, 
            "geneAliases": [], 
            "hugoSymbol": "Other Biomarkers", 
            "name": "Other Biomarkers", 
            "oncogene": false, 
            "tsg": false
        }, 
        "id": 11669, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1504282513000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Colorectal Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Nivolumab", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "E709_T710delinsD", 
                "consequence": {
                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_deletion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "E709_T710delinsD", 
                "proteinEnd": 710, 
                "proteinStart": 709, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kobayashi Y et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-15-1046", 
                "issue": "23", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "5305-13", 
                "pmid": "26206867", 
                "pubDate": "2015 Dec 1", 
                "reference": "Kobayashi Y et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Dec 1;21(23)5305-13.", 
                "title": "EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.", 
                "volume": "21"
            }, 
            {
                "abstract": null, 
                "authors": "Kris MG et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2149-58", 
                "pmid": "14570950", 
                "pubDate": "2003 Oct 22", 
                "reference": "Kris MG et al. JAMA. 2003 Oct 22;290(16)2149-58.", 
                "title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.", 
                "volume": "290"
            }, 
            {
                "abstract": null, 
                "authors": "Li D et al", 
                "elocationId": "doi: 10.1038/onc.2008.109", 
                "issue": "34", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "4702-11", 
                "pmid": "18408761", 
                "pubDate": "2008 Aug 7", 
                "reference": "Li D et al. Oncogene. 2008 Aug 7;27(34)4702-11.", 
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Perez-Soler R", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "S20-3", 
                "pmid": "15638953", 
                "pubDate": "2004 Dec", 
                "reference": "Perez-Soler R. Clinical lung cancer. 2004 Dec;6 Suppl 1()S20-3.", 
                "title": "Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": null, 
                "authors": "Wu JY et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-10-3408", 
                "issue": "11", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "3812-21", 
                "pmid": "21531810", 
                "pubDate": "2011 Jun 1", 
                "reference": "Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jun 1;17(11)3812-21.", 
                "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12181, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000261799", 
                    "curatedRefSeq": "NM_002609.3", 
                    "entrezGeneId": 5159, 
                    "geneAliases": [
                        "PDGFR1", 
                        "KOGS", 
                        "PDGFR-1", 
                        "JTK12", 
                        "PDGFR", 
                        "IBGC4", 
                        "IMF1", 
                        "PENTT", 
                        "CD140B"
                    ], 
                    "hugoSymbol": "PDGFRB", 
                    "name": "platelet derived growth factor receptor beta", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Klion AD et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "Blood", 
                "link": null, 
                "pages": "4660-6", 
                "pmid": "12676775", 
                "pubDate": "2003 Jun 15", 
                "reference": "Klion AD et al. Blood. 2003 Jun 15;101(12)4660-6.", 
                "title": "Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.", 
                "volume": "101"
            }, 
            {
                "abstract": null, 
                "authors": "Klion AD et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Blood", 
                "link": null, 
                "pages": "473-8", 
                "pmid": "14504092", 
                "pubDate": "2004 Jan 15", 
                "reference": "Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.", 
                "title": "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Roberts KG et al", 
                "elocationId": "doi: 10.1016/j.ccr.2012.06.005", 
                "issue": "2", 
                "journal": "Cancer cell", 
                "link": null, 
                "pages": "153-66", 
                "pmid": "22897847", 
                "pubDate": "2012 Aug 14", 
                "reference": "Roberts KG et al. Cancer cell. 2012 Aug 14;22(2)153-66.", 
                "title": "Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.", 
                "volume": "22"
            }, 
            {
                "abstract": null, 
                "authors": "Metzgeroth G et al", 
                "elocationId": "doi: 10.1111/j.1365-2141.2008.07294.x", 
                "issue": "5", 
                "journal": "British journal of haematology", 
                "link": null, 
                "pages": "707-15", 
                "pmid": "18950453", 
                "pubDate": "2008 Dec", 
                "reference": "Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.", 
                "title": "Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.", 
                "volume": "143"
            }, 
            {
                "abstract": null, 
                "authors": "Apperley JF et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "481-7", 
                "pmid": "12181402", 
                "pubDate": "2002 Aug 15", 
                "reference": "Apperley JF et al. The New England journal of medicine. 2002 Aug 15;347(7)481-7.", 
                "title": "Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.", 
                "volume": "347"
            }, 
            {
                "abstract": null, 
                "authors": "David M et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Blood", 
                "link": null, 
                "pages": "61-4", 
                "pmid": "16960151", 
                "pubDate": "2007 Jan 1", 
                "reference": "David M et al. Blood. 2007 Jan 1;109(1)61-4.", 
                "title": "Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.", 
                "volume": "109"
            }, 
            {
                "abstract": null, 
                "authors": "Iqbal N et al", 
                "elocationId": "doi: 10.1155/2014/357027", 
                "issue": "", 
                "journal": "Chemotherapy research and practice", 
                "link": null, 
                "pages": "357027", 
                "pmid": "24963404", 
                "pubDate": "2014", 
                "reference": "Iqbal N et al. Chemotherapy research and practice. 2014;2014()357027.", 
                "title": "Imatinib: a breakthrough of targeted therapy in cancer.", 
                "volume": "2014"
            }, 
            {
                "abstract": null, 
                "authors": "Sibille M et al", 
                "elocationId": "", 
                "issue": "4", 
                "journal": "European journal of clinical pharmacology", 
                "link": null, 
                "pages": "389-93", 
                "pmid": "1516603", 
                "pubDate": "1992", 
                "reference": "Sibille M et al. European journal of clinical pharmacology. 1992;42(4)389-93.", 
                "title": "Adverse events in phase one studies: a study in 430 healthy volunteers.", 
                "volume": "42"
            }, 
            {
                "abstract": null, 
                "authors": "Cheah CY et al", 
                "elocationId": "doi: 10.1182/blood-2014-02-555607", 
                "issue": "23", 
                "journal": "Blood", 
                "link": null, 
                "pages": "3574-7", 
                "pmid": "24687085", 
                "pubDate": "2014 Jun 5", 
                "reference": "Cheah CY et al. Blood. 2014 Jun 5;123(23)3574-7.", 
                "title": "Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.", 
                "volume": "123"
            }
        ], 
        "cancerType": "Myelodysplasia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000261799", 
            "curatedRefSeq": "NM_002609.3", 
            "entrezGeneId": 5159, 
            "geneAliases": [
                "PDGFR1", 
                "KOGS", 
                "PDGFR-1", 
                "JTK12", 
                "PDGFR", 
                "IBGC4", 
                "IMF1", 
                "PENTT", 
                "CD140B"
            ], 
            "hugoSymbol": "PDGFRB", 
            "name": "platelet derived growth factor receptor beta", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 13718, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493324796000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Myelodysplasia"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "MSI-H", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": null, 
                    "curatedRefSeq": null, 
                    "entrezGeneId": -2, 
                    "geneAliases": [], 
                    "hugoSymbol": "Other Biomarkers", 
                    "name": "Other Biomarkers", 
                    "oncogene": false, 
                    "tsg": false
                }, 
                "name": "Microsatellite Instability-High", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Le DT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1500596", 
                "issue": "26", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2509-20", 
                "pmid": "26028255", 
                "pubDate": "2015 Jun 25", 
                "reference": "Le DT et al. The New England journal of medicine. 2015 Jun 25;372(26)2509-20.", 
                "title": "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.", 
                "volume": "372"
            }
        ], 
        "cancerType": "All Solid Tumors", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": null, 
            "curatedRefSeq": null, 
            "entrezGeneId": -2, 
            "geneAliases": [], 
            "hugoSymbol": "Other Biomarkers", 
            "name": "Other Biomarkers", 
            "oncogene": false, 
            "tsg": false
        }, 
        "id": 11671, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1497371063000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Solid Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Adult and pediatric patients with unresectable or metastatic MSI-H or dMMR (MMR deficient) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Pembrolizumab", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000261799", 
                    "curatedRefSeq": "NM_002609.3", 
                    "entrezGeneId": 5159, 
                    "geneAliases": [
                        "PDGFR1", 
                        "KOGS", 
                        "PDGFR-1", 
                        "JTK12", 
                        "PDGFR", 
                        "IBGC4", 
                        "IMF1", 
                        "PENTT", 
                        "CD140B"
                    ], 
                    "hugoSymbol": "PDGFRB", 
                    "name": "platelet derived growth factor receptor beta", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Klion AD et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "Blood", 
                "link": null, 
                "pages": "4660-6", 
                "pmid": "12676775", 
                "pubDate": "2003 Jun 15", 
                "reference": "Klion AD et al. Blood. 2003 Jun 15;101(12)4660-6.", 
                "title": "Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.", 
                "volume": "101"
            }, 
            {
                "abstract": null, 
                "authors": "Klion AD et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Blood", 
                "link": null, 
                "pages": "473-8", 
                "pmid": "14504092", 
                "pubDate": "2004 Jan 15", 
                "reference": "Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.", 
                "title": "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Roberts KG et al", 
                "elocationId": "doi: 10.1016/j.ccr.2012.06.005", 
                "issue": "2", 
                "journal": "Cancer cell", 
                "link": null, 
                "pages": "153-66", 
                "pmid": "22897847", 
                "pubDate": "2012 Aug 14", 
                "reference": "Roberts KG et al. Cancer cell. 2012 Aug 14;22(2)153-66.", 
                "title": "Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.", 
                "volume": "22"
            }, 
            {
                "abstract": null, 
                "authors": "Metzgeroth G et al", 
                "elocationId": "doi: 10.1111/j.1365-2141.2008.07294.x", 
                "issue": "5", 
                "journal": "British journal of haematology", 
                "link": null, 
                "pages": "707-15", 
                "pmid": "18950453", 
                "pubDate": "2008 Dec", 
                "reference": "Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.", 
                "title": "Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.", 
                "volume": "143"
            }, 
            {
                "abstract": null, 
                "authors": "Apperley JF et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "481-7", 
                "pmid": "12181402", 
                "pubDate": "2002 Aug 15", 
                "reference": "Apperley JF et al. The New England journal of medicine. 2002 Aug 15;347(7)481-7.", 
                "title": "Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.", 
                "volume": "347"
            }, 
            {
                "abstract": null, 
                "authors": "David M et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Blood", 
                "link": null, 
                "pages": "61-4", 
                "pmid": "16960151", 
                "pubDate": "2007 Jan 1", 
                "reference": "David M et al. Blood. 2007 Jan 1;109(1)61-4.", 
                "title": "Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.", 
                "volume": "109"
            }, 
            {
                "abstract": null, 
                "authors": "Iqbal N et al", 
                "elocationId": "doi: 10.1155/2014/357027", 
                "issue": "", 
                "journal": "Chemotherapy research and practice", 
                "link": null, 
                "pages": "357027", 
                "pmid": "24963404", 
                "pubDate": "2014", 
                "reference": "Iqbal N et al. Chemotherapy research and practice. 2014;2014()357027.", 
                "title": "Imatinib: a breakthrough of targeted therapy in cancer.", 
                "volume": "2014"
            }, 
            {
                "abstract": null, 
                "authors": "Sibille M et al", 
                "elocationId": "", 
                "issue": "4", 
                "journal": "European journal of clinical pharmacology", 
                "link": null, 
                "pages": "389-93", 
                "pmid": "1516603", 
                "pubDate": "1992", 
                "reference": "Sibille M et al. European journal of clinical pharmacology. 1992;42(4)389-93.", 
                "title": "Adverse events in phase one studies: a study in 430 healthy volunteers.", 
                "volume": "42"
            }, 
            {
                "abstract": null, 
                "authors": "Cheah CY et al", 
                "elocationId": "doi: 10.1182/blood-2014-02-555607", 
                "issue": "23", 
                "journal": "Blood", 
                "link": null, 
                "pages": "3574-7", 
                "pmid": "24687085", 
                "pubDate": "2014 Jun 5", 
                "reference": "Cheah CY et al. Blood. 2014 Jun 5;123(23)3574-7.", 
                "title": "Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.", 
                "volume": "123"
            }
        ], 
        "cancerType": "Myeloproliferative Neoplasm", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000261799", 
            "curatedRefSeq": "NM_002609.3", 
            "entrezGeneId": 5159, 
            "geneAliases": [
                "PDGFR1", 
                "KOGS", 
                "PDGFR-1", 
                "JTK12", 
                "PDGFR", 
                "IBGC4", 
                "IMF1", 
                "PENTT", 
                "CD140B"
            ], 
            "hugoSymbol": "PDGFRB", 
            "name": "platelet derived growth factor receptor beta", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 13720, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493324796000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Myeloproliferative Neoplasm"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Imatinib is FDA approved for the treatment of (1) Adult patients with myelodysplastic/myeloproliferative (MDS/MPD) diseases associated with PDGFR gene re-arrangements."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "E709K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "E709K", 
                "proteinEnd": 709, 
                "proteinStart": 709, 
                "refResidues": "E", 
                "variantResidues": "K"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Locatelli-Sanchez M et al", 
                "elocationId": "doi: 10.1007/s00408-013-9482-4", 
                "issue": "5", 
                "journal": "Lung", 
                "link": null, 
                "pages": "491-9", 
                "pmid": "23749122", 
                "pubDate": "2013 Oct", 
                "reference": "Locatelli-Sanchez M et al. Lung. 2013 Oct;191(5)491-9.", 
                "title": "Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.", 
                "volume": "191"
            }, 
            {
                "abstract": null, 
                "authors": "Umekawa K et al", 
                "elocationId": "doi: 10.1186/1756-0500-6-139", 
                "issue": "", 
                "journal": "BMC research notes", 
                "link": null, 
                "pages": "139", 
                "pmid": "23566546", 
                "pubDate": "2013 Apr 8", 
                "reference": "Umekawa K et al. BMC research notes. 2013 Apr 8;6()139.", 
                "title": "Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.", 
                "volume": "6"
            }, 
            {
                "abstract": null, 
                "authors": "Chang JW et al", 
                "elocationId": "doi: 10.4103/2319-4170.138320", 
                "issue": "3", 
                "journal": "Biomedical journal", 
                "link": null, 
                "pages": "221-8", 
                "pmid": "25179728", 
                "pubDate": "2015 May-Jun", 
                "reference": "Chang JW et al. Biomedical journal. 2015 May-Jun;38(3)221-8.", 
                "title": "Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.", 
                "volume": "38"
            }, 
            {
                "abstract": null, 
                "authors": "Peng L et al", 
                "elocationId": "doi: 10.1038/srep06104", 
                "issue": "", 
                "journal": "Scientific reports", 
                "link": null, 
                "pages": "6104", 
                "pmid": "25130612", 
                "pubDate": "2014 Aug 18", 
                "reference": "Peng L et al. Scientific reports. 2014 Aug 18;4()6104.", 
                "title": "Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.", 
                "volume": "4"
            }, 
            {
                "abstract": null, 
                "authors": "Han SW et al", 
                "elocationId": "", 
                "issue": "11", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2493-501", 
                "pmid": "15710947", 
                "pubDate": "2005 Apr 10", 
                "reference": "Han SW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Apr 10;23(11)2493-501.", 
                "title": "Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.", 
                "volume": "23"
            }, 
            {
                "abstract": null, 
                "authors": "Pallis AG et al", 
                "elocationId": "", 
                "issue": "11", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "1560-6", 
                "pmid": "18000506", 
                "pubDate": "2007 Dec 3", 
                "reference": "Pallis AG et al. British journal of cancer. 2007 Dec 3;97(11)1560-6.", 
                "title": "'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.", 
                "volume": "97"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12185, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000261799", 
                    "curatedRefSeq": "NM_002609.3", 
                    "entrezGeneId": 5159, 
                    "geneAliases": [
                        "PDGFR1", 
                        "KOGS", 
                        "PDGFR-1", 
                        "JTK12", 
                        "PDGFR", 
                        "IBGC4", 
                        "IMF1", 
                        "PENTT", 
                        "CD140B"
                    ], 
                    "hugoSymbol": "PDGFRB", 
                    "name": "platelet derived growth factor receptor beta", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Han A et al", 
                "elocationId": "doi: 10.1001/archdermatol.2009.140", 
                "issue": "7", 
                "journal": "Archives of dermatology", 
                "link": null, 
                "pages": "792-6", 
                "pmid": "19620561", 
                "pubDate": "2009 Jul", 
                "reference": "Han A et al. Archives of dermatology. 2009 Jul;145(7)792-6.", 
                "title": "Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.", 
                "volume": "145"
            }, 
            {
                "abstract": null, 
                "authors": "Labropoulos SV et al", 
                "elocationId": "", 
                "issue": "4", 
                "journal": "Anti-cancer drugs", 
                "link": null, 
                "pages": "461-6", 
                "pmid": "15746584", 
                "pubDate": "2005 Apr", 
                "reference": "Labropoulos SV et al. Anti-cancer drugs. 2005 Apr;16(4)461-6.", 
                "title": "Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.", 
                "volume": "16"
            }, 
            {
                "abstract": null, 
                "authors": "Krob D et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-09-3401", 
                "issue": "12", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "3288-95", 
                "pmid": "20439456", 
                "pubDate": "2010 Jun 15", 
                "reference": "Krob D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Jun 15;16(12)3288-95.", 
                "title": "Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.", 
                "volume": "16"
            }, 
            {
                "abstract": null, 
                "authors": "Iqbal N et al", 
                "elocationId": "doi: 10.1155/2014/357027", 
                "issue": "", 
                "journal": "Chemotherapy research and practice", 
                "link": null, 
                "pages": "357027", 
                "pmid": "24963404", 
                "pubDate": "2014", 
                "reference": "Iqbal N et al. Chemotherapy research and practice. 2014;2014()357027.", 
                "title": "Imatinib: a breakthrough of targeted therapy in cancer.", 
                "volume": "2014"
            }, 
            {
                "abstract": null, 
                "authors": "Price VE et al", 
                "elocationId": "", 
                "issue": "5", 
                "journal": "Pediatric blood &amp; cancer", 
                "link": null, 
                "pages": "511-5", 
                "pmid": "15503291", 
                "pubDate": "2005 May", 
                "reference": "Price VE et al. Pediatric blood &amp; cancer. 2005 May;44(5)511-5.", 
                "title": "Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.", 
                "volume": "44"
            }, 
            {
                "abstract": null, 
                "authors": "McArthur GA et al", 
                "elocationId": "", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "866-73", 
                "pmid": "15681532", 
                "pubDate": "2005 Feb 1", 
                "reference": "McArthur GA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Feb 1;23(4)866-73.", 
                "title": "Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.", 
                "volume": "23"
            }, 
            {
                "abstract": null, 
                "authors": "Stacchiotti S et al", 
                "elocationId": "doi: 10.1002/ijc.25826", 
                "issue": "7", 
                "journal": "International journal of cancer", 
                "link": null, 
                "pages": "1761-72", 
                "pmid": "21128251", 
                "pubDate": "2011 Oct 1", 
                "reference": "Stacchiotti S et al. International journal of cancer. 2011 Oct 1;129(7)1761-72.", 
                "title": "Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.", 
                "volume": "129"
            }
        ], 
        "cancerType": "Skin Cancer, Non-Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000261799", 
            "curatedRefSeq": "NM_002609.3", 
            "entrezGeneId": 5159, 
            "geneAliases": [
                "PDGFR1", 
                "KOGS", 
                "PDGFR-1", 
                "JTK12", 
                "PDGFR", 
                "IBGC4", 
                "IMF1", 
                "PENTT", 
                "CD140B"
            ], 
            "hugoSymbol": "PDGFRB", 
            "name": "platelet derived growth factor receptor beta", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 13722, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493324796000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [
                "C4683"
            ], 
            "UMLS": [
                "C0392784"
            ], 
            "children": null, 
            "code": "DFSP", 
            "color": "Black", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 2, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Skin Cancer, Non-Melanoma"
            }, 
            "name": "Dermatofibrosarcoma Protuberans", 
            "parent": "SKIN", 
            "tissue": "Skin"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "DFSP", 
        "treatments": [
            {
                "approvedIndications": [
                    "Imatinib is FDA-approved for adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "L833V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L833V", 
                "proteinEnd": 833, 
                "proteinStart": 833, 
                "refResidues": "L", 
                "variantResidues": "V"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Keam B et al", 
                "elocationId": "doi: 10.1007/s10147-013-0602-1", 
                "issue": "4", 
                "journal": "International journal of clinical oncology", 
                "link": null, 
                "pages": "594-600", 
                "pmid": "23912954", 
                "pubDate": "2014 Aug", 
                "reference": "Keam B et al. International journal of clinical oncology. 2014 Aug;19(4)594-600.", 
                "title": "Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.", 
                "volume": "19"
            }, 
            {
                "abstract": null, 
                "authors": "Yang TY et al", 
                "elocationId": "doi: 10.1200/JCO.2010.33.5802", 
                "issue": "16", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "e468-9", 
                "pmid": "21422421", 
                "pubDate": "2011 Jun 1", 
                "reference": "Yang TY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jun 1;29(16)e468-9.", 
                "title": "Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.", 
                "volume": "29"
            }, 
            {
                "abstract": null, 
                "authors": "Peng L et al", 
                "elocationId": "doi: 10.1038/srep06104", 
                "issue": "", 
                "journal": "Scientific reports", 
                "link": null, 
                "pages": "6104", 
                "pmid": "25130612", 
                "pubDate": "2014 Aug 18", 
                "reference": "Peng L et al. Scientific reports. 2014 Aug 18;4()6104.", 
                "title": "Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.", 
                "volume": "4"
            }, 
            {
                "abstract": null, 
                "authors": "Hata A et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3181e8b3c5", 
                "issue": "10", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "1524-8", 
                "pmid": "20808254", 
                "pubDate": "2010 Oct", 
                "reference": "Hata A et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Oct;5(10)1524-8.", 
                "title": "Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Santis G et al", 
                "elocationId": "doi: 10.1371/journal.pone.0025191", 
                "issue": "9", 
                "journal": "PloS one", 
                "link": null, 
                "pages": "e25191", 
                "pmid": "21949883", 
                "pubDate": "2011", 
                "reference": "Santis G et al. PloS one. 2011;6(9)e25191.", 
                "title": "Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.", 
                "volume": "6"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12189, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "R172S", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000330062", 
                    "curatedRefSeq": "NM_002168.2", 
                    "entrezGeneId": 3418, 
                    "geneAliases": [
                        "IDHM", 
                        "IDP", 
                        "D2HGA2", 
                        "mNADP-IDH", 
                        "IDPM", 
                        "IDH", 
                        "ICD-M"
                    ], 
                    "hugoSymbol": "IDH2", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R172S", 
                "proteinEnd": 172, 
                "proteinStart": 172, 
                "refResidues": "R", 
                "variantResidues": "S"
            }, 
            {
                "alteration": "R172G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000330062", 
                    "curatedRefSeq": "NM_002168.2", 
                    "entrezGeneId": 3418, 
                    "geneAliases": [
                        "IDHM", 
                        "IDP", 
                        "D2HGA2", 
                        "mNADP-IDH", 
                        "IDPM", 
                        "IDH", 
                        "ICD-M"
                    ], 
                    "hugoSymbol": "IDH2", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R172G", 
                "proteinEnd": 172, 
                "proteinStart": 172, 
                "refResidues": "R", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "R172M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000330062", 
                    "curatedRefSeq": "NM_002168.2", 
                    "entrezGeneId": 3418, 
                    "geneAliases": [
                        "IDHM", 
                        "IDP", 
                        "D2HGA2", 
                        "mNADP-IDH", 
                        "IDPM", 
                        "IDH", 
                        "ICD-M"
                    ], 
                    "hugoSymbol": "IDH2", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R172M", 
                "proteinEnd": 172, 
                "proteinStart": 172, 
                "refResidues": "R", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "R172K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000330062", 
                    "curatedRefSeq": "NM_002168.2", 
                    "entrezGeneId": 3418, 
                    "geneAliases": [
                        "IDHM", 
                        "IDP", 
                        "D2HGA2", 
                        "mNADP-IDH", 
                        "IDPM", 
                        "IDH", 
                        "ICD-M"
                    ], 
                    "hugoSymbol": "IDH2", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R172K", 
                "proteinEnd": 172, 
                "proteinStart": 172, 
                "refResidues": "R", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "R140Q", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000330062", 
                    "curatedRefSeq": "NM_002168.2", 
                    "entrezGeneId": 3418, 
                    "geneAliases": [
                        "IDHM", 
                        "IDP", 
                        "D2HGA2", 
                        "mNADP-IDH", 
                        "IDPM", 
                        "IDH", 
                        "ICD-M"
                    ], 
                    "hugoSymbol": "IDH2", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R140Q", 
                "proteinEnd": 140, 
                "proteinStart": 140, 
                "refResidues": "R", 
                "variantResidues": "Q"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Stein EM et al", 
                "elocationId": "doi: 10.1182/blood-2017-04-779405", 
                "issue": "6", 
                "journal": "Blood", 
                "link": null, 
                "pages": "722-731", 
                "pmid": "28588020", 
                "pubDate": "2017 Aug 10", 
                "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.", 
                "title": "Enasidenib in mutant &lt;i&gt;IDH2&lt;/i&gt; relapsed or refractory acute myeloid leukemia.", 
                "volume": "130"
            }, 
            {
                "abstract": null, 
                "authors": "Stein EM", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-15-0362", 
                "issue": "1", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "16-9", 
                "pmid": "26553750", 
                "pubDate": "2016 Jan 1", 
                "reference": "Stein EM. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Jan 1;22(1)16-9.", 
                "title": "Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation.", 
                "volume": "22"
            }, 
            {
                "abstract": null, 
                "authors": "Chen J et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "Mini reviews in medicinal chemistry", 
                "link": null, 
                "pages": "1344-1358", 
                "pmid": "27292784", 
                "pubDate": "2016", 
                "reference": "Chen J et al. Mini reviews in medicinal chemistry. 2016;16(16)1344-1358.", 
                "title": "The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.", 
                "volume": "16"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000330062", 
            "curatedRefSeq": "NM_002168.2", 
            "entrezGeneId": 3418, 
            "geneAliases": [
                "IDHM", 
                "IDP", 
                "D2HGA2", 
                "mNADP-IDH", 
                "IDPM", 
                "IDH", 
                "ICD-M"
            ], 
            "hugoSymbol": "IDH2", 
            "name": "isocitrate dehydrogenase (NADP(+)) 2, mitochondrial", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 15391, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1502751045000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [
                "C3171"
            ], 
            "UMLS": [
                "C0023467"
            ], 
            "children": null, 
            "code": "AML", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Acute Myeloid Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "AML", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Enasidenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "C788_N828mut", 
                "consequence": {
                    "description": "any variant", 
                    "isGenerallyTruncating": false, 
                    "term": "any"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 17 mutations", 
                "proteinEnd": 828, 
                "proteinStart": 788, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)61857-1", 
                "issue": "9863", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "295-302", 
                "pmid": "23177515", 
                "pubDate": "2013 Jan 26", 
                "reference": "Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.", 
                "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.", 
                "volume": "381"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 291, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877695000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Regorafenib is FDA-approved for patients with advanced, unresectable gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Regorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "S768I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "S768I", 
                "proteinEnd": 768, 
                "proteinStart": 768, 
                "refResidues": "S", 
                "variantResidues": "I"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Hellmann MD et al", 
                "elocationId": "doi: 10.1097/JTO.0000000000000221", 
                "issue": "10", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "e73-4", 
                "pmid": "25521405", 
                "pubDate": "2014 Oct", 
                "reference": "Hellmann MD et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Oct;9(10)e73-4.", 
                "title": "Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.", 
                "volume": "9"
            }, 
            {
                "abstract": null, 
                "authors": "Kris MG et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2149-58", 
                "pmid": "14570950", 
                "pubDate": "2003 Oct 22", 
                "reference": "Kris MG et al. JAMA. 2003 Oct 22;290(16)2149-58.", 
                "title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.", 
                "volume": "290"
            }, 
            {
                "abstract": null, 
                "authors": "Li D et al", 
                "elocationId": "doi: 10.1038/onc.2008.109", 
                "issue": "34", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "4702-11", 
                "pmid": "18408761", 
                "pubDate": "2008 Aug 7", 
                "reference": "Li D et al. Oncogene. 2008 Aug 7;27(34)4702-11.", 
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Sequist LV et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "The oncologist", 
                "link": null, 
                "pages": "90-8", 
                "pmid": "17285735", 
                "pubDate": "2007 Jan", 
                "reference": "Sequist LV et al. The oncologist. 2007 Jan;12(1)90-8.", 
                "title": "Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.", 
                "volume": "12"
            }, 
            {
                "abstract": null, 
                "authors": "Perez-Soler R", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "S20-3", 
                "pmid": "15638953", 
                "pubDate": "2004 Dec", 
                "reference": "Perez-Soler R. Clinical lung cancer. 2004 Dec;6 Suppl 1()S20-3.", 
                "title": "Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": null, 
                "authors": "Yang JC et al", 
                "elocationId": "doi: 10.1016/S1470-2045(15)00026-1", 
                "issue": "7", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "830-8", 
                "pmid": "26051236", 
                "pubDate": "2015 Jul", 
                "reference": "Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.", 
                "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.", 
                "volume": "16"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12202, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1506088877000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000380152", 
                    "curatedRefSeq": "NM_000059.3", 
                    "entrezGeneId": 675, 
                    "geneAliases": [
                        "FANCD1", 
                        "BROVCA2", 
                        "XRCC11", 
                        "FAD", 
                        "FAD1", 
                        "BRCC2", 
                        "GLM3", 
                        "FACD", 
                        "FANCD", 
                        "PNCA2"
                    ], 
                    "hugoSymbol": "BRCA2", 
                    "name": "BRCA2, DNA repair associated", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "McNeish, I. et al. Abstract# 5508, ASCO 2015", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/150121-156", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Swisher EM et al", 
                "elocationId": "doi: 10.1016/S1470-2045(16)30559-9", 
                "issue": "1", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "75-87", 
                "pmid": "27908594", 
                "pubDate": "2017 Jan", 
                "reference": "Swisher EM et al. The Lancet. Oncology. 2017 Jan;18(1)75-87.", 
                "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.", 
                "volume": "18"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000380152", 
            "curatedRefSeq": "NM_000059.3", 
            "entrezGeneId": 675, 
            "geneAliases": [
                "FANCD1", 
                "BROVCA2", 
                "XRCC11", 
                "FAD", 
                "FAD1", 
                "BRCC2", 
                "GLM3", 
                "FACD", 
                "FANCD", 
                "PNCA2"
            ], 
            "hugoSymbol": "BRCA2", 
            "name": "BRCA2, DNA repair associated", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 7212, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493245593000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Rucaparib is FDA-approved for patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Rucaparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "L861R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L861R", 
                "proteinEnd": 861, 
                "proteinStart": 861, 
                "refResidues": "L", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "L861Q", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L861Q", 
                "proteinEnd": 861, 
                "proteinStart": 861, 
                "refResidues": "L", 
                "variantResidues": "Q"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kris MG et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2149-58", 
                "pmid": "14570950", 
                "pubDate": "2003 Oct 22", 
                "reference": "Kris MG et al. JAMA. 2003 Oct 22;290(16)2149-58.", 
                "title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.", 
                "volume": "290"
            }, 
            {
                "abstract": null, 
                "authors": "Li D et al", 
                "elocationId": "doi: 10.1038/onc.2008.109", 
                "issue": "34", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "4702-11", 
                "pmid": "18408761", 
                "pubDate": "2008 Aug 7", 
                "reference": "Li D et al. Oncogene. 2008 Aug 7;27(34)4702-11.", 
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Kancha RK et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3182021f3e", 
                "issue": "2", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "387-92", 
                "pmid": "21252719", 
                "pubDate": "2011 Feb", 
                "reference": "Kancha RK et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Feb;6(2)387-92.", 
                "title": "The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.", 
                "volume": "6"
            }, 
            {
                "abstract": null, 
                "authors": "Perez-Soler R", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "S20-3", 
                "pmid": "15638953", 
                "pubDate": "2004 Dec", 
                "reference": "Perez-Soler R. Clinical lung cancer. 2004 Dec;6 Suppl 1()S20-3.", 
                "title": "Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": null, 
                "authors": "Wu JY et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-10-3408", 
                "issue": "11", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "3812-21", 
                "pmid": "21531810", 
                "pubDate": "2011 Jun 1", 
                "reference": "Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jun 1;17(11)3812-21.", 
                "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12204, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "T670I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "T670I", 
                "proteinEnd": 670, 
                "proteinStart": 670, 
                "refResidues": "T", 
                "variantResidues": "I"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "9544", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1329-38", 
                "pmid": "17046465", 
                "pubDate": "2006 Oct 14", 
                "reference": "Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.", 
                "title": "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.", 
                "volume": "368"
            }, 
            {
                "abstract": null, 
                "authors": "Reichardt P et al", 
                "elocationId": "doi: 10.1002/cncr.29220", 
                "issue": "9", 
                "journal": "Cancer", 
                "link": null, 
                "pages": "1405-13", 
                "pmid": "25641662", 
                "pubDate": "2015 May 1", 
                "reference": "Reichardt P et al. Cancer. 2015 May 1;121(9)1405-13.", 
                "title": "Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.", 
                "volume": "121"
            }, 
            {
                "abstract": null, 
                "authors": "George S et al", 
                "elocationId": "doi: 10.1016/j.ejca.2009.02.011", 
                "issue": "11", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1959-68", 
                "pmid": "19282169", 
                "pubDate": "2009 Jul", 
                "reference": "George S et al. European journal of cancer (Oxford, England : 1990). 2009 Jul;45(11)1959-68.", 
                "title": "Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.", 
                "volume": "45"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 301, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877737000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000380152", 
                    "curatedRefSeq": "NM_000059.3", 
                    "entrezGeneId": 675, 
                    "geneAliases": [
                        "FANCD1", 
                        "BROVCA2", 
                        "XRCC11", 
                        "FAD", 
                        "FAD1", 
                        "BRCC2", 
                        "GLM3", 
                        "FACD", 
                        "FANCD", 
                        "PNCA2"
                    ], 
                    "hugoSymbol": "BRCA2", 
                    "name": "BRCA2, DNA repair associated", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Mirza MR et al", 
                "elocationId": "", 
                "issue": "22", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2154-2164", 
                "pmid": "27717299", 
                "pubDate": "2016 Dec 1", 
                "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.", 
                "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.", 
                "volume": "375"
            }, 
            {
                "abstract": null, 
                "authors": "Schram AM et al", 
                "elocationId": "", 
                "issue": "8", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "801", 
                "pmid": "28229583", 
                "pubDate": "2017 Feb 23", 
                "reference": "Schram AM et al. The New England journal of medicine. 2017 Feb 23;376(8)801.", 
                "title": "Niraparib in Recurrent Ovarian Cancer.", 
                "volume": "376"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000380152", 
            "curatedRefSeq": "NM_000059.3", 
            "entrezGeneId": 675, 
            "geneAliases": [
                "FANCD1", 
                "BROVCA2", 
                "XRCC11", 
                "FAD", 
                "FAD1", 
                "BRCC2", 
                "GLM3", 
                "FACD", 
                "FANCD", 
                "PNCA2"
            ], 
            "hugoSymbol": "BRCA2", 
            "name": "BRCA2, DNA repair associated", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 7213, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493245593000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Niraparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy irrespective of BRCA1/2 mutant status"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Niraparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "T670I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "T670I", 
                "proteinEnd": 670, 
                "proteinStart": 670, 
                "refResidues": "T", 
                "variantResidues": "I"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)61857-1", 
                "issue": "9863", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "295-302", 
                "pmid": "23177515", 
                "pubDate": "2013 Jan 26", 
                "reference": "Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.", 
                "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.", 
                "volume": "381"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 302, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877741000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Regorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "A763_Y764insFQEA", 
                "consequence": {
                    "description": "An inframe non synonymous variant that inserts bases into in the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_insertion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "A763_Y764insFQEA", 
                "proteinEnd": 764, 
                "proteinStart": 763, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Voon PJ et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-13-0192", 
                "issue": "11", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "2614-5", 
                "pmid": "23969006", 
                "pubDate": "2013 Nov", 
                "reference": "Voon PJ et al. Molecular cancer therapeutics. 2013 Nov;12(11)2614-5.", 
                "title": "EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter.", 
                "volume": "12"
            }, 
            {
                "abstract": null, 
                "authors": "Kris MG et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2149-58", 
                "pmid": "14570950", 
                "pubDate": "2003 Oct 22", 
                "reference": "Kris MG et al. JAMA. 2003 Oct 22;290(16)2149-58.", 
                "title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.", 
                "volume": "290"
            }, 
            {
                "abstract": null, 
                "authors": "Li D et al", 
                "elocationId": "doi: 10.1038/onc.2008.109", 
                "issue": "34", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "4702-11", 
                "pmid": "18408761", 
                "pubDate": "2008 Aug 7", 
                "reference": "Li D et al. Oncogene. 2008 Aug 7;27(34)4702-11.", 
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Perez-Soler R", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "S20-3", 
                "pmid": "15638953", 
                "pubDate": "2004 Dec", 
                "reference": "Perez-Soler R. Clinical lung cancer. 2004 Dec;6 Suppl 1()S20-3.", 
                "title": "Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": null, 
                "authors": "Yasuda H et al", 
                "elocationId": "doi: 10.1126/scitranslmed.3007205", 
                "issue": "216", 
                "journal": "Science translational medicine", 
                "link": null, 
                "pages": "216ra177", 
                "pmid": "24353160", 
                "pubDate": "2013 Dec 18", 
                "reference": "Yasuda H et al. Science translational medicine. 2013 Dec 18;5(216)216ra177.", 
                "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.", 
                "volume": "5"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12214, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V654A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V654A", 
                "proteinEnd": 654, 
                "proteinStart": 654, 
                "refResidues": "V", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "9544", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1329-38", 
                "pmid": "17046465", 
                "pubDate": "2006 Oct 14", 
                "reference": "Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.", 
                "title": "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.", 
                "volume": "368"
            }, 
            {
                "abstract": null, 
                "authors": "Reichardt P et al", 
                "elocationId": "doi: 10.1002/cncr.29220", 
                "issue": "9", 
                "journal": "Cancer", 
                "link": null, 
                "pages": "1405-13", 
                "pmid": "25641662", 
                "pubDate": "2015 May 1", 
                "reference": "Reichardt P et al. Cancer. 2015 May 1;121(9)1405-13.", 
                "title": "Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.", 
                "volume": "121"
            }, 
            {
                "abstract": null, 
                "authors": "George S et al", 
                "elocationId": "doi: 10.1016/j.ejca.2009.02.011", 
                "issue": "11", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1959-68", 
                "pmid": "19282169", 
                "pubDate": "2009 Jul", 
                "reference": "George S et al. European journal of cancer (Oxford, England : 1990). 2009 Jul;45(11)1959-68.", 
                "title": "Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.", 
                "volume": "45"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 312, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877785000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V654A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V654A", 
                "proteinEnd": 654, 
                "proteinStart": 654, 
                "refResidues": "V", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)61857-1", 
                "issue": "9863", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "295-302", 
                "pmid": "23177515", 
                "pubDate": "2013 Jan 26", 
                "reference": "Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.", 
                "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.", 
                "volume": "381"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 313, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877787000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Regorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "EGFR-KDD Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "EGFR-KDD Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kris MG et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2149-58", 
                "pmid": "14570950", 
                "pubDate": "2003 Oct 22", 
                "reference": "Kris MG et al. JAMA. 2003 Oct 22;290(16)2149-58.", 
                "title": "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.", 
                "volume": "290"
            }, 
            {
                "abstract": null, 
                "authors": "Li D et al", 
                "elocationId": "doi: 10.1038/onc.2008.109", 
                "issue": "34", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "4702-11", 
                "pmid": "18408761", 
                "pubDate": "2008 Aug 7", 
                "reference": "Li D et al. Oncogene. 2008 Aug 7;27(34)4702-11.", 
                "title": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Perez-Soler R", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "S20-3", 
                "pmid": "15638953", 
                "pubDate": "2004 Dec", 
                "reference": "Perez-Soler R. Clinical lung cancer. 2004 Dec;6 Suppl 1()S20-3.", 
                "title": "Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": null, 
                "authors": "Gallant JN et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0654", 
                "issue": "11", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "1155-63", 
                "pmid": "26286086", 
                "pubDate": "2015 Nov", 
                "reference": "Gallant JN et al. Cancer discovery. 2015 Nov;5(11)1155-63.", 
                "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.", 
                "volume": "5"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12218, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493405124000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Erlotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Afatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Gefitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Piccart-Gebhart MJ et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1659-72", 
                "pmid": "16236737", 
                "pubDate": "2005 Oct 20", 
                "reference": "Piccart-Gebhart MJ et al. The New England journal of medicine. 2005 Oct 20;353(16)1659-72.", 
                "title": "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.", 
                "volume": "353"
            }, 
            {
                "abstract": null, 
                "authors": "Romond EH et al", 
                "elocationId": "", 
                "issue": "16", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1673-84", 
                "pmid": "16236738", 
                "pubDate": "2005 Oct 20", 
                "reference": "Romond EH et al. The New England journal of medicine. 2005 Oct 20;353(16)1673-84.", 
                "title": "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.", 
                "volume": "353"
            }, 
            {
                "abstract": null, 
                "authors": "Goldhirsch A et al", 
                "elocationId": "doi: 10.1016/S0140-6736(13)61094-6", 
                "issue": "9897", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1021-8", 
                "pmid": "23871490", 
                "pubDate": "2013 Sep 21", 
                "reference": "Goldhirsch A et al. Lancet (London, England). 2013 Sep 21;382(9897)1021-8.", 
                "title": "2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.", 
                "volume": "382"
            }, 
            {
                "abstract": null, 
                "authors": "Slamon DJ et al", 
                "elocationId": "", 
                "issue": "11", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "783-92", 
                "pmid": "11248153", 
                "pubDate": "2001 Mar 15", 
                "reference": "Slamon DJ et al. The New England journal of medicine. 2001 Mar 15;344(11)783-92.", 
                "title": "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.", 
                "volume": "344"
            }, 
            {
                "abstract": null, 
                "authors": "Perez EA et al", 
                "elocationId": "doi: 10.1200/JCO.2011.35.0868", 
                "issue": "25", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3366-73", 
                "pmid": "21768458", 
                "pubDate": "2011 Sep 1", 
                "reference": "Perez EA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Sep 1;29(25)3366-73.", 
                "title": "Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.", 
                "volume": "29"
            }, 
            {
                "abstract": null, 
                "authors": "Cobleigh MA et al", 
                "elocationId": "", 
                "issue": "9", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2639-48", 
                "pmid": "10561337", 
                "pubDate": "1999 Sep", 
                "reference": "Cobleigh MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Sep;17(9)2639-48.", 
                "title": "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 573, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492622665000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Trastuzumab is FDA-approved for (1) Adjuvant treatment of ERBB2-overexpressing, node positive or node negative (ER/PR negative or with one high risk feature) breast cancer, either as: (a) monotherapy following anthracycline therapy (b) in combination with docetaxel and carboplatin or (c) as a part of the doxorubicin, cyclophosphamide regimen with either paclitaxel or docetaxel. (2) ERBB2-overexpressing metastatic breast cancer, administered in combination with paclitaxel as first-line metastatic treatment or as monotherapy in patients whose metastatic disease was previously treated with at least one chemotherapy regimen."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trastuzumab", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Junttila TT et al", 
                "elocationId": "doi: 10.1007/s10549-010-1090-x", 
                "issue": "2", 
                "journal": "Breast cancer research and treatment", 
                "link": null, 
                "pages": "347-56", 
                "pmid": "20730488", 
                "pubDate": "2011 Jul", 
                "reference": "Junttila TT et al. Breast cancer research and treatment. 2011 Jul;128(2)347-56.", 
                "title": "Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.", 
                "volume": "128"
            }, 
            {
                "abstract": null, 
                "authors": "Verma S et al", 
                "elocationId": "doi: 10.1056/NEJMoa1209124", 
                "issue": "19", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1783-91", 
                "pmid": "23020162", 
                "pubDate": "2012 Nov 8", 
                "reference": "Verma S et al. The New England journal of medicine. 2012 Nov 8;367(19)1783-91.", 
                "title": "Trastuzumab emtansine for HER2-positive advanced breast cancer.", 
                "volume": "367"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 574, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492622665000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Ado-Trastuzumab Emtansine is FDA-approved as single agent treatment of ERBB2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination, and have either received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Ado-Trastuzumab Emtansine", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bilancia D et al", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", 
                "link": null, 
                "pages": "vi26-30", 
                "pmid": "17591827", 
                "pubDate": "2007 Jun", 
                "reference": "Bilancia D et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Jun;18 Suppl 6()vi26-30.", 
                "title": "Lapatinib in breast cancer.", 
                "volume": "18 Suppl 6"
            }, 
            {
                "abstract": null, 
                "authors": "Konecny GE et al", 
                "elocationId": "", 
                "issue": "3", 
                "journal": "Cancer research", 
                "link": null, 
                "pages": "1630-9", 
                "pmid": "16452222", 
                "pubDate": "2006 Feb 1", 
                "reference": "Konecny GE et al. Cancer research. 2006 Feb 1;66(3)1630-9.", 
                "title": "Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.", 
                "volume": "66"
            }, 
            {
                "abstract": null, 
                "authors": "Geyer CE et al", 
                "elocationId": "", 
                "issue": "26", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2733-43", 
                "pmid": "17192538", 
                "pubDate": "2006 Dec 28", 
                "reference": "Geyer CE et al. The New England journal of medicine. 2006 Dec 28;355(26)2733-43.", 
                "title": "Lapatinib plus capecitabine for HER2-positive advanced breast cancer.", 
                "volume": "355"
            }, 
            {
                "abstract": null, 
                "authors": "Johnston S et al", 
                "elocationId": "doi: 10.1200/JCO.2009.23.3734", 
                "issue": "33", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "5538-46", 
                "pmid": "19786658", 
                "pubDate": "2009 Nov 20", 
                "reference": "Johnston S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Nov 20;27(33)5538-46.", 
                "title": "Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.", 
                "volume": "27"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 575, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492622665000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Lapatinib is FDA-approved (1) in combination with capecitabine for advanced or metastatic ERBB2-overexpressing breast cancer in patients who have received prior therapy including an anthracycline, a taxane and trastuzumab, (2) as a combination therapy with letrozole for postmenopausal women with hormone receptor positive, metastatic breast cancer that overexpressed the HER2 receptor and for whom hormonal therapy is approved."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Lapatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Baselga J et al", 
                "elocationId": "doi: 10.1056/NEJMoa1113216", 
                "issue": "2", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "109-19", 
                "pmid": "22149875", 
                "pubDate": "2012 Jan 12", 
                "reference": "Baselga J et al. The New England journal of medicine. 2012 Jan 12;366(2)109-19.", 
                "title": "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.", 
                "volume": "366"
            }, 
            {
                "abstract": null, 
                "authors": "Gianni L et al", 
                "elocationId": "doi: 10.1016/S1470-2045(11)70336-9", 
                "issue": "1", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "25-32", 
                "pmid": "22153890", 
                "pubDate": "2012 Jan", 
                "reference": "Gianni L et al. The Lancet. Oncology. 2012 Jan;13(1)25-32.", 
                "title": "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.", 
                "volume": "13"
            }, 
            {
                "abstract": null, 
                "authors": "Swain SM et al", 
                "elocationId": "doi: 10.1016/S1470-2045(13)70130-X", 
                "issue": "6", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "461-71", 
                "pmid": "23602601", 
                "pubDate": "2013 May", 
                "reference": "Swain SM et al. The Lancet. Oncology. 2013 May;14(6)461-71.", 
                "title": "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.", 
                "volume": "14"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 576, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1516665861000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Pertuzumab in combination with trastuzumab and docetaxel is FDA-approved for (1) ERBB2-positive metastatic breast cancer in patients not previously treated with anti-ERBB2 therapy or chemotherapy for metastatic disease, (2) neoadjuvant treatment of ERBB2-positive, locally advanced, inflammatory, or early stage breast cancer."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trastuzumab", 
                        "priority": 2, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Pertuzumab", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Xia W et al", 
                "elocationId": "", 
                "issue": "41", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "6213-21", 
                "pmid": "16091755", 
                "pubDate": "2005 Sep 15", 
                "reference": "Xia W et al. Oncogene. 2005 Sep 15;24(41)6213-21.", 
                "title": "Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.", 
                "volume": "24"
            }, 
            {
                "abstract": null, 
                "authors": "Scaltriti M et al", 
                "elocationId": "doi: 10.1038/onc.2008.432", 
                "issue": "6", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "803-14", 
                "pmid": "19060928", 
                "pubDate": "2009 Feb 12", 
                "reference": "Scaltriti M et al. Oncogene. 2009 Feb 12;28(6)803-14.", 
                "title": "Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.", 
                "volume": "28"
            }, 
            {
                "abstract": null, 
                "authors": "Baselga J et al", 
                "elocationId": "doi: 10.1016/S0140-6736(11)61847-3", 
                "issue": "9816", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "633-40", 
                "pmid": "22257673", 
                "pubDate": "2012 Feb 18", 
                "reference": "Baselga J et al. Lancet (London, England). 2012 Feb 18;379(9816)633-40.", 
                "title": "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.", 
                "volume": "379"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 577, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492622665000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trastuzumab", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Lapatinib", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 5
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bang YJ et al", 
                "elocationId": "doi: 10.1016/S0140-6736(10)61121-X", 
                "issue": "9742", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "687-97", 
                "pmid": "20728210", 
                "pubDate": "2010 Aug 28", 
                "reference": "Bang YJ et al. Lancet (London, England). 2010 Aug 28;376(9742)687-97.", 
                "title": "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.", 
                "volume": "376"
            }
        ], 
        "cancerType": "Esophagogastric Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 579, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492622665000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Esophagogastric Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Trastuzumab combined with cisplatin and capecitabine or 5-fluorouracil is FDA-approved for ERBB2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma in patients not previously treated for metastatic disease."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trastuzumab", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000389048", 
                    "curatedRefSeq": "NM_004304.4", 
                    "entrezGeneId": 238, 
                    "geneAliases": [
                        "NBLST3", 
                        "CD246"
                    ], 
                    "hugoSymbol": "ALK", 
                    "name": "anaplastic lymphoma receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Shaw AT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1214886", 
                "issue": "25", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2385-94", 
                "pmid": "23724913", 
                "pubDate": "2013 Jun 20", 
                "reference": "Shaw AT et al. The New England journal of medicine. 2013 Jun 20;368(25)2385-94.", 
                "title": "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.", 
                "volume": "368"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000389048", 
            "curatedRefSeq": "NM_004304.4", 
            "entrezGeneId": 238, 
            "geneAliases": [
                "NBLST3", 
                "CD246"
            ], 
            "hugoSymbol": "ALK", 
            "name": "anaplastic lymphoma receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9933, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493408984000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Crizotinib is FDA approved for the treatment of ALK fusion-positive metastatic non-small celll lung cancer"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Crizotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000357654", 
                    "curatedRefSeq": "NM_007294.3", 
                    "entrezGeneId": 672, 
                    "geneAliases": [
                        "RNF53", 
                        "IRIS", 
                        "BRCAI", 
                        "PNCA4", 
                        "PSCP", 
                        "BROVCA1", 
                        "BRCC1", 
                        "FANCS", 
                        "PPP1R53"
                    ], 
                    "hugoSymbol": "BRCA1", 
                    "name": "BRCA1, DNA repair associated", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "McNeish, I. et al. Abstract# 5508, ASCO 2015", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/150121-156", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Swisher EM et al", 
                "elocationId": "doi: 10.1016/S1470-2045(16)30559-9", 
                "issue": "1", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "75-87", 
                "pmid": "27908594", 
                "pubDate": "2017 Jan", 
                "reference": "Swisher EM et al. The Lancet. Oncology. 2017 Jan;18(1)75-87.", 
                "title": "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.", 
                "volume": "18"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000357654", 
            "curatedRefSeq": "NM_007294.3", 
            "entrezGeneId": 672, 
            "geneAliases": [
                "RNF53", 
                "IRIS", 
                "BRCAI", 
                "PNCA4", 
                "PSCP", 
                "BROVCA1", 
                "BRCC1", 
                "FANCS", 
                "PPP1R53"
            ], 
            "hugoSymbol": "BRCA1", 
            "name": "BRCA1, DNA repair associated", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 6350, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493245429000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Rucaparib is FDA-approved for patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Rucaparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000389048", 
                    "curatedRefSeq": "NM_004304.4", 
                    "entrezGeneId": 238, 
                    "geneAliases": [
                        "NBLST3", 
                        "CD246"
                    ], 
                    "hugoSymbol": "ALK", 
                    "name": "anaplastic lymphoma receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kim DW et al", 
                "elocationId": "doi: 10.1016/S1470-2045(15)00614-2", 
                "issue": "4", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "452-63", 
                "pmid": "26973324", 
                "pubDate": "2016 Apr", 
                "reference": "Kim DW et al. The Lancet. Oncology. 2016 Apr;17(4)452-63.", 
                "title": "Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.", 
                "volume": "17"
            }, 
            {
                "abstract": null, 
                "authors": "Shaw AT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1311107", 
                "issue": "13", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1189-97", 
                "pmid": "24670165", 
                "pubDate": "2014 Mar 27", 
                "reference": "Shaw AT et al. The New England journal of medicine. 2014 Mar 27;370(13)1189-97.", 
                "title": "Ceritinib in ALK-rearranged non-small-cell lung cancer.", 
                "volume": "370"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000389048", 
            "curatedRefSeq": "NM_004304.4", 
            "entrezGeneId": 238, 
            "geneAliases": [
                "NBLST3", 
                "CD246"
            ], 
            "hugoSymbol": "ALK", 
            "name": "anaplastic lymphoma receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9934, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1515008884000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Creritinib is FDA approved for the treatment of ALK-fusion positive metastatic non-small cell lung cancer with disease progression on or intolerance to crizotinib."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Ceritinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Verweij J et al", 
                "elocationId": "", 
                "issue": "9440", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1127-34", 
                "pmid": "15451219", 
                "pubDate": "2004 Sep 25-Oct 1", 
                "reference": "Verweij J et al. Lancet (London, England). 2004 Sep 25-Oct 1;364(9440)1127-34.", 
                "title": "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.", 
                "volume": "364"
            }, 
            {
                "abstract": null, 
                "authors": "Zalcberg JR et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1751-7", 
                "pmid": "16098458", 
                "pubDate": "2005 Aug", 
                "reference": "Zalcberg JR et al. European journal of cancer (Oxford, England : 1990). 2005 Aug;41(12)1751-7.", 
                "title": "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.", 
                "volume": "41"
            }, 
            {
                "abstract": "von Mehren et al. Abstract# 10016, ASCO 2011", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/82574-102", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Blanke CD et al", 
                "elocationId": "doi: 10.1200/JCO.2007.13.4403", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "620-5", 
                "pmid": "18235121", 
                "pubDate": "2008 Feb 1", 
                "reference": "Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)620-5.", 
                "title": "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "472-80", 
                "pmid": "12181401", 
                "pubDate": "2002 Aug 15", 
                "reference": "Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.", 
                "title": "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.", 
                "volume": "347"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 335, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508518665000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    " (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.", 
                    "Imatinib is FDA-approved for the treatment of (1) patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000357654", 
                    "curatedRefSeq": "NM_007294.3", 
                    "entrezGeneId": 672, 
                    "geneAliases": [
                        "RNF53", 
                        "IRIS", 
                        "BRCAI", 
                        "PNCA4", 
                        "PSCP", 
                        "BROVCA1", 
                        "BRCC1", 
                        "FANCS", 
                        "PPP1R53"
                    ], 
                    "hugoSymbol": "BRCA1", 
                    "name": "BRCA1, DNA repair associated", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Mirza MR et al", 
                "elocationId": "", 
                "issue": "22", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2154-2164", 
                "pmid": "27717299", 
                "pubDate": "2016 Dec 1", 
                "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.", 
                "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.", 
                "volume": "375"
            }, 
            {
                "abstract": null, 
                "authors": "Schram AM et al", 
                "elocationId": "", 
                "issue": "8", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "801", 
                "pmid": "28229583", 
                "pubDate": "2017 Feb 23", 
                "reference": "Schram AM et al. The New England journal of medicine. 2017 Feb 23;376(8)801.", 
                "title": "Niraparib in Recurrent Ovarian Cancer.", 
                "volume": "376"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000357654", 
            "curatedRefSeq": "NM_007294.3", 
            "entrezGeneId": 672, 
            "geneAliases": [
                "RNF53", 
                "IRIS", 
                "BRCAI", 
                "PNCA4", 
                "PSCP", 
                "BROVCA1", 
                "BRCC1", 
                "FANCS", 
                "PPP1R53"
            ], 
            "hugoSymbol": "BRCA1", 
            "name": "BRCA1, DNA repair associated", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 6351, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493245429000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Niraparib is FDA-approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy irrespective of BRCA1/2 mutant status"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Niraparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000389048", 
                    "curatedRefSeq": "NM_004304.4", 
                    "entrezGeneId": 238, 
                    "geneAliases": [
                        "NBLST3", 
                        "CD246"
                    ], 
                    "hugoSymbol": "ALK", 
                    "name": "anaplastic lymphoma receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Ou SH et al", 
                "elocationId": "doi: 10.1200/JCO.2015.63.9443", 
                "issue": "7", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "661-8", 
                "pmid": "26598747", 
                "pubDate": "2016 Mar 1", 
                "reference": "Ou SH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)661-8.", 
                "title": "Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.", 
                "volume": "34"
            }, 
            {
                "abstract": null, 
                "authors": "Shaw AT et al", 
                "elocationId": "doi: 10.1016/S1470-2045(15)00488-X", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "234-242", 
                "pmid": "26708155", 
                "pubDate": "2016 Feb", 
                "reference": "Shaw AT et al. The Lancet. Oncology. 2016 Feb;17(2)234-242.", 
                "title": "Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000389048", 
            "curatedRefSeq": "NM_004304.4", 
            "entrezGeneId": 238, 
            "geneAliases": [
                "NBLST3", 
                "CD246"
            ], 
            "hugoSymbol": "ALK", 
            "name": "anaplastic lymphoma receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9935, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493408984000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Alectinib is FDA approved for the treatment of patients with metastatic ALK-positive non-small cell lung cancer who have failed crizotinib therapy. Patients who are intolerant of crizotinib and also eligible for treatment with Alectinib."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Alectinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "9544", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1329-38", 
                "pmid": "17046465", 
                "pubDate": "2006 Oct 14", 
                "reference": "Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.", 
                "title": "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.", 
                "volume": "368"
            }, 
            {
                "abstract": null, 
                "authors": "Reichardt P et al", 
                "elocationId": "doi: 10.1002/cncr.29220", 
                "issue": "9", 
                "journal": "Cancer", 
                "link": null, 
                "pages": "1405-13", 
                "pmid": "25641662", 
                "pubDate": "2015 May 1", 
                "reference": "Reichardt P et al. Cancer. 2015 May 1;121(9)1405-13.", 
                "title": "Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.", 
                "volume": "121"
            }, 
            {
                "abstract": null, 
                "authors": "George S et al", 
                "elocationId": "doi: 10.1016/j.ejca.2009.02.011", 
                "issue": "11", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1959-68", 
                "pmid": "19282169", 
                "pubDate": "2009 Jul", 
                "reference": "George S et al. European journal of cancer (Oxford, England : 1990). 2009 Jul;45(11)1959-68.", 
                "title": "Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.", 
                "volume": "45"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 336, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508518888000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Sunitinib is FDA-approved for gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000389048", 
                    "curatedRefSeq": "NM_004304.4", 
                    "entrezGeneId": 238, 
                    "geneAliases": [
                        "NBLST3", 
                        "CD246"
                    ], 
                    "hugoSymbol": "ALK", 
                    "name": "anaplastic lymphoma receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Gettinger SN et al", 
                "elocationId": "doi: 10.1016/S1470-2045(16)30392-8", 
                "issue": "12", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "1683-1696", 
                "pmid": "27836716", 
                "pubDate": "2016 Dec", 
                "reference": "Gettinger SN et al. The Lancet. Oncology. 2016 Dec;17(12)1683-1696.", 
                "title": "Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.", 
                "volume": "17"
            }, 
            {
                "abstract": "Kim et al. Abstract# 9007, ASCO 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/165056-176", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Awad MM et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "Clinical advances in hematology &amp; oncology : H&amp;O", 
                "link": null, 
                "pages": "429-39", 
                "pmid": "25322323", 
                "pubDate": "2014 Jul", 
                "reference": "Awad MM et al. Clinical advances in hematology &amp; oncology : H&amp;O. 2014 Jul;12(7)429-39.", 
                "title": "ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.", 
                "volume": "12"
            }, 
            {
                "abstract": null, 
                "authors": "Katayama R et al", 
                "elocationId": "doi: 10.1073/pnas.1019559108", 
                "issue": "18", 
                "journal": "Proceedings of the National Academy of Sciences of the United States of America", 
                "link": null, 
                "pages": "7535-40", 
                "pmid": "21502504", 
                "pubDate": "2011 May 3", 
                "reference": "Katayama R et al. Proceedings of the National Academy of Sciences of the United States of America. 2011 May 3;108(18)7535-40.", 
                "title": "Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.", 
                "volume": "108"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000389048", 
            "curatedRefSeq": "NM_004304.4", 
            "entrezGeneId": 238, 
            "geneAliases": [
                "NBLST3", 
                "CD246"
            ], 
            "hugoSymbol": "ALK", 
            "name": "anaplastic lymphoma receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9936, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1499270736000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Brigatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)61857-1", 
                "issue": "9863", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "295-302", 
                "pmid": "23177515", 
                "pubDate": "2013 Jan 26", 
                "reference": "Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.", 
                "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.", 
                "volume": "381"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 337, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508518971000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Regorafenib is FDA-approved for patients with advanced, unresectable gastrointestinal stromal tumors (GIST) that no longer respond to imatinib and sunitinib."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Regorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000368508", 
                    "curatedRefSeq": "NM_002944.2", 
                    "entrezGeneId": 6098, 
                    "geneAliases": [
                        "MCF3", 
                        "ROS", 
                        "c-ros-1"
                    ], 
                    "hugoSymbol": "ROS1", 
                    "name": "ROS proto-oncogene 1, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Shaw AT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1406766", 
                "issue": "21", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1963-71", 
                "pmid": "25264305", 
                "pubDate": "2014 Nov 20", 
                "reference": "Shaw AT et al. The New England journal of medicine. 2014 Nov 20;371(21)1963-71.", 
                "title": "Crizotinib in ROS1-rearranged non-small-cell lung cancer.", 
                "volume": "371"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000368508", 
            "curatedRefSeq": "NM_002944.2", 
            "entrezGeneId": 6098, 
            "geneAliases": [
                "MCF3", 
                "ROS", 
                "c-ros-1"
            ], 
            "hugoSymbol": "ROS1", 
            "name": "ROS proto-oncogene 1, receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 17632, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1491850504000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Crizotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "FIP1L1-PDGFRA Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000257290", 
                    "curatedRefSeq": "NM_006206.4", 
                    "entrezGeneId": 5156, 
                    "geneAliases": [
                        "PDGFR2", 
                        "RHEPDGFRA", 
                        "GAS9", 
                        "PDGFR-2", 
                        "CD140A"
                    ], 
                    "hugoSymbol": "PDGFRA", 
                    "name": "platelet derived growth factor receptor alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "FIP1L1-PDGFRA Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Cools J et al", 
                "elocationId": "", 
                "issue": "5", 
                "journal": "Cancer cell", 
                "link": null, 
                "pages": "459-69", 
                "pmid": "12781364", 
                "pubDate": "2003 May", 
                "reference": "Cools J et al. Cancer cell. 2003 May;3(5)459-69.", 
                "title": "PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR-induced myeloproliferative disease.", 
                "volume": "3"
            }, 
            {
                "abstract": null, 
                "authors": "Heinrich MC et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-12-0625", 
                "issue": "16", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "4375-84", 
                "pmid": "22745105", 
                "pubDate": "2012 Aug 15", 
                "reference": "Heinrich MC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Aug 15;18(16)4375-84.", 
                "title": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.", 
                "volume": "18"
            }, 
            {
                "abstract": null, 
                "authors": "Cools J et al", 
                "elocationId": "", 
                "issue": "13", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1201-14", 
                "pmid": "12660384", 
                "pubDate": "2003 Mar 27", 
                "reference": "Cools J et al. The New England journal of medicine. 2003 Mar 27;348(13)1201-14.", 
                "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.", 
                "volume": "348"
            }, 
            {
                "abstract": null, 
                "authors": "Klion AD et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Blood", 
                "link": null, 
                "pages": "473-8", 
                "pmid": "14504092", 
                "pubDate": "2004 Jan 15", 
                "reference": "Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.", 
                "title": "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Elling C et al", 
                "elocationId": "doi: 10.1182/blood-2010-05-286757", 
                "issue": "10", 
                "journal": "Blood", 
                "link": null, 
                "pages": "2935-43", 
                "pmid": "21224473", 
                "pubDate": "2011 Mar 10", 
                "reference": "Elling C et al. Blood. 2011 Mar 10;117(10)2935-43.", 
                "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.", 
                "volume": "117"
            }, 
            {
                "abstract": null, 
                "authors": "Lierman E et al", 
                "elocationId": "doi: 10.1038/leu.2009.2", 
                "issue": "5", 
                "journal": "Leukemia", 
                "link": null, 
                "pages": "845-51", 
                "pmid": "19212337", 
                "pubDate": "2009 May", 
                "reference": "Lierman E et al. Leukemia. 2009 May;23(5)845-51.", 
                "title": "FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.", 
                "volume": "23"
            }, 
            {
                "abstract": null, 
                "authors": "Iqbal N et al", 
                "elocationId": "doi: 10.1155/2014/357027", 
                "issue": "", 
                "journal": "Chemotherapy research and practice", 
                "link": null, 
                "pages": "357027", 
                "pmid": "24963404", 
                "pubDate": "2014", 
                "reference": "Iqbal N et al. Chemotherapy research and practice. 2014;2014()357027.", 
                "title": "Imatinib: a breakthrough of targeted therapy in cancer.", 
                "volume": "2014"
            }, 
            {
                "abstract": null, 
                "authors": "von Bubnoff N et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "Blood", 
                "link": null, 
                "pages": "4970-1; author reply 4972", 
                "pmid": "16754777", 
                "pubDate": "2006 Jun 15", 
                "reference": "von Bubnoff N et al. Blood. 2006 Jun 15;107(12)4970-1; author reply 4972.", 
                "title": "The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).", 
                "volume": "107"
            }, 
            {
                "abstract": null, 
                "authors": "Vanden Bempt M et al", 
                "elocationId": "doi: 10.1038/leu.2016.62", 
                "issue": "9", 
                "journal": "Leukemia", 
                "link": null, 
                "pages": "1913-6", 
                "pmid": "27021554", 
                "pubDate": "2016 Sep", 
                "reference": "Vanden Bempt M et al. Leukemia. 2016 Sep;30(9)1913-6.", 
                "title": "Generation of the Fip1l1-Pdgfra fusion gene using CRISPR/Cas genome editing.", 
                "volume": "30"
            }, 
            {
                "abstract": null, 
                "authors": "Sadovnik I et al", 
                "elocationId": "doi: 10.1016/j.exphem.2013.12.007", 
                "issue": "4", 
                "journal": "Experimental hematology", 
                "link": null, 
                "pages": "282-293.e4", 
                "pmid": "24407160", 
                "pubDate": "2014 Apr", 
                "reference": "Sadovnik I et al. Experimental hematology. 2014 Apr;42(4)282-293.e4.", 
                "title": "Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.", 
                "volume": "42"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000257290", 
            "curatedRefSeq": "NM_006206.4", 
            "entrezGeneId": 5156, 
            "geneAliases": [
                "PDGFR2", 
                "RHEPDGFRA", 
                "GAS9", 
                "PDGFR-2", 
                "CD140A"
            ], 
            "hugoSymbol": "PDGFRA", 
            "name": "platelet derived growth factor receptor alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 15329, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493063804000, 
        "levelOfEvidence": "LEVEL_1", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Imatinib is FDA-approved for the treatment of patients with hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL) harboring the FIP1L1- PDGFRA fusion."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "C788_N828mut", 
                "consequence": {
                    "description": "any variant", 
                    "isGenerallyTruncating": false, 
                    "term": "any"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 17 mutations", 
                "proteinEnd": 828, 
                "proteinStart": 788, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Verweij J et al", 
                "elocationId": "", 
                "issue": "9440", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1127-34", 
                "pmid": "15451219", 
                "pubDate": "2004 Sep 25-Oct 1", 
                "reference": "Verweij J et al. Lancet (London, England). 2004 Sep 25-Oct 1;364(9440)1127-34.", 
                "title": "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.", 
                "volume": "364"
            }, 
            {
                "abstract": null, 
                "authors": "Zalcberg JR et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1751-7", 
                "pmid": "16098458", 
                "pubDate": "2005 Aug", 
                "reference": "Zalcberg JR et al. European journal of cancer (Oxford, England : 1990). 2005 Aug;41(12)1751-7.", 
                "title": "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.", 
                "volume": "41"
            }, 
            {
                "abstract": null, 
                "authors": "Hodi FS et al", 
                "elocationId": "doi: 10.1200/JCO.2012.47.7836", 
                "issue": "26", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3182-90", 
                "pmid": "23775962", 
                "pubDate": "2013 Sep 10", 
                "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.", 
                "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Carvajal RD et al", 
                "elocationId": "doi: 10.1001/jama.2011.746", 
                "issue": "22", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2327-34", 
                "pmid": "21642685", 
                "pubDate": "2011 Jun 8", 
                "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.", 
                "title": "KIT as a therapeutic target in metastatic melanoma.", 
                "volume": "305"
            }, 
            {
                "abstract": null, 
                "authors": "Blanke CD et al", 
                "elocationId": "doi: 10.1200/JCO.2007.13.4403", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "620-5", 
                "pmid": "18235121", 
                "pubDate": "2008 Feb 1", 
                "reference": "Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)620-5.", 
                "title": "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "472-80", 
                "pmid": "12181401", 
                "pubDate": "2002 Aug 15", 
                "reference": "Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.", 
                "title": "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.", 
                "volume": "347"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 293, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877706000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "C788_N828mut", 
                "consequence": {
                    "description": "any variant", 
                    "isGenerallyTruncating": false, 
                    "term": "any"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 17 mutations", 
                "proteinEnd": 828, 
                "proteinStart": 788, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Strbel P et al", 
                "elocationId": "doi: 10.1038/sj.bjc.6605740", 
                "issue": "2", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "196-200", 
                "pmid": "20571495", 
                "pubDate": "2010 Jul 13", 
                "reference": "Strbel P et al. British journal of cancer. 2010 Jul 13;103(2)196-200.", 
                "title": "Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Thomas A et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)71181-7", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "177-86", 
                "pmid": "25592632", 
                "pubDate": "2015 Feb", 
                "reference": "Thomas A et al. The Lancet. Oncology. 2015 Feb;16(2)177-86.", 
                "title": "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.", 
                "volume": "16"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 295, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877717000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "C788_N828mut", 
                "consequence": {
                    "description": "any variant", 
                    "isGenerallyTruncating": false, 
                    "term": "any"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 17 mutations", 
                "proteinEnd": 828, 
                "proteinStart": 788, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bisagni G et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3181a52e25", 
                "issue": "6", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "773-5", 
                "pmid": "19461405", 
                "pubDate": "2009 Jun", 
                "reference": "Bisagni G et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Jun;4(6)773-5.", 
                "title": "Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.", 
                "volume": "4"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 296, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877722000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000380152", 
                    "curatedRefSeq": "NM_000059.3", 
                    "entrezGeneId": 675, 
                    "geneAliases": [
                        "FANCD1", 
                        "BROVCA2", 
                        "XRCC11", 
                        "FAD", 
                        "FAD1", 
                        "BRCC2", 
                        "GLM3", 
                        "FACD", 
                        "FANCD", 
                        "PNCA2"
                    ], 
                    "hugoSymbol": "BRCA2", 
                    "name": "BRCA2, DNA repair associated", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Gelmon KA et al", 
                "elocationId": "doi: 10.1016/S1470-2045(11)70214-5", 
                "issue": "9", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "852-61", 
                "pmid": "21862407", 
                "pubDate": "2011 Sep", 
                "reference": "Gelmon KA et al. The Lancet. Oncology. 2011 Sep;12(9)852-61.", 
                "title": "Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.", 
                "volume": "12"
            }, 
            {
                "abstract": null, 
                "authors": "Audeh MW et al", 
                "elocationId": "doi: 10.1016/S0140-6736(10)60893-8", 
                "issue": "9737", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "245-51", 
                "pmid": "20609468", 
                "pubDate": "2010 Jul 24", 
                "reference": "Audeh MW et al. Lancet (London, England). 2010 Jul 24;376(9737)245-51.", 
                "title": "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.", 
                "volume": "376"
            }, 
            {
                "abstract": null, 
                "authors": "Kaufman B et al", 
                "elocationId": "doi: 10.1200/JCO.2014.56.2728", 
                "issue": "3", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "244-50", 
                "pmid": "25366685", 
                "pubDate": "2015 Jan 20", 
                "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.", 
                "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.", 
                "volume": "33"
            }, 
            {
                "abstract": null, 
                "authors": "Fong PC et al", 
                "elocationId": "doi: 10.1200/JCO.2009.26.9589", 
                "issue": "15", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2512-9", 
                "pmid": "20406929", 
                "pubDate": "2010 May 20", 
                "reference": "Fong PC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 May 20;28(15)2512-9.", 
                "title": "Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.", 
                "volume": "28"
            }, 
            {
                "abstract": null, 
                "authors": "Fong PC et al", 
                "elocationId": "doi: 10.1056/NEJMoa0900212", 
                "issue": "2", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "123-34", 
                "pmid": "19553641", 
                "pubDate": "2009 Jul 9", 
                "reference": "Fong PC et al. The New England journal of medicine. 2009 Jul 9;361(2)123-34.", 
                "title": "Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.", 
                "volume": "361"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000380152", 
            "curatedRefSeq": "NM_000059.3", 
            "entrezGeneId": 675, 
            "geneAliases": [
                "FANCD1", 
                "BROVCA2", 
                "XRCC11", 
                "FAD", 
                "FAD1", 
                "BRCC2", 
                "GLM3", 
                "FACD", 
                "FANCD", 
                "PNCA2"
            ], 
            "hugoSymbol": "BRCA2", 
            "name": "BRCA2, DNA repair associated", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 7211, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493245593000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Olaparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000298552", 
                    "curatedRefSeq": "NM_000368.4", 
                    "entrezGeneId": 7248, 
                    "geneAliases": [
                        "TSC", 
                        "LAM"
                    ], 
                    "hugoSymbol": "TSC1", 
                    "name": "tuberous sclerosis 1", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kwiatkowski DJ et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-15-2631", 
                "issue": "10", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "2445-2452", 
                "pmid": "26831717", 
                "pubDate": "2016 May 15", 
                "reference": "Kwiatkowski DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 May 15;22(10)2445-2452.", 
                "title": "Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.", 
                "volume": "22"
            }
        ], 
        "cancerType": "Renal Cell Carcinoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000298552", 
            "curatedRefSeq": "NM_000368.4", 
            "entrezGeneId": 7248, 
            "geneAliases": [
                "TSC", 
                "LAM"
            ], 
            "hugoSymbol": "TSC1", 
            "name": "tuberous sclerosis 1", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 8940, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1490395785000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Renal Cell Carcinoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Everolimus is FDA approved for adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Everolimus", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000298552", 
                    "curatedRefSeq": "NM_000368.4", 
                    "entrezGeneId": 7248, 
                    "geneAliases": [
                        "TSC", 
                        "LAM"
                    ], 
                    "hugoSymbol": "TSC1", 
                    "name": "tuberous sclerosis 1", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kingswood JC et al", 
                "elocationId": "doi: 10.1093/ndt/gfu013", 
                "issue": "6", 
                "journal": "Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association", 
                "link": null, 
                "pages": "1203-10", 
                "pmid": "24729041", 
                "pubDate": "2014 Jun", 
                "reference": "Kingswood JC et al. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2014 Jun;29(6)1203-10.", 
                "title": "The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.", 
                "volume": "29"
            }, 
            {
                "abstract": null, 
                "authors": "Tyburczy ME et al", 
                "elocationId": "doi: 10.1371/journal.pgen.1005637", 
                "issue": "11", 
                "journal": "PLoS genetics", 
                "link": null, 
                "pages": "e1005637", 
                "pmid": "26540169", 
                "pubDate": "2015 Nov", 
                "reference": "Tyburczy ME et al. PLoS genetics. 2015 Nov;11(11)e1005637.", 
                "title": "Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.", 
                "volume": "11"
            }, 
            {
                "abstract": null, 
                "authors": "Franz DN", 
                "elocationId": "doi: 10.2147/BTT.S25095", 
                "issue": "", 
                "journal": "Biologics : targets &amp; therapy", 
                "link": null, 
                "pages": "211-21", 
                "pmid": "24143074", 
                "pubDate": "2013", 
                "reference": "Franz DN. Biologics : targets &amp; therapy. 2013;7()211-21.", 
                "title": "Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.", 
                "volume": "7"
            }, 
            {
                "abstract": null, 
                "authors": "Ali M et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Acta neurologica Scandinavica", 
                "link": null, 
                "pages": "54-63", 
                "pmid": "15595939", 
                "pubDate": "2005 Jan", 
                "reference": "Ali M et al. Acta neurologica Scandinavica. 2005 Jan;111(1)54-63.", 
                "title": "Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian patients with tuberous sclerosis complex.", 
                "volume": "111"
            }, 
            {
                "abstract": null, 
                "authors": "Bissler JJ et al", 
                "elocationId": "", 
                "issue": "9869", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "817-24", 
                "pmid": "23312829", 
                "pubDate": "2013 Mar 9", 
                "reference": "Bissler JJ et al. Lancet (London, England). 2013 Mar 9;381(9869)817-24.", 
                "title": "Everolimus for angiomyolipoma associated with tuberous  sclerosis complex or sporadic lymphangioleiomyomatosis  (EXIST-2): a multicentre, randomised, double-blind,  placebo-controlled trial.", 
                "volume": "381"
            }, 
            {
                "abstract": null, 
                "authors": "Hung CC et al", 
                "elocationId": "", 
                "issue": "", 
                "journal": "BMC medical genetics", 
                "link": null, 
                "pages": "72", 
                "pmid": "16981987", 
                "pubDate": "2006 Sep 18", 
                "reference": "Hung CC et al. BMC medical genetics. 2006 Sep 18;7()72.", 
                "title": "Molecular and clinical analyses of 84 patients with tuberous sclerosis complex.", 
                "volume": "7"
            }, 
            {
                "abstract": null, 
                "authors": "Au KS et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Genetics in medicine : official journal of the American College of Medical Genetics", 
                "link": null, 
                "pages": "88-100", 
                "pmid": "17304050", 
                "pubDate": "2007 Feb", 
                "reference": "Au KS et al. Genetics in medicine : official journal of the American College of Medical Genetics. 2007 Feb;9(2)88-100.", 
                "title": "Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.", 
                "volume": "9"
            }, 
            {
                "abstract": null, 
                "authors": "Niida Y et al", 
                "elocationId": "", 
                "issue": "5", 
                "journal": "Human mutation", 
                "link": null, 
                "pages": "412-22", 
                "pmid": "10533067", 
                "pubDate": "1999", 
                "reference": "Niida Y et al. Human mutation. 1999;14(5)412-22.", 
                "title": "Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.", 
                "volume": "14"
            }, 
            {
                "abstract": null, 
                "authors": "Franz DN et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)61134-9", 
                "issue": "9861", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "125-32", 
                "pmid": "23158522", 
                "pubDate": "2013 Jan 12", 
                "reference": "Franz DN et al. Lancet (London, England). 2013 Jan 12;381(9861)125-32.", 
                "title": "Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.", 
                "volume": "381"
            }, 
            {
                "abstract": null, 
                "authors": "Krueger DA et al", 
                "elocationId": "doi: 10.1056/NEJMoa1001671", 
                "issue": "19", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1801-11", 
                "pmid": "21047224", 
                "pubDate": "2010 Nov 4", 
                "reference": "Krueger DA et al. The New England journal of medicine. 2010 Nov 4;363(19)1801-11.", 
                "title": "Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.", 
                "volume": "363"
            }
        ], 
        "cancerType": "CNS Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000298552", 
            "curatedRefSeq": "NM_000368.4", 
            "entrezGeneId": 7248, 
            "geneAliases": [
                "TSC", 
                "LAM"
            ], 
            "hugoSymbol": "TSC1", 
            "name": "tuberous sclerosis 1", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 8942, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492053792000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "CNS Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Everolimus is FDA-approved for the treatment of pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Everolimus", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000257290", 
                    "curatedRefSeq": "NM_006206.4", 
                    "entrezGeneId": 5156, 
                    "geneAliases": [
                        "PDGFR2", 
                        "RHEPDGFRA", 
                        "GAS9", 
                        "PDGFR-2", 
                        "CD140A"
                    ], 
                    "hugoSymbol": "PDGFRA", 
                    "name": "platelet derived growth factor receptor alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Iqbal N et al", 
                "elocationId": "doi: 10.1155/2014/357027", 
                "issue": "", 
                "journal": "Chemotherapy research and practice", 
                "link": null, 
                "pages": "357027", 
                "pmid": "24963404", 
                "pubDate": "2014", 
                "reference": "Iqbal N et al. Chemotherapy research and practice. 2014;2014()357027.", 
                "title": "Imatinib: a breakthrough of targeted therapy in cancer.", 
                "volume": "2014"
            }, 
            {
                "abstract": null, 
                "authors": "Corless CL et al", 
                "elocationId": "", 
                "issue": "23", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "5357-64", 
                "pmid": "15928335", 
                "pubDate": "2005 Aug 10", 
                "reference": "Corless CL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Aug 10;23(23)5357-64.", 
                "title": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.", 
                "volume": "23"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000257290", 
            "curatedRefSeq": "NM_006206.4", 
            "entrezGeneId": 5156, 
            "geneAliases": [
                "PDGFR2", 
                "RHEPDGFRA", 
                "GAS9", 
                "PDGFR-2", 
                "CD140A"
            ], 
            "hugoSymbol": "PDGFRA", 
            "name": "platelet derived growth factor receptor alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 15342, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    " (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.", 
                    "Imatinib is FDA approved for the treatment of: (1) patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "T670I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "T670I", 
                "proteinEnd": 670, 
                "proteinStart": 670, 
                "refResidues": "T", 
                "variantResidues": "I"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Verweij J et al", 
                "elocationId": "", 
                "issue": "9440", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1127-34", 
                "pmid": "15451219", 
                "pubDate": "2004 Sep 25-Oct 1", 
                "reference": "Verweij J et al. Lancet (London, England). 2004 Sep 25-Oct 1;364(9440)1127-34.", 
                "title": "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.", 
                "volume": "364"
            }, 
            {
                "abstract": null, 
                "authors": "Zalcberg JR et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1751-7", 
                "pmid": "16098458", 
                "pubDate": "2005 Aug", 
                "reference": "Zalcberg JR et al. European journal of cancer (Oxford, England : 1990). 2005 Aug;41(12)1751-7.", 
                "title": "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.", 
                "volume": "41"
            }, 
            {
                "abstract": null, 
                "authors": "Hodi FS et al", 
                "elocationId": "doi: 10.1200/JCO.2012.47.7836", 
                "issue": "26", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3182-90", 
                "pmid": "23775962", 
                "pubDate": "2013 Sep 10", 
                "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.", 
                "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Carvajal RD et al", 
                "elocationId": "doi: 10.1001/jama.2011.746", 
                "issue": "22", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2327-34", 
                "pmid": "21642685", 
                "pubDate": "2011 Jun 8", 
                "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.", 
                "title": "KIT as a therapeutic target in metastatic melanoma.", 
                "volume": "305"
            }, 
            {
                "abstract": null, 
                "authors": "Blanke CD et al", 
                "elocationId": "doi: 10.1200/JCO.2007.13.4403", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "620-5", 
                "pmid": "18235121", 
                "pubDate": "2008 Feb 1", 
                "reference": "Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)620-5.", 
                "title": "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "472-80", 
                "pmid": "12181401", 
                "pubDate": "2002 Aug 15", 
                "reference": "Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.", 
                "title": "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.", 
                "volume": "347"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 304, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877752000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000219476", 
                    "curatedRefSeq": "NM_000548.3", 
                    "entrezGeneId": 7249, 
                    "geneAliases": [
                        "PPP1R160", 
                        "TSC4", 
                        "LAM"
                    ], 
                    "hugoSymbol": "TSC2", 
                    "name": "tuberous sclerosis 2", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kingswood JC et al", 
                "elocationId": "doi: 10.1093/ndt/gfu013", 
                "issue": "6", 
                "journal": "Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association", 
                "link": null, 
                "pages": "1203-10", 
                "pmid": "24729041", 
                "pubDate": "2014 Jun", 
                "reference": "Kingswood JC et al. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2014 Jun;29(6)1203-10.", 
                "title": "The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.", 
                "volume": "29"
            }, 
            {
                "abstract": null, 
                "authors": "Tyburczy ME et al", 
                "elocationId": "doi: 10.1371/journal.pgen.1005637", 
                "issue": "11", 
                "journal": "PLoS genetics", 
                "link": null, 
                "pages": "e1005637", 
                "pmid": "26540169", 
                "pubDate": "2015 Nov", 
                "reference": "Tyburczy ME et al. PLoS genetics. 2015 Nov;11(11)e1005637.", 
                "title": "Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.", 
                "volume": "11"
            }, 
            {
                "abstract": null, 
                "authors": "Franz DN", 
                "elocationId": "doi: 10.2147/BTT.S25095", 
                "issue": "", 
                "journal": "Biologics : targets &amp; therapy", 
                "link": null, 
                "pages": "211-21", 
                "pmid": "24143074", 
                "pubDate": "2013", 
                "reference": "Franz DN. Biologics : targets &amp; therapy. 2013;7()211-21.", 
                "title": "Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.", 
                "volume": "7"
            }, 
            {
                "abstract": null, 
                "authors": "Ali M et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Acta neurologica Scandinavica", 
                "link": null, 
                "pages": "54-63", 
                "pmid": "15595939", 
                "pubDate": "2005 Jan", 
                "reference": "Ali M et al. Acta neurologica Scandinavica. 2005 Jan;111(1)54-63.", 
                "title": "Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian patients with tuberous sclerosis complex.", 
                "volume": "111"
            }, 
            {
                "abstract": null, 
                "authors": "Bissler JJ et al", 
                "elocationId": "", 
                "issue": "9869", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "817-24", 
                "pmid": "23312829", 
                "pubDate": "2013 Mar 9", 
                "reference": "Bissler JJ et al. Lancet (London, England). 2013 Mar 9;381(9869)817-24.", 
                "title": "Everolimus for angiomyolipoma associated with tuberous  sclerosis complex or sporadic lymphangioleiomyomatosis  (EXIST-2): a multicentre, randomised, double-blind,  placebo-controlled trial.", 
                "volume": "381"
            }, 
            {
                "abstract": null, 
                "authors": "Hung CC et al", 
                "elocationId": "", 
                "issue": "", 
                "journal": "BMC medical genetics", 
                "link": null, 
                "pages": "72", 
                "pmid": "16981987", 
                "pubDate": "2006 Sep 18", 
                "reference": "Hung CC et al. BMC medical genetics. 2006 Sep 18;7()72.", 
                "title": "Molecular and clinical analyses of 84 patients with tuberous sclerosis complex.", 
                "volume": "7"
            }, 
            {
                "abstract": null, 
                "authors": "Au KS et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Genetics in medicine : official journal of the American College of Medical Genetics", 
                "link": null, 
                "pages": "88-100", 
                "pmid": "17304050", 
                "pubDate": "2007 Feb", 
                "reference": "Au KS et al. Genetics in medicine : official journal of the American College of Medical Genetics. 2007 Feb;9(2)88-100.", 
                "title": "Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.", 
                "volume": "9"
            }, 
            {
                "abstract": null, 
                "authors": "Niida Y et al", 
                "elocationId": "", 
                "issue": "5", 
                "journal": "Human mutation", 
                "link": null, 
                "pages": "412-22", 
                "pmid": "10533067", 
                "pubDate": "1999", 
                "reference": "Niida Y et al. Human mutation. 1999;14(5)412-22.", 
                "title": "Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.", 
                "volume": "14"
            }, 
            {
                "abstract": null, 
                "authors": "Franz DN et al", 
                "elocationId": "doi: 10.1016/S0140-6736(12)61134-9", 
                "issue": "9861", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "125-32", 
                "pmid": "23158522", 
                "pubDate": "2013 Jan 12", 
                "reference": "Franz DN et al. Lancet (London, England). 2013 Jan 12;381(9861)125-32.", 
                "title": "Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.", 
                "volume": "381"
            }, 
            {
                "abstract": null, 
                "authors": "Krueger DA et al", 
                "elocationId": "doi: 10.1056/NEJMoa1001671", 
                "issue": "19", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1801-11", 
                "pmid": "21047224", 
                "pubDate": "2010 Nov 4", 
                "reference": "Krueger DA et al. The New England journal of medicine. 2010 Nov 4;363(19)1801-11.", 
                "title": "Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.", 
                "volume": "363"
            }
        ], 
        "cancerType": "CNS Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000219476", 
            "curatedRefSeq": "NM_000548.3", 
            "entrezGeneId": 7249, 
            "geneAliases": [
                "PPP1R160", 
                "TSC4", 
                "LAM"
            ], 
            "hugoSymbol": "TSC2", 
            "name": "tuberous sclerosis 2", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 18673, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492568645000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "CNS Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Everolimus is FDA-approved for the treatment of pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Everolimus", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "T670I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "T670I", 
                "proteinEnd": 670, 
                "proteinStart": 670, 
                "refResidues": "T", 
                "variantResidues": "I"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Strbel P et al", 
                "elocationId": "doi: 10.1038/sj.bjc.6605740", 
                "issue": "2", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "196-200", 
                "pmid": "20571495", 
                "pubDate": "2010 Jul 13", 
                "reference": "Strbel P et al. British journal of cancer. 2010 Jul 13;103(2)196-200.", 
                "title": "Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Thomas A et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)71181-7", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "177-86", 
                "pmid": "25592632", 
                "pubDate": "2015 Feb", 
                "reference": "Thomas A et al. The Lancet. Oncology. 2015 Feb;16(2)177-86.", 
                "title": "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.", 
                "volume": "16"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 306, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877764000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "T670I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "T670I", 
                "proteinEnd": 670, 
                "proteinStart": 670, 
                "refResidues": "T", 
                "variantResidues": "I"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bisagni G et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3181a52e25", 
                "issue": "6", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "773-5", 
                "pmid": "19461405", 
                "pubDate": "2009 Jun", 
                "reference": "Bisagni G et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Jun;4(6)773-5.", 
                "title": "Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.", 
                "volume": "4"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 307, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877770000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000257904", 
                    "curatedRefSeq": "NM_000075.3", 
                    "entrezGeneId": 1019, 
                    "geneAliases": [
                        "PSK-J3", 
                        "CMM3"
                    ], 
                    "hugoSymbol": "CDK4", 
                    "name": "cyclin dependent kinase 4", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Barretina J et al", 
                "elocationId": "doi: 10.1038/ng.619", 
                "issue": "8", 
                "journal": "Nature genetics", 
                "link": null, 
                "pages": "715-21", 
                "pmid": "20601955", 
                "pubDate": "2010 Aug", 
                "reference": "Barretina J et al. Nature genetics. 2010 Aug;42(8)715-21.", 
                "title": "Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.", 
                "volume": "42"
            }, 
            {
                "abstract": null, 
                "authors": "Schwartz GK et al", 
                "elocationId": "doi: 10.1038/bjc.2011.177", 
                "issue": "12", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "1862-8", 
                "pmid": "21610706", 
                "pubDate": "2011 Jun 7", 
                "reference": "Schwartz GK et al. British journal of cancer. 2011 Jun 7;104(12)1862-8.", 
                "title": "Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).", 
                "volume": "104"
            }, 
            {
                "abstract": null, 
                "authors": "Beaver JA et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-15-1185", 
                "issue": "21", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "4760-6", 
                "pmid": "26324739", 
                "pubDate": "2015 Nov 1", 
                "reference": "Beaver JA et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Nov 1;21(21)4760-6.", 
                "title": "FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.", 
                "volume": "21"
            }, 
            {
                "abstract": null, 
                "authors": "Dickson MA et al", 
                "elocationId": "doi: 10.1200/JCO.2012.46.5476", 
                "issue": "16", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2024-8", 
                "pmid": "23569312", 
                "pubDate": "2013 Jun 1", 
                "reference": "Dickson MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 1;31(16)2024-8.", 
                "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.", 
                "volume": "31"
            }
        ], 
        "cancerType": "Soft Tissue Sarcoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000257904", 
            "curatedRefSeq": "NM_000075.3", 
            "entrezGeneId": 1019, 
            "geneAliases": [
                "PSK-J3", 
                "CMM3"
            ], 
            "hugoSymbol": "CDK4", 
            "name": "cyclin dependent kinase 4", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9909, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492467562000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [
                "C3704"
            ], 
            "UMLS": [
                "C0205824"
            ], 
            "children": null, 
            "code": "DDLS", 
            "color": "LightYellow", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Soft Tissue Sarcoma"
            }, 
            "name": "Dedifferentiated Liposarcoma", 
            "parent": "LIPO", 
            "tissue": "Soft Tissue"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "DDLS", 
        "treatments": [
            {
                "approvedIndications": [
                    "Palbociclib is FDA-approved (1) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, (2) in combination with letrozole for the treatment of HR-positive, HER2-negative advanced breast cancer as initial endocrine based therapy in postmenopausal women."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Abemaciclib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [
                    "Palbociclib is FDA-approved (1) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, (2) in combination with letrozole for the treatment of HR-positive, HER2-negative advanced breast cancer as initial endocrine based therapy in postmenopausal women."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Palbociclib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000257904", 
                    "curatedRefSeq": "NM_000075.3", 
                    "entrezGeneId": 1019, 
                    "geneAliases": [
                        "PSK-J3", 
                        "CMM3"
                    ], 
                    "hugoSymbol": "CDK4", 
                    "name": "cyclin dependent kinase 4", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Barretina J et al", 
                "elocationId": "doi: 10.1038/ng.619", 
                "issue": "8", 
                "journal": "Nature genetics", 
                "link": null, 
                "pages": "715-21", 
                "pmid": "20601955", 
                "pubDate": "2010 Aug", 
                "reference": "Barretina J et al. Nature genetics. 2010 Aug;42(8)715-21.", 
                "title": "Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.", 
                "volume": "42"
            }, 
            {
                "abstract": null, 
                "authors": "Schwartz GK et al", 
                "elocationId": "doi: 10.1038/bjc.2011.177", 
                "issue": "12", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "1862-8", 
                "pmid": "21610706", 
                "pubDate": "2011 Jun 7", 
                "reference": "Schwartz GK et al. British journal of cancer. 2011 Jun 7;104(12)1862-8.", 
                "title": "Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).", 
                "volume": "104"
            }, 
            {
                "abstract": null, 
                "authors": "Beaver JA et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-15-1185", 
                "issue": "21", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "4760-6", 
                "pmid": "26324739", 
                "pubDate": "2015 Nov 1", 
                "reference": "Beaver JA et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Nov 1;21(21)4760-6.", 
                "title": "FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.", 
                "volume": "21"
            }, 
            {
                "abstract": null, 
                "authors": "Dickson MA et al", 
                "elocationId": "doi: 10.1200/JCO.2012.46.5476", 
                "issue": "16", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2024-8", 
                "pmid": "23569312", 
                "pubDate": "2013 Jun 1", 
                "reference": "Dickson MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 1;31(16)2024-8.", 
                "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.", 
                "volume": "31"
            }
        ], 
        "cancerType": "Soft Tissue Sarcoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000257904", 
            "curatedRefSeq": "NM_000075.3", 
            "entrezGeneId": 1019, 
            "geneAliases": [
                "PSK-J3", 
                "CMM3"
            ], 
            "hugoSymbol": "CDK4", 
            "name": "cyclin dependent kinase 4", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9911, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1492467562000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [
                "C4250"
            ], 
            "UMLS": [
                "C1370889"
            ], 
            "children": null, 
            "code": "WDLS", 
            "color": "LightYellow", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Soft Tissue Sarcoma"
            }, 
            "name": "Well-Differentiated Liposarcoma", 
            "parent": "LIPO", 
            "tissue": "Soft Tissue"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "WDLS", 
        "treatments": [
            {
                "approvedIndications": [
                    "Palbociclib is FDA-approved (1) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, (2) in combination with letrozole for the treatment of HR-positive, HER2-negative advanced breast cancer as initial endocrine based therapy in postmenopausal women."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Abemaciclib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [
                    "Palbociclib is FDA-approved (1) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, (2) in combination with letrozole for the treatment of HR-positive, HER2-negative advanced breast cancer as initial endocrine based therapy in postmenopausal women."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Palbociclib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V654A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V654A", 
                "proteinEnd": 654, 
                "proteinStart": 654, 
                "refResidues": "V", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Verweij J et al", 
                "elocationId": "", 
                "issue": "9440", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1127-34", 
                "pmid": "15451219", 
                "pubDate": "2004 Sep 25-Oct 1", 
                "reference": "Verweij J et al. Lancet (London, England). 2004 Sep 25-Oct 1;364(9440)1127-34.", 
                "title": "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.", 
                "volume": "364"
            }, 
            {
                "abstract": null, 
                "authors": "Zalcberg JR et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1751-7", 
                "pmid": "16098458", 
                "pubDate": "2005 Aug", 
                "reference": "Zalcberg JR et al. European journal of cancer (Oxford, England : 1990). 2005 Aug;41(12)1751-7.", 
                "title": "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.", 
                "volume": "41"
            }, 
            {
                "abstract": null, 
                "authors": "Hodi FS et al", 
                "elocationId": "doi: 10.1200/JCO.2012.47.7836", 
                "issue": "26", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3182-90", 
                "pmid": "23775962", 
                "pubDate": "2013 Sep 10", 
                "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.", 
                "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Carvajal RD et al", 
                "elocationId": "doi: 10.1001/jama.2011.746", 
                "issue": "22", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2327-34", 
                "pmid": "21642685", 
                "pubDate": "2011 Jun 8", 
                "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.", 
                "title": "KIT as a therapeutic target in metastatic melanoma.", 
                "volume": "305"
            }, 
            {
                "abstract": null, 
                "authors": "Blanke CD et al", 
                "elocationId": "doi: 10.1200/JCO.2007.13.4403", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "620-5", 
                "pmid": "18235121", 
                "pubDate": "2008 Feb 1", 
                "reference": "Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)620-5.", 
                "title": "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "472-80", 
                "pmid": "12181401", 
                "pubDate": "2002 Aug 15", 
                "reference": "Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.", 
                "title": "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.", 
                "volume": "347"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 315, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877796000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V654A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V654A", 
                "proteinEnd": 654, 
                "proteinStart": 654, 
                "refResidues": "V", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Strbel P et al", 
                "elocationId": "doi: 10.1038/sj.bjc.6605740", 
                "issue": "2", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "196-200", 
                "pmid": "20571495", 
                "pubDate": "2010 Jul 13", 
                "reference": "Strbel P et al. British journal of cancer. 2010 Jul 13;103(2)196-200.", 
                "title": "Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Thomas A et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)71181-7", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "177-86", 
                "pmid": "25592632", 
                "pubDate": "2015 Feb", 
                "reference": "Thomas A et al. The Lancet. Oncology. 2015 Feb;16(2)177-86.", 
                "title": "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.", 
                "volume": "16"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 317, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877802000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V654A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V654A", 
                "proteinEnd": 654, 
                "proteinStart": 654, 
                "refResidues": "V", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bisagni G et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3181a52e25", 
                "issue": "6", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "773-5", 
                "pmid": "19461405", 
                "pubDate": "2009 Jun", 
                "reference": "Bisagni G et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Jun;4(6)773-5.", 
                "title": "Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.", 
                "volume": "4"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 318, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877806000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D816H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816H", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "D816G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816G", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "D816Y", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816Y", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "Y"
            }, 
            {
                "alteration": "D816N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816N", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "D816E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816E", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "D816A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816A", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "A"
            }, 
            {
                "alteration": "D816F", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816F", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "F"
            }, 
            {
                "alteration": "D816V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816V", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "V"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Verweij J et al", 
                "elocationId": "", 
                "issue": "9440", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1127-34", 
                "pmid": "15451219", 
                "pubDate": "2004 Sep 25-Oct 1", 
                "reference": "Verweij J et al. Lancet (London, England). 2004 Sep 25-Oct 1;364(9440)1127-34.", 
                "title": "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.", 
                "volume": "364"
            }, 
            {
                "abstract": null, 
                "authors": "Zalcberg JR et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1751-7", 
                "pmid": "16098458", 
                "pubDate": "2005 Aug", 
                "reference": "Zalcberg JR et al. European journal of cancer (Oxford, England : 1990). 2005 Aug;41(12)1751-7.", 
                "title": "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.", 
                "volume": "41"
            }, 
            {
                "abstract": null, 
                "authors": "Hodi FS et al", 
                "elocationId": "doi: 10.1200/JCO.2012.47.7836", 
                "issue": "26", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3182-90", 
                "pmid": "23775962", 
                "pubDate": "2013 Sep 10", 
                "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.", 
                "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Carvajal RD et al", 
                "elocationId": "doi: 10.1001/jama.2011.746", 
                "issue": "22", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2327-34", 
                "pmid": "21642685", 
                "pubDate": "2011 Jun 8", 
                "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.", 
                "title": "KIT as a therapeutic target in metastatic melanoma.", 
                "volume": "305"
            }, 
            {
                "abstract": null, 
                "authors": "Blanke CD et al", 
                "elocationId": "doi: 10.1200/JCO.2007.13.4403", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "620-5", 
                "pmid": "18235121", 
                "pubDate": "2008 Feb 1", 
                "reference": "Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)620-5.", 
                "title": "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "472-80", 
                "pmid": "12181401", 
                "pubDate": "2002 Aug 15", 
                "reference": "Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.", 
                "title": "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.", 
                "volume": "347"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 323, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877932000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D816H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816H", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "D816G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816G", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "D816Y", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816Y", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "Y"
            }, 
            {
                "alteration": "D816N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816N", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "D816E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816E", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "D816A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816A", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "A"
            }, 
            {
                "alteration": "D816F", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816F", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "F"
            }, 
            {
                "alteration": "D816V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816V", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "V"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Strbel P et al", 
                "elocationId": "doi: 10.1038/sj.bjc.6605740", 
                "issue": "2", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "196-200", 
                "pmid": "20571495", 
                "pubDate": "2010 Jul 13", 
                "reference": "Strbel P et al. British journal of cancer. 2010 Jul 13;103(2)196-200.", 
                "title": "Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Thomas A et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)71181-7", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "177-86", 
                "pmid": "25592632", 
                "pubDate": "2015 Feb", 
                "reference": "Thomas A et al. The Lancet. Oncology. 2015 Feb;16(2)177-86.", 
                "title": "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.", 
                "volume": "16"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 325, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877906000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Peters S et al", 
                "elocationId": "doi: 10.1200/JCO.2012.47.6143", 
                "issue": "20", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "e341-4", 
                "pmid": "23733758", 
                "pubDate": "2013 Jul 10", 
                "reference": "Peters S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jul 10;31(20)e341-4.", 
                "title": "Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Gautschi O et al", 
                "elocationId": "doi: 10.1097/JTO.0000000000000625", 
                "issue": "10", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "1451-7", 
                "pmid": "26200454", 
                "pubDate": "2015 Oct", 
                "reference": "Gautschi O et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Oct;10(10)1451-7.", 
                "title": "Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.", 
                "volume": "10"
            }, 
            {
                "abstract": null, 
                "authors": "Myall NJ et al", 
                "elocationId": "doi: 10.1016/j.cllc.2015.12.001", 
                "issue": "2", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "e17-21", 
                "pmid": "26776917", 
                "pubDate": "2016 Mar", 
                "reference": "Myall NJ et al. Clinical lung cancer. 2016 Mar;17(2)e17-21.", 
                "title": "Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.", 
                "volume": "17"
            }, 
            {
                "abstract": null, 
                "authors": "Robinson SD et al", 
                "elocationId": "doi: 10.1016/j.lungcan.2014.05.009", 
                "issue": "2", 
                "journal": "Lung cancer (Amsterdam, Netherlands)", 
                "link": null, 
                "pages": "326-30", 
                "pmid": "24888229", 
                "pubDate": "2014 Aug", 
                "reference": "Robinson SD et al. Lung cancer (Amsterdam, Netherlands). 2014 Aug;85(2)326-30.", 
                "title": "BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.", 
                "volume": "85"
            }, 
            {
                "abstract": null, 
                "authors": "Schmid S et al", 
                "elocationId": "doi: 10.1016/j.lungcan.2014.11.008", 
                "issue": "1", 
                "journal": "Lung cancer (Amsterdam, Netherlands)", 
                "link": null, 
                "pages": "85-7", 
                "pmid": "25466451", 
                "pubDate": "2015 Jan", 
                "reference": "Schmid S et al. Lung cancer (Amsterdam, Netherlands). 2015 Jan;87(1)85-7.", 
                "title": "Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.", 
                "volume": "87"
            }, 
            {
                "abstract": null, 
                "authors": "Hyman DM et al", 
                "elocationId": "doi: 10.1056/NEJMoa1502309", 
                "issue": "8", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "726-36", 
                "pmid": "26287849", 
                "pubDate": "2015 Aug 20", 
                "reference": "Hyman DM et al. The New England journal of medicine. 2015 Aug 20;373(8)726-36.", 
                "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.", 
                "volume": "373"
            }, 
            {
                "abstract": null, 
                "authors": "Flaherty KT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1002011", 
                "issue": "9", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "809-19", 
                "pmid": "20818844", 
                "pubDate": "2010 Aug 26", 
                "reference": "Flaherty KT et al. The New England journal of medicine. 2010 Aug 26;363(9)809-19.", 
                "title": "Inhibition of mutated, activated BRAF in metastatic melanoma.", 
                "volume": "363"
            }, 
            {
                "abstract": null, 
                "authors": "Gautschi O et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3182629903", 
                "issue": "10", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "e23-4", 
                "pmid": "22743296", 
                "pubDate": "2012 Oct", 
                "reference": "Gautschi O et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Oct;7(10)e23-4.", 
                "title": "A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.", 
                "volume": "7"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4613, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493057315000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Vemurafenib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Vemurafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D816H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816H", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "D816G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816G", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "D816Y", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816Y", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "Y"
            }, 
            {
                "alteration": "D816N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816N", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "D816E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816E", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "D816A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816A", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "A"
            }, 
            {
                "alteration": "D816F", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816F", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "F"
            }, 
            {
                "alteration": "D816V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816V", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "V"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bisagni G et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3181a52e25", 
                "issue": "6", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "773-5", 
                "pmid": "19461405", 
                "pubDate": "2009 Jun", 
                "reference": "Bisagni G et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Jun;4(6)773-5.", 
                "title": "Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.", 
                "volume": "4"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 326, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877925000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000355710", 
                    "curatedRefSeq": "NM_020975.4", 
                    "entrezGeneId": 5979, 
                    "geneAliases": [
                        "MTC1", 
                        "CDHF12", 
                        "CDHR16", 
                        "MEN2A", 
                        "RET51", 
                        "HSCR1", 
                        "MEN2B", 
                        "PTC", 
                        "RET-ELE1"
                    ], 
                    "hugoSymbol": "RET", 
                    "name": "ret proto-oncogene", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-13-0035", 
                "issue": "6", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "630-5", 
                "pmid": "23533264", 
                "pubDate": "2013 Jun", 
                "reference": "Drilon A et al. Cancer discovery. 2013 Jun;3(6)630-5.", 
                "title": "Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.", 
                "volume": "3"
            }, 
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1016/S1470-2045(16)30562-9", 
                "issue": "12", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "1653-1660", 
                "pmid": "27825636", 
                "pubDate": "2016 Dec", 
                "reference": "Drilon A et al. The Lancet. Oncology. 2016 Dec;17(12)1653-1660.", 
                "title": "Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000355710", 
            "curatedRefSeq": "NM_020975.4", 
            "entrezGeneId": 5979, 
            "geneAliases": [
                "MTC1", 
                "CDHF12", 
                "CDHR16", 
                "MEN2A", 
                "RET51", 
                "HSCR1", 
                "MEN2B", 
                "PTC", 
                "RET-ELE1"
            ], 
            "hugoSymbol": "RET", 
            "name": "ret proto-oncogene", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1479, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1515459132000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Cabozantinib is FDA-approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cabozantinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "V600D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600D", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "V600M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600M", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "V600R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600R", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "V600G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600G", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "G"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Peters S et al", 
                "elocationId": "doi: 10.1200/JCO.2012.47.6143", 
                "issue": "20", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "e341-4", 
                "pmid": "23733758", 
                "pubDate": "2013 Jul 10", 
                "reference": "Peters S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jul 10;31(20)e341-4.", 
                "title": "Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Gautschi O et al", 
                "elocationId": "doi: 10.1097/JTO.0000000000000625", 
                "issue": "10", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "1451-7", 
                "pmid": "26200454", 
                "pubDate": "2015 Oct", 
                "reference": "Gautschi O et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Oct;10(10)1451-7.", 
                "title": "Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.", 
                "volume": "10"
            }, 
            {
                "abstract": null, 
                "authors": "Myall NJ et al", 
                "elocationId": "doi: 10.1016/j.cllc.2015.12.001", 
                "issue": "2", 
                "journal": "Clinical lung cancer", 
                "link": null, 
                "pages": "e17-21", 
                "pmid": "26776917", 
                "pubDate": "2016 Mar", 
                "reference": "Myall NJ et al. Clinical lung cancer. 2016 Mar;17(2)e17-21.", 
                "title": "Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.", 
                "volume": "17"
            }, 
            {
                "abstract": null, 
                "authors": "Robinson SD et al", 
                "elocationId": "doi: 10.1016/j.lungcan.2014.05.009", 
                "issue": "2", 
                "journal": "Lung cancer (Amsterdam, Netherlands)", 
                "link": null, 
                "pages": "326-30", 
                "pmid": "24888229", 
                "pubDate": "2014 Aug", 
                "reference": "Robinson SD et al. Lung cancer (Amsterdam, Netherlands). 2014 Aug;85(2)326-30.", 
                "title": "BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.", 
                "volume": "85"
            }, 
            {
                "abstract": null, 
                "authors": "Schmid S et al", 
                "elocationId": "doi: 10.1016/j.lungcan.2014.11.008", 
                "issue": "1", 
                "journal": "Lung cancer (Amsterdam, Netherlands)", 
                "link": null, 
                "pages": "85-7", 
                "pmid": "25466451", 
                "pubDate": "2015 Jan", 
                "reference": "Schmid S et al. Lung cancer (Amsterdam, Netherlands). 2015 Jan;87(1)85-7.", 
                "title": "Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.", 
                "volume": "87"
            }, 
            {
                "abstract": null, 
                "authors": "McGettigan S", 
                "elocationId": "", 
                "issue": "3", 
                "journal": "Journal of the advanced practitioner in oncology", 
                "link": null, 
                "pages": "211-5", 
                "pmid": "25089220", 
                "pubDate": "2014 May", 
                "reference": "McGettigan S. Journal of the advanced practitioner in oncology. 2014 May;5(3)211-5.", 
                "title": "Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Planchard D et al", 
                "elocationId": "doi: 10.1016/S1470-2045(16)00077-2", 
                "issue": "5", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "642-50", 
                "pmid": "27080216", 
                "pubDate": "2016 May", 
                "reference": "Planchard D et al. The Lancet. Oncology. 2016 May;17(5)642-50.", 
                "title": "Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.", 
                "volume": "17"
            }, 
            {
                "abstract": null, 
                "authors": "Gautschi O et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3182629903", 
                "issue": "10", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "e23-4", 
                "pmid": "22743296", 
                "pubDate": "2012 Oct", 
                "reference": "Gautschi O et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Oct;7(10)e23-4.", 
                "title": "A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.", 
                "volume": "7"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4615, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493057315000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Dabrafenib is FDA-approved for for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Dabrafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Ou SH et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e31821528d3", 
                "issue": "5", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "942-6", 
                "pmid": "21623265", 
                "pubDate": "2011 May", 
                "reference": "Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.", 
                "title": "Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.", 
                "volume": "6"
            }, 
            {
                "abstract": "Camidge et al. Abstract# 8001, ASCO 2014", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/132030-144", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000397752", 
            "curatedRefSeq": "NM_000245.2", 
            "entrezGeneId": 4233, 
            "geneAliases": [
                "RCCP2", 
                "HGFR", 
                "c-Met", 
                "DFNB97", 
                "AUTS9"
            ], 
            "hugoSymbol": "MET", 
            "name": "MET proto-oncogene, receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2569, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493227274000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Crizotinib is FDA-approved for (1) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive as detected by an FDA-approved test (2) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Crizotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Grassi P et al", 
                "elocationId": "doi: 10.2147/DDDT.S104225", 
                "issue": "", 
                "journal": "Drug design, development and therapy", 
                "link": null, 
                "pages": "2167-72", 
                "pmid": "27462141", 
                "pubDate": "2016", 
                "reference": "Grassi P et al. Drug design, development and therapy. 2016;10()2167-72.", 
                "title": "Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.", 
                "volume": "10"
            }, 
            {
                "abstract": null, 
                "authors": "Choueiri TK et al", 
                "elocationId": "doi: 10.1016/S1470-2045(16)30107-3", 
                "issue": "7", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "917-927", 
                "pmid": "27279544", 
                "pubDate": "2016 Jul", 
                "reference": "Choueiri TK et al. The Lancet. Oncology. 2016 Jul;17(7)917-927.", 
                "title": "Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Renal Cell Carcinoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000397752", 
            "curatedRefSeq": "NM_000245.2", 
            "entrezGeneId": 4233, 
            "geneAliases": [
                "RCCP2", 
                "HGFR", 
                "c-Met", 
                "DFNB97", 
                "AUTS9"
            ], 
            "hugoSymbol": "MET", 
            "name": "MET proto-oncogene, receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2572, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493227274000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Renal Cell Carcinoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cabozantinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000357654", 
                    "curatedRefSeq": "NM_007294.3", 
                    "entrezGeneId": 672, 
                    "geneAliases": [
                        "RNF53", 
                        "IRIS", 
                        "BRCAI", 
                        "PNCA4", 
                        "PSCP", 
                        "BROVCA1", 
                        "BRCC1", 
                        "FANCS", 
                        "PPP1R53"
                    ], 
                    "hugoSymbol": "BRCA1", 
                    "name": "BRCA1, DNA repair associated", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Gelmon KA et al", 
                "elocationId": "doi: 10.1016/S1470-2045(11)70214-5", 
                "issue": "9", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "852-61", 
                "pmid": "21862407", 
                "pubDate": "2011 Sep", 
                "reference": "Gelmon KA et al. The Lancet. Oncology. 2011 Sep;12(9)852-61.", 
                "title": "Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.", 
                "volume": "12"
            }, 
            {
                "abstract": null, 
                "authors": "Audeh MW et al", 
                "elocationId": "doi: 10.1016/S0140-6736(10)60893-8", 
                "issue": "9737", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "245-51", 
                "pmid": "20609468", 
                "pubDate": "2010 Jul 24", 
                "reference": "Audeh MW et al. Lancet (London, England). 2010 Jul 24;376(9737)245-51.", 
                "title": "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.", 
                "volume": "376"
            }, 
            {
                "abstract": null, 
                "authors": "Kaufman B et al", 
                "elocationId": "doi: 10.1200/JCO.2014.56.2728", 
                "issue": "3", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "244-50", 
                "pmid": "25366685", 
                "pubDate": "2015 Jan 20", 
                "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.", 
                "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.", 
                "volume": "33"
            }, 
            {
                "abstract": null, 
                "authors": "Fong PC et al", 
                "elocationId": "doi: 10.1200/JCO.2009.26.9589", 
                "issue": "15", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2512-9", 
                "pmid": "20406929", 
                "pubDate": "2010 May 20", 
                "reference": "Fong PC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 May 20;28(15)2512-9.", 
                "title": "Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.", 
                "volume": "28"
            }, 
            {
                "abstract": null, 
                "authors": "Fong PC et al", 
                "elocationId": "doi: 10.1056/NEJMoa0900212", 
                "issue": "2", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "123-34", 
                "pmid": "19553641", 
                "pubDate": "2009 Jul 9", 
                "reference": "Fong PC et al. The New England journal of medicine. 2009 Jul 9;361(2)123-34.", 
                "title": "Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.", 
                "volume": "361"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000357654", 
            "curatedRefSeq": "NM_007294.3", 
            "entrezGeneId": 672, 
            "geneAliases": [
                "RNF53", 
                "IRIS", 
                "BRCAI", 
                "PNCA4", 
                "PSCP", 
                "BROVCA1", 
                "BRCC1", 
                "FANCS", 
                "PPP1R53"
            ], 
            "hugoSymbol": "BRCA1", 
            "name": "BRCA1, DNA repair associated", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 6349, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493245429000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Olaparib is FDA-approved as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Olaparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000389048", 
                    "curatedRefSeq": "NM_004304.4", 
                    "entrezGeneId": 238, 
                    "geneAliases": [
                        "NBLST3", 
                        "CD246"
                    ], 
                    "hugoSymbol": "ALK", 
                    "name": "anaplastic lymphoma receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Moss YP et al", 
                "elocationId": "doi: 10.1016/S1470-2045(13)70095-0", 
                "issue": "6", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "472-80", 
                "pmid": "23598171", 
                "pubDate": "2013 May", 
                "reference": "Moss YP et al. The Lancet. Oncology. 2013 May;14(6)472-80.", 
                "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.", 
                "volume": "14"
            }, 
            {
                "abstract": null, 
                "authors": "Butrynski JE et al", 
                "elocationId": "doi: 10.1056/NEJMoa1007056", 
                "issue": "18", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1727-33", 
                "pmid": "20979472", 
                "pubDate": "2010 Oct 28", 
                "reference": "Butrynski JE et al. The New England journal of medicine. 2010 Oct 28;363(18)1727-33.", 
                "title": "Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.", 
                "volume": "363"
            }
        ], 
        "cancerType": "Soft Tissue Sarcoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000389048", 
            "curatedRefSeq": "NM_004304.4", 
            "entrezGeneId": 238, 
            "geneAliases": [
                "NBLST3", 
                "CD246"
            ], 
            "hugoSymbol": "ALK", 
            "name": "anaplastic lymphoma receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9938, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493408984000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [
                "C6481"
            ], 
            "UMLS": [
                "C0334121"
            ], 
            "children": null, 
            "code": "IMT", 
            "color": "LightYellow", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 2, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Soft Tissue Sarcoma"
            }, 
            "name": "Inflammatory Myofibroblastic Tumor", 
            "parent": "SOFT_TISSUE", 
            "tissue": "Soft Tissue"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "IMT", 
        "treatments": [
            {
                "approvedIndications": [
                    "Crizotinib is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive as detected by an FDA-approved test."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Crizotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Verweij J et al", 
                "elocationId": "", 
                "issue": "9440", 
                "journal": "Lancet (London, England)", 
                "link": null, 
                "pages": "1127-34", 
                "pmid": "15451219", 
                "pubDate": "2004 Sep 25-Oct 1", 
                "reference": "Verweij J et al. Lancet (London, England). 2004 Sep 25-Oct 1;364(9440)1127-34.", 
                "title": "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.", 
                "volume": "364"
            }, 
            {
                "abstract": null, 
                "authors": "Zalcberg JR et al", 
                "elocationId": "", 
                "issue": "12", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1751-7", 
                "pmid": "16098458", 
                "pubDate": "2005 Aug", 
                "reference": "Zalcberg JR et al. European journal of cancer (Oxford, England : 1990). 2005 Aug;41(12)1751-7.", 
                "title": "Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.", 
                "volume": "41"
            }, 
            {
                "abstract": null, 
                "authors": "Hodi FS et al", 
                "elocationId": "doi: 10.1200/JCO.2012.47.7836", 
                "issue": "26", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3182-90", 
                "pmid": "23775962", 
                "pubDate": "2013 Sep 10", 
                "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.", 
                "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Carvajal RD et al", 
                "elocationId": "doi: 10.1001/jama.2011.746", 
                "issue": "22", 
                "journal": "JAMA", 
                "link": null, 
                "pages": "2327-34", 
                "pmid": "21642685", 
                "pubDate": "2011 Jun 8", 
                "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.", 
                "title": "KIT as a therapeutic target in metastatic melanoma.", 
                "volume": "305"
            }, 
            {
                "abstract": null, 
                "authors": "Blanke CD et al", 
                "elocationId": "doi: 10.1200/JCO.2007.13.4403", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "620-5", 
                "pmid": "18235121", 
                "pubDate": "2008 Feb 1", 
                "reference": "Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)620-5.", 
                "title": "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Demetri GD et al", 
                "elocationId": "", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "472-80", 
                "pmid": "12181401", 
                "pubDate": "2002 Aug 15", 
                "reference": "Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.", 
                "title": "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.", 
                "volume": "347"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 339, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508518255000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    " (2) adjuvant treatment of adult patients following complete gross resection of KIT-positive GIST.", 
                    "Imatinib is FDA approved for the treatment of: (1) patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000389048", 
                    "curatedRefSeq": "NM_004304.4", 
                    "entrezGeneId": 238, 
                    "geneAliases": [
                        "NBLST3", 
                        "CD246"
                    ], 
                    "hugoSymbol": "ALK", 
                    "name": "anaplastic lymphoma receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Shaw AT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1311107", 
                "issue": "13", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1189-97", 
                "pmid": "24670165", 
                "pubDate": "2014 Mar 27", 
                "reference": "Shaw AT et al. The New England journal of medicine. 2014 Mar 27;370(13)1189-97.", 
                "title": "Ceritinib in ALK-rearranged non-small-cell lung cancer.", 
                "volume": "370"
            }
        ], 
        "cancerType": "Soft Tissue Sarcoma", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000389048", 
            "curatedRefSeq": "NM_004304.4", 
            "entrezGeneId": 238, 
            "geneAliases": [
                "NBLST3", 
                "CD246"
            ], 
            "hugoSymbol": "ALK", 
            "name": "anaplastic lymphoma receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9939, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493408984000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [
                "C6481"
            ], 
            "UMLS": [
                "C0334121"
            ], 
            "children": null, 
            "code": "IMT", 
            "color": "LightYellow", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 2, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Soft Tissue Sarcoma"
            }, 
            "name": "Inflammatory Myofibroblastic Tumor", 
            "parent": "SOFT_TISSUE", 
            "tissue": "Soft Tissue"
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": "IMT", 
        "treatments": [
            {
                "approvedIndications": [
                    "Ceritinib is FDA-approved for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) with disease progression on or who are intolerant to crizotinib."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Ceritinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Strbel P et al", 
                "elocationId": "doi: 10.1038/sj.bjc.6605740", 
                "issue": "2", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "196-200", 
                "pmid": "20571495", 
                "pubDate": "2010 Jul 13", 
                "reference": "Strbel P et al. British journal of cancer. 2010 Jul 13;103(2)196-200.", 
                "title": "Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.", 
                "volume": "103"
            }, 
            {
                "abstract": null, 
                "authors": "Thomas A et al", 
                "elocationId": "doi: 10.1016/S1470-2045(14)71181-7", 
                "issue": "2", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "177-86", 
                "pmid": "25592632", 
                "pubDate": "2015 Feb", 
                "reference": "Thomas A et al. The Lancet. Oncology. 2015 Feb;16(2)177-86.", 
                "title": "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.", 
                "volume": "16"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 341, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508861529000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sunitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bisagni G et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3181a52e25", 
                "issue": "6", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "773-5", 
                "pmid": "19461405", 
                "pubDate": "2009 Jun", 
                "reference": "Bisagni G et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Jun;4(6)773-5.", 
                "title": "Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.", 
                "volume": "4"
            }
        ], 
        "cancerType": "Thymic Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 342, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508864017000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thymic Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D842V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000257290", 
                    "curatedRefSeq": "NM_006206.4", 
                    "entrezGeneId": 5156, 
                    "geneAliases": [
                        "PDGFR2", 
                        "RHEPDGFRA", 
                        "GAS9", 
                        "PDGFR-2", 
                        "CD140A"
                    ], 
                    "hugoSymbol": "PDGFRA", 
                    "name": "platelet derived growth factor receptor alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D842V", 
                "proteinEnd": 842, 
                "proteinStart": 842, 
                "refResidues": "D", 
                "variantResidues": "V"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "von Mehren M", 
                "elocationId": "", 
                "issue": "", 
                "journal": "Clinical colorectal cancer", 
                "link": null, 
                "pages": "S30-4", 
                "pmid": "17419150", 
                "pubDate": "2006 Nov", 
                "reference": "von Mehren M. Clinical colorectal cancer. 2006 Nov;6 Suppl 1()S30-4.", 
                "title": "Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.", 
                "volume": "6 Suppl 1"
            }, 
            {
                "abstract": "Trent et al. Abstract# 10006, ASCO 2011", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/79120-102", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Dewaele B et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-08-0533", 
                "issue": "18", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "5749-58", 
                "pmid": "18794084", 
                "pubDate": "2008 Sep 15", 
                "reference": "Dewaele B et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Sep 15;14(18)5749-58.", 
                "title": "Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.", 
                "volume": "14"
            }, 
            {
                "abstract": null, 
                "authors": "Corless CL et al", 
                "elocationId": "", 
                "issue": "23", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "5357-64", 
                "pmid": "15928335", 
                "pubDate": "2005 Aug 10", 
                "reference": "Corless CL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Aug 10;23(23)5357-64.", 
                "title": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.", 
                "volume": "23"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000257290", 
            "curatedRefSeq": "NM_006206.4", 
            "entrezGeneId": 5156, 
            "geneAliases": [
                "PDGFR2", 
                "RHEPDGFRA", 
                "GAS9", 
                "PDGFR-2", 
                "CD140A"
            ], 
            "hugoSymbol": "PDGFRA", 
            "name": "platelet derived growth factor receptor alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 15255, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493063804000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Dasatinib is FDA-approved for 1) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase", 
                    " 2) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib", 
                    " 3) adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Dasatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D1010H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010H", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "X1009_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1009_splice", 
                "proteinEnd": 1009, 
                "proteinStart": 1009, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X963_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X963_splice", 
                "proteinEnd": 963, 
                "proteinStart": 963, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1006_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1006_splice", 
                "proteinEnd": 1006, 
                "proteinStart": 1006, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "D1010N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010N", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "D1010Y", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010Y", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "Y"
            }, 
            {
                "alteration": "X1010_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1010_splice", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "981_1028splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "981_1028splice", 
                "proteinEnd": 1028, 
                "proteinStart": 981, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1008_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1008_splice", 
                "proteinEnd": 1008, 
                "proteinStart": 1008, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1007_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1007_splice", 
                "proteinEnd": 1007, 
                "proteinStart": 1007, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "Y1003N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Y1003N", 
                "proteinEnd": 1003, 
                "proteinStart": 1003, 
                "refResidues": "Y", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "963_D1010splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "963_D1010splice", 
                "proteinEnd": 1010, 
                "proteinStart": 963, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Liu X et al", 
                "elocationId": "doi: 10.1200/JCO.2015.62.0674", 
                "issue": "8", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "794-802", 
                "pmid": "26215952", 
                "pubDate": "2016 Mar 10", 
                "reference": "Liu X et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 10;34(8)794-802.", 
                "title": "Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.", 
                "volume": "34"
            }, 
            {
                "abstract": null, 
                "authors": "Onozato R et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3181913e0e", 
                "issue": "1", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "5-11", 
                "pmid": "19096300", 
                "pubDate": "2009 Jan", 
                "reference": "Onozato R et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Jan;4(1)5-11.", 
                "title": "Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.", 
                "volume": "4"
            }, 
            {
                "abstract": null, 
                "authors": "Paik PK et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-14-1467", 
                "issue": "8", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "842-9", 
                "pmid": "25971939", 
                "pubDate": "2015 Aug", 
                "reference": "Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.", 
                "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Frampton GM et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0285", 
                "issue": "8", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "850-9", 
                "pmid": "25971938", 
                "pubDate": "2015 Aug", 
                "reference": "Frampton GM et al. Cancer discovery. 2015 Aug;5(8)850-9.", 
                "title": "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Kong-Beltran M et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Cancer research", 
                "link": null, 
                "pages": "283-9", 
                "pmid": "16397241", 
                "pubDate": "2006 Jan 1", 
                "reference": "Kong-Beltran M et al. Cancer research. 2006 Jan 1;66(1)283-9.", 
                "title": "Somatic mutations lead to an oncogenic deletion of met in lung cancer.", 
                "volume": "66"
            }, 
            {
                "abstract": null, 
                "authors": "Ma PC et al", 
                "elocationId": "", 
                "issue": "4", 
                "journal": "Cancer research", 
                "link": null, 
                "pages": "1479-88", 
                "pmid": "15735036", 
                "pubDate": "2005 Feb 15", 
                "reference": "Ma PC et al. Cancer research. 2005 Feb 15;65(4)1479-88.", 
                "title": "Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.", 
                "volume": "65"
            }, 
            {
                "abstract": null, 
                "authors": "Awad MM et al", 
                "elocationId": "doi: 10.1200/JCO.2015.63.4600", 
                "issue": "7", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "721-30", 
                "pmid": "26729443", 
                "pubDate": "2016 Mar 1", 
                "reference": "Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.", 
                "title": "MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.", 
                "volume": "34"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000397752", 
            "curatedRefSeq": "NM_000245.2", 
            "entrezGeneId": 4233, 
            "geneAliases": [
                "RCCP2", 
                "HGFR", 
                "c-Met", 
                "DFNB97", 
                "AUTS9"
            ], 
            "hugoSymbol": "MET", 
            "name": "MET proto-oncogene, receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2590, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493227274000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    "Crizotinib is FDA-approved for (1) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive as detected by an FDA-approved test (2) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive."
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Crizotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "C788_N828mut", 
                "consequence": {
                    "description": "any variant", 
                    "isGenerallyTruncating": false, 
                    "term": "any"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 17 mutations", 
                "proteinEnd": 828, 
                "proteinStart": 788, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Kindler et al. Abstract# 10009, ASCO 2011", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/80567-102", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Montemurro M et al", 
                "elocationId": "doi: 10.1016/j.ejca.2012.10.009", 
                "issue": "5", 
                "journal": "European journal of cancer (Oxford, England : 1990)", 
                "link": null, 
                "pages": "1027-31", 
                "pmid": "23140824", 
                "pubDate": "2013 Mar", 
                "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.", 
                "title": "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.", 
                "volume": "49"
            }, 
            {
                "abstract": null, 
                "authors": "Park SH et al", 
                "elocationId": "doi: 10.1007/s10637-012-9795-9", 
                "issue": "6", 
                "journal": "Investigational new drugs", 
                "link": null, 
                "pages": "2377-83", 
                "pmid": "22270258", 
                "pubDate": "2012 Dec", 
                "reference": "Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.", 
                "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.", 
                "volume": "30"
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 290, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1508877690000, 
        "levelOfEvidence": "LEVEL_2A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_2B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [
                    " 3) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment", 
                    " 2) Advanced renal cell carcinoma", 
                    "Sorafenib is FDA-approved for 1) Unresectable hepatocellular carcinoma"
                ], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Juric et al. Abstract# 334, MBCC 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://www.onclive.com/conference-coverage/mbcc-2016/alpelisib-combo-promising-in-pik3ca-altered-heavily-pretreated-breast-cancer", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Bosch A et al", 
                "elocationId": "doi: 10.1126/scitranslmed.aaa4442", 
                "issue": "283", 
                "journal": "Science translational medicine", 
                "link": null, 
                "pages": "283ra51", 
                "pmid": "25877889", 
                "pubDate": "2015 Apr 15", 
                "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.", 
                "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.", 
                "volume": "7"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1648, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504070000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Fulvestrant", 
                        "priority": 2, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Alpelisib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000391945", 
                    "curatedRefSeq": "NM_000400.3", 
                    "entrezGeneId": 2068, 
                    "geneAliases": [
                        "EM9", 
                        "TTD", 
                        "TFIIH", 
                        "TTD1", 
                        "COFS2", 
                        "XPD"
                    ], 
                    "hugoSymbol": "ERCC2", 
                    "name": "ERCC excision repair 2, TFIIH core complex helicase subunit", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Van Allen EM et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-14-0623", 
                "issue": "10", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "1140-53", 
                "pmid": "25096233", 
                "pubDate": "2014 Oct", 
                "reference": "Van Allen EM et al. Cancer discovery. 2014 Oct;4(10)1140-53.", 
                "title": "Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.", 
                "volume": "4"
            }, 
            {
                "abstract": null, 
                "authors": "Liu D et al", 
                "elocationId": "doi: 10.1001/jamaoncol.2016.1056", 
                "issue": "8", 
                "journal": "JAMA oncology", 
                "link": null, 
                "pages": "1094-6", 
                "pmid": "27310333", 
                "pubDate": "2016 Aug 1", 
                "reference": "Liu D et al. JAMA oncology. 2016 Aug 1;2(8)1094-6.", 
                "title": "Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.", 
                "volume": "2"
            }, 
            {
                "abstract": null, 
                "authors": "Furuta T et al", 
                "elocationId": "", 
                "issue": "17", 
                "journal": "Cancer research", 
                "link": null, 
                "pages": "4899-902", 
                "pmid": "12208738", 
                "pubDate": "2002 Sep 1", 
                "reference": "Furuta T et al. Cancer research. 2002 Sep 1;62(17)4899-902.", 
                "title": "Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.", 
                "volume": "62"
            }
        ], 
        "cancerType": "Bladder Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000391945", 
            "curatedRefSeq": "NM_000400.3", 
            "entrezGeneId": 2068, 
            "geneAliases": [
                "EM9", 
                "TTD", 
                "TFIIH", 
                "TTD1", 
                "COFS2", 
                "XPD"
            ], 
            "hugoSymbol": "ERCC2", 
            "name": "ERCC excision repair 2, TFIIH core complex helicase subunit", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 4464, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435431000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Bladder Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cisplatin", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Di Leo et al. Abstract# S4-07, SABCS 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/77/4_Supplement/S4-07", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Miller TW et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-11-0101", 
                "issue": "4", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "338-51", 
                "pmid": "22049316", 
                "pubDate": "2011 Sep", 
                "reference": "Miller TW et al. Cancer discovery. 2011 Sep;1(4)338-51.", 
                "title": "ER-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.", 
                "volume": "1"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1649, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504143000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Fulvestrant", 
                        "priority": 2, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Buparlisib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Juric et al. Abstract# 334, MBCC 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://www.onclive.com/conference-coverage/mbcc-2016/alpelisib-combo-promising-in-pik3ca-altered-heavily-pretreated-breast-cancer", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Fritsch C et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-13-0865", 
                "issue": "5", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "1117-29", 
                "pmid": "24608574", 
                "pubDate": "2014 May", 
                "reference": "Fritsch C et al. Molecular cancer therapeutics. 2014 May;13(5)1117-29.", 
                "title": "Characterization of the novel and specific PI3K inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.", 
                "volume": "13"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1650, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504172000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Alpelisib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Rodon J et al", 
                "elocationId": "doi: 10.1007/s10637-014-0082-9", 
                "issue": "4", 
                "journal": "Investigational new drugs", 
                "link": null, 
                "pages": "670-81", 
                "pmid": "24652201", 
                "pubDate": "2014 Aug", 
                "reference": "Rodon J et al. Investigational new drugs. 2014 Aug;32(4)670-81.", 
                "title": "Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.", 
                "volume": "32"
            }, 
            {
                "abstract": null, 
                "authors": "Maira SM et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-11-0474", 
                "issue": "2", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "317-28", 
                "pmid": "22188813", 
                "pubDate": "2012 Feb", 
                "reference": "Maira SM et al. Molecular cancer therapeutics. 2012 Feb;11(2)317-28.", 
                "title": "Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.", 
                "volume": "11"
            }, 
            {
                "abstract": "Di Leo et al. Abstract# S4-07, SABCS 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/77/4_Supplement/S4-07", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1651, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504214000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Buparlisib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Juric D et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-16-2888", 
                "issue": "17", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "5015-5023", 
                "pmid": "28490463", 
                "pubDate": "2017 Sep 1", 
                "reference": "Juric D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Sep 1;23(17)5015-5023.", 
                "title": "A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K Isoform Inhibitor, in Patients with Advanced Solid Malignancies.", 
                "volume": "23"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1652, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504233000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Serabelisib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 5
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Wade et al. Abstract# 9054, ASCO 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9054", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Ndubaku CO et al", 
                "elocationId": "doi: 10.1021/jm4003632", 
                "issue": "11", 
                "journal": "Journal of medicinal chemistry", 
                "link": null, 
                "pages": "4597-610", 
                "pmid": "23662903", 
                "pubDate": "2013 Jun 13", 
                "reference": "Ndubaku CO et al. Journal of medicinal chemistry. 2013 Jun 13;56(11)4597-610.", 
                "title": "Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzoimidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a -sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.", 
                "volume": "56"
            }, 
            {
                "abstract": null, 
                "authors": "Lopez S et al", 
                "elocationId": "doi: 10.1016/j.ygyno.2014.08.024", 
                "issue": "2", 
                "journal": "Gynecologic oncology", 
                "link": null, 
                "pages": "312-7", 
                "pmid": "25172762", 
                "pubDate": "2014 Nov", 
                "reference": "Lopez S et al. Gynecologic oncology. 2014 Nov;135(2)312-7.", 
                "title": "Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.", 
                "volume": "135"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1653, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504263000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Taselisib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 6
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000277120", 
                    "curatedRefSeq": "NM_006180.3", 
                    "entrezGeneId": 4915, 
                    "geneAliases": [
                        "TRKB", 
                        "GP145-TrkB", 
                        "trk-B"
                    ], 
                    "hugoSymbol": "NTRK2", 
                    "name": "neurotrophic receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Hyman et al. Abstract# LBA2501, ASCO 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA2501", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Doebele RC et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0443", 
                "issue": "10", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "1049-57", 
                "pmid": "26216294", 
                "pubDate": "2015 Oct", 
                "reference": "Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.", 
                "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.", 
                "volume": "5"
            }
        ], 
        "cancerType": "All Solid Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000277120", 
            "curatedRefSeq": "NM_006180.3", 
            "entrezGeneId": 4915, 
            "geneAliases": [
                "TRKB", 
                "GP145-TrkB", 
                "trk-B"
            ], 
            "hugoSymbol": "NTRK2", 
            "name": "neurotrophic receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2165, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503775000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Solid Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Larotrectinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Patnaik A et al", 
                "elocationId": "doi: 10.1093/annonc/mdw282", 
                "issue": "10", 
                "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", 
                "link": null, 
                "pages": "1928-40", 
                "pmid": "27672108", 
                "pubDate": "2016 Oct", 
                "reference": "Patnaik A et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Oct;27(10)1928-40.", 
                "title": "First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.", 
                "volume": "27"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1654, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504281000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Copanlisib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 7
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000277120", 
                    "curatedRefSeq": "NM_006180.3", 
                    "entrezGeneId": 4915, 
                    "geneAliases": [
                        "TRKB", 
                        "GP145-TrkB", 
                        "trk-B"
                    ], 
                    "hugoSymbol": "NTRK2", 
                    "name": "neurotrophic receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-16-1237", 
                "issue": "4", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "400-409", 
                "pmid": "28183697", 
                "pubDate": "2017 Apr", 
                "reference": "Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.", 
                "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).", 
                "volume": "7"
            }, 
            {
                "abstract": "Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "https://meetinglibrary.asco.org/record/155954/abstract", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "All Solid Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000277120", 
            "curatedRefSeq": "NM_006180.3", 
            "entrezGeneId": 4915, 
            "geneAliases": [
                "TRKB", 
                "GP145-TrkB", 
                "trk-B"
            ], 
            "hugoSymbol": "NTRK2", 
            "name": "neurotrophic receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2166, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503802000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Solid Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Entrectinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000377045", 
                    "curatedRefSeq": "NM_001654.4", 
                    "entrezGeneId": 369, 
                    "geneAliases": [
                        "ARAF1", 
                        "A-RAF", 
                        "RAFA1", 
                        "PKS2"
                    ], 
                    "hugoSymbol": "ARAF", 
                    "name": "A-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Imielinski M et al", 
                "elocationId": "doi: 10.1172/JCI72763", 
                "issue": "4", 
                "journal": "The Journal of clinical investigation", 
                "link": null, 
                "pages": "1582-6", 
                "pmid": "24569458", 
                "pubDate": "2014 Apr", 
                "reference": "Imielinski M et al. The Journal of clinical investigation. 2014 Apr;124(4)1582-6.", 
                "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.", 
                "volume": "124"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000377045", 
            "curatedRefSeq": "NM_001654.4", 
            "entrezGeneId": 369, 
            "geneAliases": [
                "ARAF1", 
                "A-RAF", 
                "RAFA1", 
                "PKS2"
            ], 
            "hugoSymbol": "ARAF", 
            "name": "A-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 5238, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434741000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Edgar et al. Abstract# 156, AACR 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/156", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1655, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504299000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_4", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "GDC-0077", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 8
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000263967", 
                    "curatedRefSeq": "NM_006218.2", 
                    "entrezGeneId": 5290, 
                    "geneAliases": [
                        "MCAP", 
                        "p110-alpha", 
                        "PI3K", 
                        "CLOVE", 
                        "MCM", 
                        "PI3K-alpha", 
                        "CWS5", 
                        "MCMTC"
                    ], 
                    "hugoSymbol": "PIK3CA", 
                    "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Dickler et al. Abstract# 520, ASCO 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/165518-176", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Bosch A et al", 
                "elocationId": "doi: 10.1126/scitranslmed.aaa4442", 
                "issue": "283", 
                "journal": "Science translational medicine", 
                "link": null, 
                "pages": "283ra51", 
                "pmid": "25877889", 
                "pubDate": "2015 Apr 15", 
                "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.", 
                "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.", 
                "volume": "7"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000263967", 
            "curatedRefSeq": "NM_006218.2", 
            "entrezGeneId": 5290, 
            "geneAliases": [
                "MCAP", 
                "p110-alpha", 
                "PI3K", 
                "CLOVE", 
                "MCM", 
                "PI3K-alpha", 
                "CWS5", 
                "MCMTC"
            ], 
            "hugoSymbol": "PIK3CA", 
            "name": "phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1656, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504319000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Taselisib", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Fulvestrant", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 9
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000377045", 
                    "curatedRefSeq": "NM_001654.4", 
                    "entrezGeneId": 369, 
                    "geneAliases": [
                        "ARAF1", 
                        "A-RAF", 
                        "RAFA1", 
                        "PKS2"
                    ], 
                    "hugoSymbol": "ARAF", 
                    "name": "A-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Diamond EL et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0913", 
                "issue": "2", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "154-65", 
                "pmid": "26566875", 
                "pubDate": "2016 Feb", 
                "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.", 
                "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.", 
                "volume": "6"
            }, 
            {
                "abstract": null, 
                "authors": "Imielinski M et al", 
                "elocationId": "doi: 10.1172/JCI72763", 
                "issue": "4", 
                "journal": "The Journal of clinical investigation", 
                "link": null, 
                "pages": "1582-6", 
                "pmid": "24569458", 
                "pubDate": "2014 Apr", 
                "reference": "Imielinski M et al. The Journal of clinical investigation. 2014 Apr;124(4)1582-6.", 
                "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.", 
                "volume": "124"
            }
        ], 
        "cancerType": "Histiocytosis", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000377045", 
            "curatedRefSeq": "NM_001654.4", 
            "entrezGeneId": 369, 
            "geneAliases": [
                "ARAF1", 
                "A-RAF", 
                "RAFA1", 
                "PKS2"
            ], 
            "hugoSymbol": "ARAF", 
            "name": "A-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 5240, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434764000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Histiocytosis"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000369535", 
                    "curatedRefSeq": "NM_002524.4", 
                    "entrezGeneId": 4893, 
                    "geneAliases": [
                        "CMNS", 
                        "NS6", 
                        "ALPS4", 
                        "N-ras", 
                        "NRAS1", 
                        "NCMS"
                    ], 
                    "hugoSymbol": "NRAS", 
                    "name": "neuroblastoma RAS viral oncogene homolog", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Dummer R et al", 
                "elocationId": "doi: 10.1016/S1470-2045(17)30180-8", 
                "issue": "4", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "435-445", 
                "pmid": "28284557", 
                "pubDate": "2017 Apr", 
                "reference": "Dummer R et al. The Lancet. Oncology. 2017 Apr;18(4)435-445.", 
                "title": "Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.", 
                "volume": "18"
            }, 
            {
                "abstract": null, 
                "authors": "Solit DB et al", 
                "elocationId": "", 
                "issue": "7074", 
                "journal": "Nature", 
                "link": null, 
                "pages": "358-62", 
                "pmid": "16273091", 
                "pubDate": "2006 Jan 19", 
                "reference": "Solit DB et al. Nature. 2006 Jan 19;439(7074)358-62.", 
                "title": "BRAF mutation predicts sensitivity to MEK inhibition.", 
                "volume": "439"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000369535", 
            "curatedRefSeq": "NM_002524.4", 
            "entrezGeneId": 4893, 
            "geneAliases": [
                "CMNS", 
                "NS6", 
                "ALPS4", 
                "N-ras", 
                "NRAS1", 
                "NCMS"
            ], 
            "hugoSymbol": "NRAS", 
            "name": "neuroblastoma RAS viral oncogene homolog", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2301, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503522000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Binimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000369535", 
                    "curatedRefSeq": "NM_002524.4", 
                    "entrezGeneId": 4893, 
                    "geneAliases": [
                        "CMNS", 
                        "NS6", 
                        "ALPS4", 
                        "N-ras", 
                        "NRAS1", 
                        "NCMS"
                    ], 
                    "hugoSymbol": "NRAS", 
                    "name": "neuroblastoma RAS viral oncogene homolog", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Kwong LN et al", 
                "elocationId": "doi: 10.1038/nm.2941", 
                "issue": "10", 
                "journal": "Nature medicine", 
                "link": null, 
                "pages": "1503-10", 
                "pmid": "22983396", 
                "pubDate": "2012 Oct", 
                "reference": "Kwong LN et al. Nature medicine. 2012 Oct;18(10)1503-10.", 
                "title": "Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.", 
                "volume": "18"
            }, 
            {
                "abstract": "Schuler et al. Abstract #9519, ASCO 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9519", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000369535", 
            "curatedRefSeq": "NM_002524.4", 
            "entrezGeneId": 4893, 
            "geneAliases": [
                "CMNS", 
                "NS6", 
                "ALPS4", 
                "N-ras", 
                "NRAS1", 
                "NCMS"
            ], 
            "hugoSymbol": "NRAS", 
            "name": "neuroblastoma RAS viral oncogene homolog", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2302, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503542000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Binimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Ribociclib", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000369535", 
                    "curatedRefSeq": "NM_002524.4", 
                    "entrezGeneId": 4893, 
                    "geneAliases": [
                        "CMNS", 
                        "NS6", 
                        "ALPS4", 
                        "N-ras", 
                        "NRAS1", 
                        "NCMS"
                    ], 
                    "hugoSymbol": "NRAS", 
                    "name": "neuroblastoma RAS viral oncogene homolog", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Chakravarty D et al", 
                "elocationId": "doi: 10.1172/JCI46382", 
                "issue": "12", 
                "journal": "The Journal of clinical investigation", 
                "link": null, 
                "pages": "4700-11", 
                "pmid": "22105174", 
                "pubDate": "2011 Dec", 
                "reference": "Chakravarty D et al. The Journal of clinical investigation. 2011 Dec;121(12)4700-11.", 
                "title": "Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.", 
                "volume": "121"
            }, 
            {
                "abstract": null, 
                "authors": "Ho AL et al", 
                "elocationId": "doi: 10.1056/NEJMoa1209288", 
                "issue": "7", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "623-32", 
                "pmid": "23406027", 
                "pubDate": "2013 Feb 14", 
                "reference": "Ho AL et al. The New England journal of medicine. 2013 Feb 14;368(7)623-32.", 
                "title": "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.", 
                "volume": "368"
            }
        ], 
        "cancerType": "Thyroid Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000369535", 
            "curatedRefSeq": "NM_002524.4", 
            "entrezGeneId": 4893, 
            "geneAliases": [
                "CMNS", 
                "NS6", 
                "ALPS4", 
                "N-ras", 
                "NRAS1", 
                "NCMS"
            ], 
            "hugoSymbol": "NRAS", 
            "name": "neuroblastoma RAS viral oncogene homolog", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2305, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507563035000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thyroid Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "NO", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Selumetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Radioiodine Uptake Therapy", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000307102", 
                    "curatedRefSeq": "NM_002755.3", 
                    "entrezGeneId": 5604, 
                    "geneAliases": [
                        "MKK1", 
                        "PRKMK1", 
                        "MEK1", 
                        "MAPKK1", 
                        "CFC3"
                    ], 
                    "hugoSymbol": "MAP2K1", 
                    "name": "mitogen-activated protein kinase kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Diamond EL et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0913", 
                "issue": "2", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "154-65", 
                "pmid": "26566875", 
                "pubDate": "2016 Feb", 
                "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.", 
                "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.", 
                "volume": "6"
            }, 
            {
                "abstract": null, 
                "authors": "Carlino MS et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759", 
                "issue": "1", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "98-105", 
                "pmid": "25370473", 
                "pubDate": "2015 Jan 1", 
                "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.", 
                "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.", 
                "volume": "21"
            }, 
            {
                "abstract": "Papapanagiotou et al. JCOPO, 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Grisham RN et al", 
                "elocationId": "doi: 10.1200/JCO.2015.62.4726", 
                "issue": "34", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4099-105", 
                "pmid": "26324360", 
                "pubDate": "2015 Dec 1", 
                "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.", 
                "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.", 
                "volume": "33"
            }, 
            {
                "abstract": null, 
                "authors": "Arcila ME et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124", 
                "issue": "8", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1935-43", 
                "pmid": "25351745", 
                "pubDate": "2015 Apr 15", 
                "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.", 
                "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.", 
                "volume": "21"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000307102", 
            "curatedRefSeq": "NM_002755.3", 
            "entrezGeneId": 5604, 
            "geneAliases": [
                "MKK1", 
                "PRKMK1", 
                "MEK1", 
                "MAPKK1", 
                "CFC3"
            ], 
            "hugoSymbol": "MAP2K1", 
            "name": "mitogen-activated protein kinase kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3075, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502563000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cobimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000307102", 
                    "curatedRefSeq": "NM_002755.3", 
                    "entrezGeneId": 5604, 
                    "geneAliases": [
                        "MKK1", 
                        "PRKMK1", 
                        "MEK1", 
                        "MAPKK1", 
                        "CFC3"
                    ], 
                    "hugoSymbol": "MAP2K1", 
                    "name": "mitogen-activated protein kinase kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Diamond EL et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0913", 
                "issue": "2", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "154-65", 
                "pmid": "26566875", 
                "pubDate": "2016 Feb", 
                "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.", 
                "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.", 
                "volume": "6"
            }, 
            {
                "abstract": "Papapanagiotou et al. JCOPO, 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Carlino MS et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759", 
                "issue": "1", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "98-105", 
                "pmid": "25370473", 
                "pubDate": "2015 Jan 1", 
                "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.", 
                "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.", 
                "volume": "21"
            }, 
            {
                "abstract": null, 
                "authors": "Grisham RN et al", 
                "elocationId": "doi: 10.1200/JCO.2015.62.4726", 
                "issue": "34", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4099-105", 
                "pmid": "26324360", 
                "pubDate": "2015 Dec 1", 
                "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.", 
                "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.", 
                "volume": "33"
            }, 
            {
                "abstract": null, 
                "authors": "Arcila ME et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124", 
                "issue": "8", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1935-43", 
                "pmid": "25351745", 
                "pubDate": "2015 Apr 15", 
                "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.", 
                "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.", 
                "volume": "21"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000307102", 
            "curatedRefSeq": "NM_002755.3", 
            "entrezGeneId": 5604, 
            "geneAliases": [
                "MKK1", 
                "PRKMK1", 
                "MEK1", 
                "MAPKK1", 
                "CFC3"
            ], 
            "hugoSymbol": "MAP2K1", 
            "name": "mitogen-activated protein kinase kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3076, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502563000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cobimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000307102", 
                    "curatedRefSeq": "NM_002755.3", 
                    "entrezGeneId": 5604, 
                    "geneAliases": [
                        "MKK1", 
                        "PRKMK1", 
                        "MEK1", 
                        "MAPKK1", 
                        "CFC3"
                    ], 
                    "hugoSymbol": "MAP2K1", 
                    "name": "mitogen-activated protein kinase kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Diamond EL et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0913", 
                "issue": "2", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "154-65", 
                "pmid": "26566875", 
                "pubDate": "2016 Feb", 
                "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.", 
                "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.", 
                "volume": "6"
            }, 
            {
                "abstract": "Papapanagiotou et al. JCOPO, 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Carlino MS et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759", 
                "issue": "1", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "98-105", 
                "pmid": "25370473", 
                "pubDate": "2015 Jan 1", 
                "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.", 
                "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.", 
                "volume": "21"
            }, 
            {
                "abstract": null, 
                "authors": "Grisham RN et al", 
                "elocationId": "doi: 10.1200/JCO.2015.62.4726", 
                "issue": "34", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4099-105", 
                "pmid": "26324360", 
                "pubDate": "2015 Dec 1", 
                "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.", 
                "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.", 
                "volume": "33"
            }, 
            {
                "abstract": null, 
                "authors": "Arcila ME et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124", 
                "issue": "8", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1935-43", 
                "pmid": "25351745", 
                "pubDate": "2015 Apr 15", 
                "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.", 
                "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.", 
                "volume": "21"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000307102", 
            "curatedRefSeq": "NM_002755.3", 
            "entrezGeneId": 5604, 
            "geneAliases": [
                "MKK1", 
                "PRKMK1", 
                "MEK1", 
                "MAPKK1", 
                "CFC3"
            ], 
            "hugoSymbol": "MAP2K1", 
            "name": "mitogen-activated protein kinase kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3077, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502563000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C105556"
            ], 
            "UMLS": [
                "CL446432"
            ], 
            "children": null, 
            "code": "LGSOC", 
            "color": "LightBlue", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 4, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": "Low-Grade Serous Ovarian Cancer", 
            "parent": "SOC", 
            "tissue": "Ovary/Fallopian Tube"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "LGSOC", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cobimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000307102", 
                    "curatedRefSeq": "NM_002755.3", 
                    "entrezGeneId": 5604, 
                    "geneAliases": [
                        "MKK1", 
                        "PRKMK1", 
                        "MEK1", 
                        "MAPKK1", 
                        "CFC3"
                    ], 
                    "hugoSymbol": "MAP2K1", 
                    "name": "mitogen-activated protein kinase kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Diamond EL et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0913", 
                "issue": "2", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "154-65", 
                "pmid": "26566875", 
                "pubDate": "2016 Feb", 
                "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.", 
                "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.", 
                "volume": "6"
            }, 
            {
                "abstract": "Papapanagiotou et al. JCOPO, 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Carlino MS et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759", 
                "issue": "1", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "98-105", 
                "pmid": "25370473", 
                "pubDate": "2015 Jan 1", 
                "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.", 
                "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.", 
                "volume": "21"
            }, 
            {
                "abstract": null, 
                "authors": "Grisham RN et al", 
                "elocationId": "doi: 10.1200/JCO.2015.62.4726", 
                "issue": "34", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4099-105", 
                "pmid": "26324360", 
                "pubDate": "2015 Dec 1", 
                "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.", 
                "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.", 
                "volume": "33"
            }, 
            {
                "abstract": null, 
                "authors": "Arcila ME et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124", 
                "issue": "8", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1935-43", 
                "pmid": "25351745", 
                "pubDate": "2015 Apr 15", 
                "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.", 
                "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.", 
                "volume": "21"
            }
        ], 
        "cancerType": "Histiocytic Disorder", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000307102", 
            "curatedRefSeq": "NM_002755.3", 
            "entrezGeneId": 5604, 
            "geneAliases": [
                "MKK1", 
                "PRKMK1", 
                "MEK1", 
                "MAPKK1", 
                "CFC3"
            ], 
            "hugoSymbol": "MAP2K1", 
            "name": "mitogen-activated protein kinase kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3078, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502563000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Histiocytic Disorder"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cobimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "E17K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000349310", 
                    "curatedRefSeq": "NM_001014431.1", 
                    "entrezGeneId": 207, 
                    "geneAliases": [
                        "PRKBA", 
                        "RAC", 
                        "PKB", 
                        "CWS6", 
                        "AKT", 
                        "RAC-ALPHA", 
                        "PKB-ALPHA"
                    ], 
                    "hugoSymbol": "AKT1", 
                    "name": "AKT serine/threonine kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "E17K", 
                "proteinEnd": 17, 
                "proteinStart": 17, 
                "refResidues": "E", 
                "variantResidues": "K"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Davies BR et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-11-0824-T", 
                "issue": "4", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "873-87", 
                "pmid": "22294718", 
                "pubDate": "2012 Apr", 
                "reference": "Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.", 
                "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.", 
                "volume": "11"
            }, 
            {
                "abstract": null, 
                "authors": "Hyman DM et al", 
                "elocationId": "doi: 10.1200/JCO.2017.73.0143", 
                "issue": "20", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2251-2259", 
                "pmid": "28489509", 
                "pubDate": "2017 Jul 10", 
                "reference": "Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.", 
                "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.", 
                "volume": "35"
            }, 
            {
                "abstract": null, 
                "authors": "Addie M et al", 
                "elocationId": "doi: 10.1021/jm301762v", 
                "issue": "5", 
                "journal": "Journal of medicinal chemistry", 
                "link": null, 
                "pages": "2059-73", 
                "pmid": "23394218", 
                "pubDate": "2013 Mar 14", 
                "reference": "Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.", 
                "title": "Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.", 
                "volume": "56"
            }, 
            {
                "abstract": null, 
                "authors": "Davies BR et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-15-0230", 
                "issue": "11", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "2441-51", 
                "pmid": "26351323", 
                "pubDate": "2015 Nov", 
                "reference": "Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.", 
                "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.", 
                "volume": "14"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000349310", 
            "curatedRefSeq": "NM_001014431.1", 
            "entrezGeneId": 207, 
            "geneAliases": [
                "PRKBA", 
                "RAC", 
                "PKB", 
                "CWS6", 
                "AKT", 
                "RAC-ALPHA", 
                "PKB-ALPHA"
            ], 
            "hugoSymbol": "AKT1", 
            "name": "AKT serine/threonine kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 5257, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434586000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD5363", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "E17K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000349310", 
                    "curatedRefSeq": "NM_001014431.1", 
                    "entrezGeneId": 207, 
                    "geneAliases": [
                        "PRKBA", 
                        "RAC", 
                        "PKB", 
                        "CWS6", 
                        "AKT", 
                        "RAC-ALPHA", 
                        "PKB-ALPHA"
                    ], 
                    "hugoSymbol": "AKT1", 
                    "name": "AKT serine/threonine kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "E17K", 
                "proteinEnd": 17, 
                "proteinStart": 17, 
                "refResidues": "E", 
                "variantResidues": "K"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Davies BR et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-11-0824-T", 
                "issue": "4", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "873-87", 
                "pmid": "22294718", 
                "pubDate": "2012 Apr", 
                "reference": "Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.", 
                "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.", 
                "volume": "11"
            }, 
            {
                "abstract": null, 
                "authors": "Hyman DM et al", 
                "elocationId": "doi: 10.1200/JCO.2017.73.0143", 
                "issue": "20", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2251-2259", 
                "pmid": "28489509", 
                "pubDate": "2017 Jul 10", 
                "reference": "Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.", 
                "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.", 
                "volume": "35"
            }, 
            {
                "abstract": null, 
                "authors": "Addie M et al", 
                "elocationId": "doi: 10.1021/jm301762v", 
                "issue": "5", 
                "journal": "Journal of medicinal chemistry", 
                "link": null, 
                "pages": "2059-73", 
                "pmid": "23394218", 
                "pubDate": "2013 Mar 14", 
                "reference": "Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.", 
                "title": "Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.", 
                "volume": "56"
            }, 
            {
                "abstract": null, 
                "authors": "Davies BR et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-15-0230", 
                "issue": "11", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "2441-51", 
                "pmid": "26351323", 
                "pubDate": "2015 Nov", 
                "reference": "Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.", 
                "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.", 
                "volume": "14"
            }
        ], 
        "cancerType": "Endometrial Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000349310", 
            "curatedRefSeq": "NM_001014431.1", 
            "entrezGeneId": 207, 
            "geneAliases": [
                "PRKBA", 
                "RAC", 
                "PKB", 
                "CWS6", 
                "AKT", 
                "RAC-ALPHA", 
                "PKB-ALPHA"
            ], 
            "hugoSymbol": "AKT1", 
            "name": "AKT serine/threonine kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 5259, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434686000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Endometrial Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD5363", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000462284", 
                    "curatedRefSeq": "NM_002392.5", 
                    "entrezGeneId": 4193, 
                    "geneAliases": [
                        "hdm2", 
                        "HDMX", 
                        "ACTFS"
                    ], 
                    "hugoSymbol": "MDM2", 
                    "name": "MDM2 proto-oncogene", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Ray-Coquard I et al", 
                "elocationId": "doi: 10.1016/S1470-2045(12)70474-6", 
                "issue": "11", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "1133-40", 
                "pmid": "23084521", 
                "pubDate": "2012 Nov", 
                "reference": "Ray-Coquard I et al. The Lancet. Oncology. 2012 Nov;13(11)1133-40.", 
                "title": "Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.", 
                "volume": "13"
            }, 
            {
                "abstract": null, 
                "authors": "Tovar C et al", 
                "elocationId": "doi: 10.1158/0008-5472.CAN-12-2807", 
                "issue": "8", 
                "journal": "Cancer research", 
                "link": null, 
                "pages": "2587-97", 
                "pmid": "23400593", 
                "pubDate": "2013 Apr 15", 
                "reference": "Tovar C et al. Cancer research. 2013 Apr 15;73(8)2587-97.", 
                "title": "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.", 
                "volume": "73"
            }
        ], 
        "cancerType": "Soft Tissue Sarcoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000462284", 
            "curatedRefSeq": "NM_002392.5", 
            "entrezGeneId": 4193, 
            "geneAliases": [
                "hdm2", 
                "HDMX", 
                "ACTFS"
            ], 
            "hugoSymbol": "MDM2", 
            "name": "MDM2 proto-oncogene", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2956, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502638000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C3194"
            ], 
            "UMLS": [
                "C0023827"
            ], 
            "children": null, 
            "code": "LIPO", 
            "color": "LightYellow", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 2, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Soft Tissue Sarcoma"
            }, 
            "name": "Liposarcoma", 
            "parent": "SOFT_TISSUE", 
            "tissue": "Soft Tissue"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "LIPO", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "RG7112", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000462284", 
                    "curatedRefSeq": "NM_002392.5", 
                    "entrezGeneId": 4193, 
                    "geneAliases": [
                        "hdm2", 
                        "HDMX", 
                        "ACTFS"
                    ], 
                    "hugoSymbol": "MDM2", 
                    "name": "MDM2 proto-oncogene", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Gounder et al. Abstract# 2581, ASCO 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/166204-176", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Tovar C et al", 
                "elocationId": "doi: 10.1158/0008-5472.CAN-12-2807", 
                "issue": "8", 
                "journal": "Cancer research", 
                "link": null, 
                "pages": "2587-97", 
                "pmid": "23400593", 
                "pubDate": "2013 Apr 15", 
                "reference": "Tovar C et al. Cancer research. 2013 Apr 15;73(8)2587-97.", 
                "title": "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.", 
                "volume": "73"
            }
        ], 
        "cancerType": "Soft Tissue Sarcoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000462284", 
            "curatedRefSeq": "NM_002392.5", 
            "entrezGeneId": 4193, 
            "geneAliases": [
                "hdm2", 
                "HDMX", 
                "ACTFS"
            ], 
            "hugoSymbol": "MDM2", 
            "name": "MDM2 proto-oncogene", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2957, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502661000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C3194"
            ], 
            "UMLS": [
                "C0023827"
            ], 
            "children": null, 
            "code": "LIPO", 
            "color": "LightYellow", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 2, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Soft Tissue Sarcoma"
            }, 
            "name": "Liposarcoma", 
            "parent": "SOFT_TISSUE", 
            "tissue": "Soft Tissue"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "LIPO", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "DS-3032b", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "E17K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000349310", 
                    "curatedRefSeq": "NM_001014431.1", 
                    "entrezGeneId": 207, 
                    "geneAliases": [
                        "PRKBA", 
                        "RAC", 
                        "PKB", 
                        "CWS6", 
                        "AKT", 
                        "RAC-ALPHA", 
                        "PKB-ALPHA"
                    ], 
                    "hugoSymbol": "AKT1", 
                    "name": "AKT serine/threonine kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "E17K", 
                "proteinEnd": 17, 
                "proteinStart": 17, 
                "refResidues": "E", 
                "variantResidues": "K"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Davies BR et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-11-0824-T", 
                "issue": "4", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "873-87", 
                "pmid": "22294718", 
                "pubDate": "2012 Apr", 
                "reference": "Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.", 
                "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.", 
                "volume": "11"
            }, 
            {
                "abstract": null, 
                "authors": "Hyman DM et al", 
                "elocationId": "doi: 10.1200/JCO.2017.73.0143", 
                "issue": "20", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2251-2259", 
                "pmid": "28489509", 
                "pubDate": "2017 Jul 10", 
                "reference": "Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.", 
                "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.", 
                "volume": "35"
            }, 
            {
                "abstract": null, 
                "authors": "Addie M et al", 
                "elocationId": "doi: 10.1021/jm301762v", 
                "issue": "5", 
                "journal": "Journal of medicinal chemistry", 
                "link": null, 
                "pages": "2059-73", 
                "pmid": "23394218", 
                "pubDate": "2013 Mar 14", 
                "reference": "Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.", 
                "title": "Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.", 
                "volume": "56"
            }, 
            {
                "abstract": null, 
                "authors": "Davies BR et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-15-0230", 
                "issue": "11", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "2441-51", 
                "pmid": "26351323", 
                "pubDate": "2015 Nov", 
                "reference": "Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.", 
                "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.", 
                "volume": "14"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000349310", 
            "curatedRefSeq": "NM_001014431.1", 
            "entrezGeneId": 207, 
            "geneAliases": [
                "PRKBA", 
                "RAC", 
                "PKB", 
                "CWS6", 
                "AKT", 
                "RAC-ALPHA", 
                "PKB-ALPHA"
            ], 
            "hugoSymbol": "AKT1", 
            "name": "AKT serine/threonine kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 5261, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434686000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD5363", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000524377", 
                    "curatedRefSeq": "NM_002529.3", 
                    "entrezGeneId": 4914, 
                    "geneAliases": [
                        "TRK1", 
                        "TRKA", 
                        "Trk-A", 
                        "TRK", 
                        "p140-TrkA", 
                        "MTC"
                    ], 
                    "hugoSymbol": "NTRK1", 
                    "name": "neurotrophic receptor tyrosine kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Hyman et al. Abstract# LBA2501, ASCO 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA2501", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Doebele RC et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0443", 
                "issue": "10", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "1049-57", 
                "pmid": "26216294", 
                "pubDate": "2015 Oct", 
                "reference": "Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.", 
                "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.", 
                "volume": "5"
            }
        ], 
        "cancerType": "All Solid Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000524377", 
            "curatedRefSeq": "NM_002529.3", 
            "entrezGeneId": 4914, 
            "geneAliases": [
                "TRK1", 
                "TRKA", 
                "Trk-A", 
                "TRK", 
                "p140-TrkA", 
                "MTC"
            ], 
            "hugoSymbol": "NTRK1", 
            "name": "neurotrophic receptor tyrosine kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2192, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503906000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Solid Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Larotrectinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000524377", 
                    "curatedRefSeq": "NM_002529.3", 
                    "entrezGeneId": 4914, 
                    "geneAliases": [
                        "TRK1", 
                        "TRKA", 
                        "Trk-A", 
                        "TRK", 
                        "p140-TrkA", 
                        "MTC"
                    ], 
                    "hugoSymbol": "NTRK1", 
                    "name": "neurotrophic receptor tyrosine kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-16-1237", 
                "issue": "4", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "400-409", 
                "pmid": "28183697", 
                "pubDate": "2017 Apr", 
                "reference": "Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.", 
                "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).", 
                "volume": "7"
            }, 
            {
                "abstract": "Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "https://meetinglibrary.asco.org/record/155954/abstract", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "All Solid Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000524377", 
            "curatedRefSeq": "NM_002529.3", 
            "entrezGeneId": 4914, 
            "geneAliases": [
                "TRK1", 
                "TRKA", 
                "Trk-A", 
                "TRK", 
                "p140-TrkA", 
                "MTC"
            ], 
            "hugoSymbol": "NTRK1", 
            "name": "neurotrophic receptor tyrosine kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2193, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503706000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Solid Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Entrectinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "L597R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L597R", 
                "proteinEnd": 597, 
                "proteinStart": 597, 
                "refResidues": "L", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "L597S", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L597S", 
                "proteinEnd": 597, 
                "proteinStart": 597, 
                "refResidues": "L", 
                "variantResidues": "S"
            }, 
            {
                "alteration": "L597V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L597V", 
                "proteinEnd": 597, 
                "proteinStart": 597, 
                "refResidues": "L", 
                "variantResidues": "V"
            }, 
            {
                "alteration": "L597Q", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L597Q", 
                "proteinEnd": 597, 
                "proteinStart": 597, 
                "refResidues": "L", 
                "variantResidues": "Q"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bowyer SE et al", 
                "elocationId": "doi: 10.1097/CMR.0000000000000099", 
                "issue": "5", 
                "journal": "Melanoma research", 
                "link": null, 
                "pages": "504-8", 
                "pmid": "24933606", 
                "pubDate": "2014 Oct", 
                "reference": "Bowyer SE et al. Melanoma research. 2014 Oct;24(5)504-8.", 
                "title": "Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.", 
                "volume": "24"
            }, 
            {
                "abstract": null, 
                "authors": "Dahlman KB et al", 
                "elocationId": "", 
                "issue": "9", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "791-7", 
                "pmid": "22798288", 
                "pubDate": "2012 Sep", 
                "reference": "Dahlman KB et al. Cancer discovery. 2012 Sep;2(9)791-7.", 
                "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.", 
                "volume": "2"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4631, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434911000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "K601E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "K601E", 
                "proteinEnd": 601, 
                "proteinStart": 601, 
                "refResidues": "K", 
                "variantResidues": "E"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bowyer SE et al", 
                "elocationId": "doi: 10.1097/CMR.0000000000000099", 
                "issue": "5", 
                "journal": "Melanoma research", 
                "link": null, 
                "pages": "504-8", 
                "pmid": "24933606", 
                "pubDate": "2014 Oct", 
                "reference": "Bowyer SE et al. Melanoma research. 2014 Oct;24(5)504-8.", 
                "title": "Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.", 
                "volume": "24"
            }, 
            {
                "abstract": null, 
                "authors": "Kim KB et al", 
                "elocationId": "doi: 10.1200/JCO.2012.43.5966", 
                "issue": "4", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "482-9", 
                "pmid": "23248257", 
                "pubDate": "2013 Feb 1", 
                "reference": "Kim KB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Feb 1;31(4)482-9.", 
                "title": "Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Marconcini R et al", 
                "elocationId": "doi: 10.1186/s40164-017-0067-4", 
                "issue": "", 
                "journal": "Experimental hematology &amp; oncology", 
                "link": null, 
                "pages": "6", 
                "pmid": "28344857", 
                "pubDate": "2017", 
                "reference": "Marconcini R et al. Experimental hematology &amp; oncology. 2017;6()6.", 
                "title": "Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36months.", 
                "volume": "6"
            }, 
            {
                "abstract": null, 
                "authors": "Dahlman KB et al", 
                "elocationId": "", 
                "issue": "9", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "791-7", 
                "pmid": "22798288", 
                "pubDate": "2012 Sep", 
                "reference": "Dahlman KB et al. Cancer discovery. 2012 Sep;2(9)791-7.", 
                "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.", 
                "volume": "2"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4636, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434939000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000206249", 
                    "curatedRefSeq": "NM_001122740.1", 
                    "entrezGeneId": 2099, 
                    "geneAliases": [
                        "ESR", 
                        "ESTRR", 
                        "Era", 
                        "ER", 
                        "ESRA", 
                        "NR3A1"
                    ], 
                    "hugoSymbol": "ESR1", 
                    "name": "estrogen receptor 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Toy W et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-1523", 
                "issue": "3", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "277-287", 
                "pmid": "27986707", 
                "pubDate": "2017 Mar", 
                "reference": "Toy W et al. Cancer discovery. 2017 Mar;7(3)277-287.", 
                "title": "Activating &lt;i&gt;ESR1&lt;/i&gt; Mutations Differentially Affect the Efficacy of ER Antagonists.", 
                "volume": "7"
            }, 
            {
                "abstract": null, 
                "authors": "Fribbens C et al", 
                "elocationId": "doi: 10.1200/JCO.2016.67.3061", 
                "issue": "25", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "2961-8", 
                "pmid": "27269946", 
                "pubDate": "2016 Sep 1", 
                "reference": "Fribbens C et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Sep 1;34(25)2961-8.", 
                "title": "Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.", 
                "volume": "34"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000206249", 
            "curatedRefSeq": "NM_001122740.1", 
            "entrezGeneId": 2099, 
            "geneAliases": [
                "ESR", 
                "ESTRR", 
                "Era", 
                "ER", 
                "ESRA", 
                "NR3A1"
            ], 
            "hugoSymbol": "ESR1", 
            "name": "estrogen receptor 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4382, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435496000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Fulvestrant", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD9496", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D1010H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010H", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "X1009_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1009_splice", 
                "proteinEnd": 1009, 
                "proteinStart": 1009, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X963_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X963_splice", 
                "proteinEnd": 963, 
                "proteinStart": 963, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1006_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1006_splice", 
                "proteinEnd": 1006, 
                "proteinStart": 1006, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "D1010N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010N", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "D1010Y", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010Y", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "Y"
            }, 
            {
                "alteration": "X1010_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1010_splice", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "981_1028splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "981_1028splice", 
                "proteinEnd": 1028, 
                "proteinStart": 981, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1008_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1008_splice", 
                "proteinEnd": 1008, 
                "proteinStart": 1008, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1007_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1007_splice", 
                "proteinEnd": 1007, 
                "proteinStart": 1007, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "Y1003N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Y1003N", 
                "proteinEnd": 1003, 
                "proteinStart": 1003, 
                "refResidues": "Y", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "963_D1010splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "963_D1010splice", 
                "proteinEnd": 1010, 
                "proteinStart": 963, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Frampton GM et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0285", 
                "issue": "8", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "850-9", 
                "pmid": "25971938", 
                "pubDate": "2015 Aug", 
                "reference": "Frampton GM et al. Cancer discovery. 2015 Aug;5(8)850-9.", 
                "title": "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Liu X et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-11-1157", 
                "issue": "22", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "7127-38", 
                "pmid": "21918175", 
                "pubDate": "2011 Nov 15", 
                "reference": "Liu X et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Nov 15;17(22)7127-38.", 
                "title": "A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.", 
                "volume": "17"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000397752", 
            "curatedRefSeq": "NM_000245.2", 
            "entrezGeneId": 4233, 
            "geneAliases": [
                "RCCP2", 
                "HGFR", 
                "c-Met", 
                "DFNB97", 
                "AUTS9"
            ], 
            "hugoSymbol": "MET", 
            "name": "MET proto-oncogene, receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2591, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503386000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Capmatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D1010H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010H", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "X1009_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1009_splice", 
                "proteinEnd": 1009, 
                "proteinStart": 1009, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X963_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X963_splice", 
                "proteinEnd": 963, 
                "proteinStart": 963, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1006_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1006_splice", 
                "proteinEnd": 1006, 
                "proteinStart": 1006, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "D1010N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010N", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "D1010Y", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D1010Y", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": "D", 
                "variantResidues": "Y"
            }, 
            {
                "alteration": "X1010_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1010_splice", 
                "proteinEnd": 1010, 
                "proteinStart": 1010, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "981_1028splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "981_1028splice", 
                "proteinEnd": 1028, 
                "proteinStart": 981, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1008_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1008_splice", 
                "proteinEnd": 1008, 
                "proteinStart": 1008, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "X1007_splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "X1007_splice", 
                "proteinEnd": 1007, 
                "proteinStart": 1007, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "Y1003N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Y1003N", 
                "proteinEnd": 1003, 
                "proteinStart": 1003, 
                "refResidues": "Y", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "963_D1010splice", 
                "consequence": {
                    "description": "A sequence variant in which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 bases of the intron", 
                    "isGenerallyTruncating": true, 
                    "term": "splice_region_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397752", 
                    "curatedRefSeq": "NM_000245.2", 
                    "entrezGeneId": 4233, 
                    "geneAliases": [
                        "RCCP2", 
                        "HGFR", 
                        "c-Met", 
                        "DFNB97", 
                        "AUTS9"
                    ], 
                    "hugoSymbol": "MET", 
                    "name": "MET proto-oncogene, receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "963_D1010splice", 
                "proteinEnd": 1010, 
                "proteinStart": 963, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Paik PK et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-14-1467", 
                "issue": "8", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "842-9", 
                "pmid": "25971939", 
                "pubDate": "2015 Aug", 
                "reference": "Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.", 
                "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Klempner SJ et al", 
                "elocationId": "doi: 10.1016/j.jtho.2016.09.127", 
                "issue": "1", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "152-156", 
                "pmid": "27693535", 
                "pubDate": "2017 Jan", 
                "reference": "Klempner SJ et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Jan;12(1)152-156.", 
                "title": "Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.", 
                "volume": "12"
            }, 
            {
                "abstract": null, 
                "authors": "Frampton GM et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0285", 
                "issue": "8", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "850-9", 
                "pmid": "25971938", 
                "pubDate": "2015 Aug", 
                "reference": "Frampton GM et al. Cancer discovery. 2015 Aug;5(8)850-9.", 
                "title": "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.", 
                "volume": "5"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000397752", 
            "curatedRefSeq": "NM_000245.2", 
            "entrezGeneId": 4233, 
            "geneAliases": [
                "RCCP2", 
                "HGFR", 
                "c-Met", 
                "DFNB97", 
                "AUTS9"
            ], 
            "hugoSymbol": "MET", 
            "name": "MET proto-oncogene, receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2592, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503404000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cabozantinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Amplification", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000425967", 
                    "curatedRefSeq": "NM_001174067.1", 
                    "entrezGeneId": 2260, 
                    "geneAliases": [
                        "N-SAM", 
                        "FLT2", 
                        "ECCL", 
                        "CEK", 
                        "HBGFR", 
                        "HRTFDS", 
                        "BFGFR", 
                        "FGFR-1", 
                        "FLT-2", 
                        "OGD", 
                        "FGFBR", 
                        "HH2", 
                        "bFGF-R-1", 
                        "CD331", 
                        "KAL2"
                    ], 
                    "hugoSymbol": "FGFR1", 
                    "name": "fibroblast growth factor receptor 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Amplification", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Zhang J et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694", 
                "issue": "24", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "6658-67", 
                "pmid": "23082000", 
                "pubDate": "2012 Dec 15", 
                "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.", 
                "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.", 
                "volume": "18"
            }, 
            {
                "abstract": null, 
                "authors": "Nogova L et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "157-165", 
                "pmid": "27870574", 
                "pubDate": "2017 Jan 10", 
                "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.", 
                "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.", 
                "volume": "35"
            }, 
            {
                "abstract": "Voss, MH et al. Abstract# 2500, ASCO 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/record/144575/abstract", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000425967", 
            "curatedRefSeq": "NM_001174067.1", 
            "entrezGeneId": 2260, 
            "geneAliases": [
                "N-SAM", 
                "FLT2", 
                "ECCL", 
                "CEK", 
                "HBGFR", 
                "HRTFDS", 
                "BFGFR", 
                "FGFR-1", 
                "FLT-2", 
                "OGD", 
                "FGFBR", 
                "HH2", 
                "bFGF-R-1", 
                "CD331", 
                "KAL2"
            ], 
            "hugoSymbol": "FGFR1", 
            "name": "fibroblast growth factor receptor 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4260, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435570000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C3493"
            ], 
            "UMLS": [
                "C0149782"
            ], 
            "children": null, 
            "code": "LUSC", 
            "color": "Gainsboro", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": "Lung Squamous Cell Carcinoma", 
            "parent": "NSCLC", 
            "tissue": "Lung"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "LUSC", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "JNJ-42756493", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Debio1347", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD4547", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "BGJ398", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Singh D et al", 
                "elocationId": "doi: 10.1126/science.1220834", 
                "issue": "6099", 
                "journal": "Science (New York, N.Y.)", 
                "link": null, 
                "pages": "1231-5", 
                "pmid": "22837387", 
                "pubDate": "2012 Sep 7", 
                "reference": "Singh D et al. Science (New York, N.Y.). 2012 Sep 7;337(6099)1231-5.", 
                "title": "Transforming fusions of FGFR and TACC genes in human glioblastoma.", 
                "volume": "337"
            }, 
            {
                "abstract": null, 
                "authors": "Tabernero J et al", 
                "elocationId": "doi: 10.1200/JCO.2014.60.7341", 
                "issue": "30", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3401-8", 
                "pmid": "26324363", 
                "pubDate": "2015 Oct 20", 
                "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.", 
                "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.", 
                "volume": "33"
            }
        ], 
        "cancerType": "Bladder Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000260795", 
            "curatedRefSeq": "NM_000142.4", 
            "entrezGeneId": 2261, 
            "geneAliases": [
                "JTK4", 
                "HSFGFR3EX", 
                "ACH", 
                "CEK2", 
                "CD333"
            ], 
            "hugoSymbol": "FGFR3", 
            "name": "fibroblast growth factor receptor 3", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3750, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435731000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Bladder Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Debio1347", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD4547", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "BGJ398", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "JNJ-42756493", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Y572_Y630ins", 
                "consequence": {
                    "description": "An inframe non synonymous variant that inserts bases into in the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_insertion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000241453", 
                    "curatedRefSeq": "NM_004119.2", 
                    "entrezGeneId": 2322, 
                    "geneAliases": [
                        "STK1", 
                        "FLK-2", 
                        "CD135", 
                        "FLK2"
                    ], 
                    "hugoSymbol": "FLT3", 
                    "name": "fms related tyrosine kinase 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "FLT3 internal tandem duplications", 
                "proteinEnd": 630, 
                "proteinStart": 572, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Zhang W et al", 
                "elocationId": "doi: 10.1093/jnci/djm328", 
                "issue": "3", 
                "journal": "Journal of the National Cancer Institute", 
                "link": null, 
                "pages": "184-98", 
                "pmid": "18230792", 
                "pubDate": "2008 Feb 6", 
                "reference": "Zhang W et al. Journal of the National Cancer Institute. 2008 Feb 6;100(3)184-98.", 
                "title": "Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.", 
                "volume": "100"
            }, 
            {
                "abstract": null, 
                "authors": "Man CH et al", 
                "elocationId": "doi: 10.1182/blood-2011-06-363960", 
                "issue": "22", 
                "journal": "Blood", 
                "link": null, 
                "pages": "5133-43", 
                "pmid": "22368270", 
                "pubDate": "2012 May 31", 
                "reference": "Man CH et al. Blood. 2012 May 31;119(22)5133-43.", 
                "title": "Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.", 
                "volume": "119"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000241453", 
            "curatedRefSeq": "NM_004119.2", 
            "entrezGeneId": 2322, 
            "geneAliases": [
                "STK1", 
                "FLK-2", 
                "CD135", 
                "FLK2"
            ], 
            "hugoSymbol": "FLT3", 
            "name": "fms related tyrosine kinase 3", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3623, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435833000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C3171"
            ], 
            "UMLS": [
                "C0023467"
            ], 
            "children": null, 
            "code": "AML", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Acute Myeloid Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "AML", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sorafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "K650Q", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "K650Q", 
                "proteinEnd": 650, 
                "proteinStart": 650, 
                "refResidues": "K", 
                "variantResidues": "Q"
            }, 
            {
                "alteration": "G370C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G370C", 
                "proteinEnd": 370, 
                "proteinStart": 370, 
                "refResidues": "G", 
                "variantResidues": "C"
            }, 
            {
                "alteration": "S249C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "S249C", 
                "proteinEnd": 249, 
                "proteinStart": 249, 
                "refResidues": "S", 
                "variantResidues": "C"
            }, 
            {
                "alteration": "G380R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G380R", 
                "proteinEnd": 380, 
                "proteinStart": 380, 
                "refResidues": "G", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "K650M", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "K650M", 
                "proteinEnd": 650, 
                "proteinStart": 650, 
                "refResidues": "K", 
                "variantResidues": "M"
            }, 
            {
                "alteration": "K650R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "K650R", 
                "proteinEnd": 650, 
                "proteinStart": 650, 
                "refResidues": "K", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "K650T", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "K650T", 
                "proteinEnd": 650, 
                "proteinStart": 650, 
                "refResidues": "K", 
                "variantResidues": "T"
            }, 
            {
                "alteration": "S371C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "S371C", 
                "proteinEnd": 371, 
                "proteinStart": 371, 
                "refResidues": "S", 
                "variantResidues": "C"
            }, 
            {
                "alteration": "R248C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R248C", 
                "proteinEnd": 248, 
                "proteinStart": 248, 
                "refResidues": "R", 
                "variantResidues": "C"
            }, 
            {
                "alteration": "K650N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "K650N", 
                "proteinEnd": 650, 
                "proteinStart": 650, 
                "refResidues": "K", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "Y373C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Y373C", 
                "proteinEnd": 373, 
                "proteinStart": 373, 
                "refResidues": "Y", 
                "variantResidues": "C"
            }, 
            {
                "alteration": "K650E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000260795", 
                    "curatedRefSeq": "NM_000142.4", 
                    "entrezGeneId": 2261, 
                    "geneAliases": [
                        "JTK4", 
                        "HSFGFR3EX", 
                        "ACH", 
                        "CEK2", 
                        "CD333"
                    ], 
                    "hugoSymbol": "FGFR3", 
                    "name": "fibroblast growth factor receptor 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "K650E", 
                "proteinEnd": 650, 
                "proteinStart": 650, 
                "refResidues": "K", 
                "variantResidues": "E"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Nogova L et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "157-165", 
                "pmid": "27870574", 
                "pubDate": "2017 Jan 10", 
                "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.", 
                "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.", 
                "volume": "35"
            }, 
            {
                "abstract": null, 
                "authors": "Lamont FR et al", 
                "elocationId": "doi: 10.1038/sj.bjc.6606016", 
                "issue": "1", 
                "journal": "British journal of cancer", 
                "link": null, 
                "pages": "75-82", 
                "pmid": "21119661", 
                "pubDate": "2011 Jan 4", 
                "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.", 
                "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.", 
                "volume": "104"
            }, 
            {
                "abstract": null, 
                "authors": "Tabernero J et al", 
                "elocationId": "doi: 10.1200/JCO.2014.60.7341", 
                "issue": "30", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3401-8", 
                "pmid": "26324363", 
                "pubDate": "2015 Oct 20", 
                "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.", 
                "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.", 
                "volume": "33"
            }
        ], 
        "cancerType": "Bladder Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000260795", 
            "curatedRefSeq": "NM_000142.4", 
            "entrezGeneId": 2261, 
            "geneAliases": [
                "JTK4", 
                "HSFGFR3EX", 
                "ACH", 
                "CEK2", 
                "CD333"
            ], 
            "hugoSymbol": "FGFR3", 
            "name": "fibroblast growth factor receptor 3", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3753, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435756000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Bladder Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD-4575", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Debio1347", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "BGJ-398", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "JNJ-42756493", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000358487", 
                    "curatedRefSeq": "NM_000141.4", 
                    "entrezGeneId": 2263, 
                    "geneAliases": [
                        "BBDS", 
                        "BFR-1", 
                        "CEK3", 
                        "JWS", 
                        "BEK", 
                        "K-SAM", 
                        "KGFR", 
                        "ECT1", 
                        "TK14", 
                        "TK25", 
                        "CD332", 
                        "CFD1"
                    ], 
                    "hugoSymbol": "FGFR2", 
                    "name": "fibroblast growth factor receptor 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Nogova L et al", 
                "elocationId": "", 
                "issue": "2", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "157-165", 
                "pmid": "27870574", 
                "pubDate": "2017 Jan 10", 
                "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.", 
                "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.", 
                "volume": "35"
            }, 
            {
                "abstract": null, 
                "authors": "Arai Y et al", 
                "elocationId": "doi: 10.1002/hep.26890", 
                "issue": "4", 
                "journal": "Hepatology (Baltimore, Md.)", 
                "link": null, 
                "pages": "1427-34", 
                "pmid": "24122810", 
                "pubDate": "2014 Apr", 
                "reference": "Arai Y et al. Hepatology (Baltimore, Md.). 2014 Apr;59(4)1427-34.", 
                "title": "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.", 
                "volume": "59"
            }, 
            {
                "abstract": null, 
                "authors": "Tabernero J et al", 
                "elocationId": "doi: 10.1200/JCO.2014.60.7341", 
                "issue": "30", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "3401-8", 
                "pmid": "26324363", 
                "pubDate": "2015 Oct 20", 
                "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.", 
                "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.", 
                "volume": "33"
            }
        ], 
        "cancerType": "Bladder Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000358487", 
            "curatedRefSeq": "NM_000141.4", 
            "entrezGeneId": 2263, 
            "geneAliases": [
                "BBDS", 
                "BFR-1", 
                "CEK3", 
                "JWS", 
                "BEK", 
                "K-SAM", 
                "KGFR", 
                "ECT1", 
                "TK14", 
                "TK25", 
                "CD332", 
                "CFD1"
            ], 
            "hugoSymbol": "FGFR2", 
            "name": "fibroblast growth factor receptor 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4015, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435655000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Bladder Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "BGJ-398", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Debio1347", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD4575", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "JNJ-42756493", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000358487", 
                    "curatedRefSeq": "NM_000141.4", 
                    "entrezGeneId": 2263, 
                    "geneAliases": [
                        "BBDS", 
                        "BFR-1", 
                        "CEK3", 
                        "JWS", 
                        "BEK", 
                        "K-SAM", 
                        "KGFR", 
                        "ECT1", 
                        "TK14", 
                        "TK25", 
                        "CD332", 
                        "CFD1"
                    ], 
                    "hugoSymbol": "FGFR2", 
                    "name": "fibroblast growth factor receptor 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Cleary et al. Abstract# 447, Gastrointestinal Cancer Symposium, 2018", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "https://meetinglibrary.asco.org/record/155948/abstract", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Arai Y et al", 
                "elocationId": "doi: 10.1002/hep.26890", 
                "issue": "4", 
                "journal": "Hepatology (Baltimore, Md.)", 
                "link": null, 
                "pages": "1427-34", 
                "pmid": "24122810", 
                "pubDate": "2014 Apr", 
                "reference": "Arai Y et al. Hepatology (Baltimore, Md.). 2014 Apr;59(4)1427-34.", 
                "title": "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.", 
                "volume": "59"
            }, 
            {
                "abstract": null, 
                "authors": "Javle M et al", 
                "elocationId": "doi: 10.1200/JCO.2017.75.5009", 
                "issue": "3", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "276-282", 
                "pmid": "29182496", 
                "pubDate": "2018 Jan 20", 
                "reference": "Javle M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 20;36(3)276-282.", 
                "title": "Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.", 
                "volume": "36"
            }
        ], 
        "cancerType": "Hepatobiliary Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000358487", 
            "curatedRefSeq": "NM_000141.4", 
            "entrezGeneId": 2263, 
            "geneAliases": [
                "BBDS", 
                "BFR-1", 
                "CEK3", 
                "JWS", 
                "BEK", 
                "K-SAM", 
                "KGFR", 
                "ECT1", 
                "TK14", 
                "TK25", 
                "CD332", 
                "CFD1"
            ], 
            "hugoSymbol": "FGFR2", 
            "name": "fibroblast growth factor receptor 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4017, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435677000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C4436"
            ], 
            "UMLS": [
                "C0206698"
            ], 
            "children": null, 
            "code": "CHOL", 
            "color": "Green", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 2, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Hepatobiliary Cancer"
            }, 
            "name": "Cholangiocarcinoma", 
            "parent": "BILIARY_TRACT", 
            "tissue": "Biliary Tract"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "CHOL", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD4575", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Debio1347", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "BGJ-398", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "JNJ-42756493", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bose R et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-12-0349", 
                "issue": "2", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "224-37", 
                "pmid": "23220880", 
                "pubDate": "2013 Feb", 
                "reference": "Bose R et al. Cancer discovery. 2013 Feb;3(2)224-37.", 
                "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.", 
                "volume": "3"
            }, 
            {
                "abstract": "Hyman et al. Abstract# CT001, AACR 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/CT001", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 562, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435263000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Neratinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Bose R et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-12-0349", 
                "issue": "2", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "224-37", 
                "pmid": "23220880", 
                "pubDate": "2013 Feb", 
                "reference": "Bose R et al. Cancer discovery. 2013 Feb;3(2)224-37.", 
                "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.", 
                "volume": "3"
            }, 
            {
                "abstract": "Hyman et al. Abstract# CT001, AACR 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/CT001", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 565, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517435221000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Neratinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "PCM1-JAK2 Fusion", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000381652", 
                    "curatedRefSeq": "NM_004972.3", 
                    "entrezGeneId": 3717, 
                    "geneAliases": [
                        "THCYT3", 
                        "JTK10"
                    ], 
                    "hugoSymbol": "JAK2", 
                    "name": "Janus kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "PCM1-JAK2 Fusion", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Roberts KG et al", 
                "elocationId": "doi: 10.1056/NEJMoa1403088", 
                "issue": "11", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1005-15", 
                "pmid": "25207766", 
                "pubDate": "2014 Sep 11", 
                "reference": "Roberts KG et al. The New England journal of medicine. 2014 Sep 11;371(11)1005-15.", 
                "title": "Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.", 
                "volume": "371"
            }, 
            {
                "abstract": null, 
                "authors": "Schinnerl D et al", 
                "elocationId": "doi: 10.1182/blood-2014-04-570960", 
                "issue": "8", 
                "journal": "Blood", 
                "link": null, 
                "pages": "1282-91", 
                "pmid": "25515960", 
                "pubDate": "2015 Feb 19", 
                "reference": "Schinnerl D et al. Blood. 2015 Feb 19;125(8)1282-91.", 
                "title": "The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.", 
                "volume": "125"
            }, 
            {
                "abstract": null, 
                "authors": "Rumi E et al", 
                "elocationId": "doi: 10.1200/JCO.2012.46.4370", 
                "issue": "17", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "e269-71", 
                "pmid": "23630205", 
                "pubDate": "2013 Jun 10", 
                "reference": "Rumi E et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 10;31(17)e269-71.", 
                "title": "Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.", 
                "volume": "31"
            }, 
            {
                "abstract": null, 
                "authors": "Patterer V et al", 
                "elocationId": "doi: 10.1007/s00277-013-1695-3", 
                "issue": "6", 
                "journal": "Annals of hematology", 
                "link": null, 
                "pages": "759-69", 
                "pmid": "23400675", 
                "pubDate": "2013 Jun", 
                "reference": "Patterer V et al. Annals of hematology. 2013 Jun;92(6)759-69.", 
                "title": "Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.", 
                "volume": "92"
            }, 
            {
                "abstract": null, 
                "authors": "Chase A et al", 
                "elocationId": "doi: 10.3324/haematol.2012.067959", 
                "issue": "3", 
                "journal": "Haematologica", 
                "link": null, 
                "pages": "404-8", 
                "pmid": "22875628", 
                "pubDate": "2013 Mar", 
                "reference": "Chase A et al. Haematologica. 2013 Mar;98(3)404-8.", 
                "title": "Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.", 
                "volume": "98"
            }, 
            {
                "abstract": null, 
                "authors": "Schwaab J et al", 
                "elocationId": "doi: 10.1007/s00277-014-2221-y", 
                "issue": "2", 
                "journal": "Annals of hematology", 
                "link": null, 
                "pages": "233-8", 
                "pmid": "25260694", 
                "pubDate": "2015 Feb", 
                "reference": "Schwaab J et al. Annals of hematology. 2015 Feb;94(2)233-8.", 
                "title": "Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.", 
                "volume": "94"
            }, 
            {
                "abstract": null, 
                "authors": "Rumi E et al", 
                "elocationId": "doi: 10.1007/s00277-015-2451-7", 
                "issue": "11", 
                "journal": "Annals of hematology", 
                "link": null, 
                "pages": "1927-8", 
                "pmid": "26202607", 
                "pubDate": "2015 Nov", 
                "reference": "Rumi E et al. Annals of hematology. 2015 Nov;94(11)1927-8.", 
                "title": "Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.", 
                "volume": "94"
            }, 
            {
                "abstract": null, 
                "authors": "Lierman E et al", 
                "elocationId": "doi: 10.1182/blood-2012-06-433821", 
                "issue": "7", 
                "journal": "Blood", 
                "link": null, 
                "pages": "1529-31", 
                "pmid": "22899477", 
                "pubDate": "2012 Aug 16", 
                "reference": "Lierman E et al. Blood. 2012 Aug 16;120(7)1529-31.", 
                "title": "Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.", 
                "volume": "120"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000381652", 
            "curatedRefSeq": "NM_004972.3", 
            "entrezGeneId": 3717, 
            "geneAliases": [
                "THCYT3", 
                "JTK10"
            ], 
            "hugoSymbol": "JAK2", 
            "name": "Janus kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3258, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502485000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Ruxolitinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000360948", 
                    "curatedRefSeq": "NM_001012338.2", 
                    "entrezGeneId": 4916, 
                    "geneAliases": [
                        "TRKC", 
                        "GP145-TrkC", 
                        "gp145(trkC)"
                    ], 
                    "hugoSymbol": "NTRK3", 
                    "name": "neurotrophic receptor tyrosine kinase 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Hyman et al. Abstract# LBA2501, ASCO 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA2501", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Doebele RC et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-15-0443", 
                "issue": "10", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "1049-57", 
                "pmid": "26216294", 
                "pubDate": "2015 Oct", 
                "reference": "Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.", 
                "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.", 
                "volume": "5"
            }
        ], 
        "cancerType": "All Solid Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000360948", 
            "curatedRefSeq": "NM_001012338.2", 
            "entrezGeneId": 4916, 
            "geneAliases": [
                "TRKC", 
                "GP145-TrkC", 
                "gp145(trkC)"
            ], 
            "hugoSymbol": "NTRK3", 
            "name": "neurotrophic receptor tyrosine kinase 3", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2107, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503855000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Solid Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Larotrectinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000360948", 
                    "curatedRefSeq": "NM_001012338.2", 
                    "entrezGeneId": 4916, 
                    "geneAliases": [
                        "TRKC", 
                        "GP145-TrkC", 
                        "gp145(trkC)"
                    ], 
                    "hugoSymbol": "NTRK3", 
                    "name": "neurotrophic receptor tyrosine kinase 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-16-1237", 
                "issue": "4", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "400-409", 
                "pmid": "28183697", 
                "pubDate": "2017 Apr", 
                "reference": "Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.", 
                "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).", 
                "volume": "7"
            }, 
            {
                "abstract": "Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "https://meetinglibrary.asco.org/record/155954/abstract", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "All Solid Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000360948", 
            "curatedRefSeq": "NM_001012338.2", 
            "entrezGeneId": 4916, 
            "geneAliases": [
                "TRKC", 
                "GP145-TrkC", 
                "gp145(trkC)"
            ], 
            "hugoSymbol": "NTRK3", 
            "name": "neurotrophic receptor tyrosine kinase 3", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2108, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503869000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Solid Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Entrectinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "R132H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000345146", 
                    "curatedRefSeq": "NM_005896.2", 
                    "entrezGeneId": 3417, 
                    "geneAliases": [
                        "IDP", 
                        "HEL-216", 
                        "IDH", 
                        "IDPC", 
                        "IDCD", 
                        "HEL-S-26", 
                        "PICD"
                    ], 
                    "hugoSymbol": "IDH1", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R132H", 
                "proteinEnd": 132, 
                "proteinStart": 132, 
                "refResidues": "R", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "R132C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000345146", 
                    "curatedRefSeq": "NM_005896.2", 
                    "entrezGeneId": 3417, 
                    "geneAliases": [
                        "IDP", 
                        "HEL-216", 
                        "IDH", 
                        "IDPC", 
                        "IDCD", 
                        "HEL-S-26", 
                        "PICD"
                    ], 
                    "hugoSymbol": "IDH1", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R132C", 
                "proteinEnd": 132, 
                "proteinStart": 132, 
                "refResidues": "R", 
                "variantResidues": "C"
            }, 
            {
                "alteration": "R132S", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000345146", 
                    "curatedRefSeq": "NM_005896.2", 
                    "entrezGeneId": 3417, 
                    "geneAliases": [
                        "IDP", 
                        "HEL-216", 
                        "IDH", 
                        "IDPC", 
                        "IDCD", 
                        "HEL-S-26", 
                        "PICD"
                    ], 
                    "hugoSymbol": "IDH1", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R132S", 
                "proteinEnd": 132, 
                "proteinStart": 132, 
                "refResidues": "R", 
                "variantResidues": "S"
            }, 
            {
                "alteration": "R132G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000345146", 
                    "curatedRefSeq": "NM_005896.2", 
                    "entrezGeneId": 3417, 
                    "geneAliases": [
                        "IDP", 
                        "HEL-216", 
                        "IDH", 
                        "IDPC", 
                        "IDCD", 
                        "HEL-S-26", 
                        "PICD"
                    ], 
                    "hugoSymbol": "IDH1", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R132G", 
                "proteinEnd": 132, 
                "proteinStart": 132, 
                "refResidues": "R", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "R132Q", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000345146", 
                    "curatedRefSeq": "NM_005896.2", 
                    "entrezGeneId": 3417, 
                    "geneAliases": [
                        "IDP", 
                        "HEL-216", 
                        "IDH", 
                        "IDPC", 
                        "IDCD", 
                        "HEL-S-26", 
                        "PICD"
                    ], 
                    "hugoSymbol": "IDH1", 
                    "name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "R132Q", 
                "proteinEnd": 132, 
                "proteinStart": 132, 
                "refResidues": "R", 
                "variantResidues": "Q"
            }
        ], 
        "articles": [
            {
                "abstract": "Hansen et al. Abstract# 3734, ASH 2014", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://www.bloodjournal.org/content/124/21/3734?sso-checked=true", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Losman JA et al", 
                "elocationId": "doi: 10.1126/science.1231677", 
                "issue": "6127", 
                "journal": "Science (New York, N.Y.)", 
                "link": null, 
                "pages": "1621-5", 
                "pmid": "23393090", 
                "pubDate": "2013 Mar 29", 
                "reference": "Losman JA et al. Science (New York, N.Y.). 2013 Mar 29;339(6127)1621-5.", 
                "title": "(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.", 
                "volume": "339"
            }, 
            {
                "abstract": null, 
                "authors": "Rohle D et al", 
                "elocationId": "doi: 10.1126/science.1236062", 
                "issue": "6132", 
                "journal": "Science (New York, N.Y.)", 
                "link": null, 
                "pages": "626-30", 
                "pmid": "23558169", 
                "pubDate": "2013 May 3", 
                "reference": "Rohle D et al. Science (New York, N.Y.). 2013 May 3;340(6132)626-30.", 
                "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.", 
                "volume": "340"
            }
        ], 
        "cancerType": "Leukemia", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000345146", 
            "curatedRefSeq": "NM_005896.2", 
            "entrezGeneId": 3417, 
            "geneAliases": [
                "IDP", 
                "HEL-216", 
                "IDH", 
                "IDPC", 
                "IDCD", 
                "HEL-S-26", 
                "PICD"
            ], 
            "hugoSymbol": "IDH1", 
            "name": "isocitrate dehydrogenase (NADP(+)) 1, cytosolic", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 3393, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517502399000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C3171"
            ], 
            "UMLS": [
                "C0023467"
            ], 
            "children": null, 
            "code": "AML", 
            "color": "LightSalmon", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Leukemia"
            }, 
            "name": "Acute Myeloid Leukemia", 
            "parent": "LEUK", 
            "tissue": "Blood"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "AML", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Ivosidenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000355710", 
                    "curatedRefSeq": "NM_020975.4", 
                    "entrezGeneId": 5979, 
                    "geneAliases": [
                        "MTC1", 
                        "CDHF12", 
                        "CDHR16", 
                        "MEN2A", 
                        "RET51", 
                        "HSCR1", 
                        "MEN2B", 
                        "PTC", 
                        "RET-ELE1"
                    ], 
                    "hugoSymbol": "RET", 
                    "name": "ret proto-oncogene", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Yoh K et al", 
                "elocationId": "doi: 10.1016/S2213-2600(16)30322-8", 
                "issue": "1", 
                "journal": "The Lancet. Respiratory medicine", 
                "link": null, 
                "pages": "42-50", 
                "pmid": "27825616", 
                "pubDate": "2017 Jan", 
                "reference": "Yoh K et al. The Lancet. Respiratory medicine. 2017 Jan;5(1)42-50.", 
                "title": "Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.", 
                "volume": "5"
            }, 
            {
                "abstract": null, 
                "authors": "Kohno T et al", 
                "elocationId": "doi: 10.1111/cas.12275", 
                "issue": "11", 
                "journal": "Cancer science", 
                "link": null, 
                "pages": "1396-400", 
                "pmid": "23991695", 
                "pubDate": "2013 Nov", 
                "reference": "Kohno T et al. Cancer science. 2013 Nov;104(11)1396-400.", 
                "title": "RET fusion gene: translation to personalized lung cancer therapy.", 
                "volume": "104"
            }, 
            {
                "abstract": null, 
                "authors": "Suzuki M et al", 
                "elocationId": "doi: 10.1111/cas.12175", 
                "issue": "7", 
                "journal": "Cancer science", 
                "link": null, 
                "pages": "896-903", 
                "pmid": "23578175", 
                "pubDate": "2013 Jul", 
                "reference": "Suzuki M et al. Cancer science. 2013 Jul;104(7)896-903.", 
                "title": "Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.", 
                "volume": "104"
            }, 
            {
                "abstract": null, 
                "authors": "Lee SH et al", 
                "elocationId": "doi: 10.1093/annonc/mdw559", 
                "issue": "2", 
                "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", 
                "link": null, 
                "pages": "292-297", 
                "pmid": "27803005", 
                "pubDate": "2017 Feb 1", 
                "reference": "Lee SH et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Feb 1;28(2)292-297.", 
                "title": "Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.", 
                "volume": "28"
            }, 
            {
                "abstract": null, 
                "authors": "Matsubara D et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e3182721ed1", 
                "issue": "12", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "1872-6", 
                "pmid": "23154560", 
                "pubDate": "2012 Dec", 
                "reference": "Matsubara D et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Dec;7(12)1872-6.", 
                "title": "Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.", 
                "volume": "7"
            }, 
            {
                "abstract": null, 
                "authors": "Falchook GS et al", 
                "elocationId": "doi: 10.1200/JCO.2013.50.5016", 
                "issue": "15", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "e141-4", 
                "pmid": "25366691", 
                "pubDate": "2016 May 20", 
                "reference": "Falchook GS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 May 20;34(15)e141-4.", 
                "title": "Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.", 
                "volume": "34"
            }, 
            {
                "abstract": null, 
                "authors": "Gautschi O et al", 
                "elocationId": "doi: 10.1097/JTO.0b013e31828a4d07", 
                "issue": "5", 
                "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", 
                "link": null, 
                "pages": "e43-4", 
                "pmid": "23584301", 
                "pubDate": "2013 May", 
                "reference": "Gautschi O et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 May;8(5)e43-4.", 
                "title": "A patient with lung adenocarcinoma and RET fusion treated with vandetanib.", 
                "volume": "8"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000355710", 
            "curatedRefSeq": "NM_020975.4", 
            "entrezGeneId": 5979, 
            "geneAliases": [
                "MTC1", 
                "CDHF12", 
                "CDHR16", 
                "MEN2A", 
                "RET51", 
                "HSCR1", 
                "MEN2B", 
                "PTC", 
                "RET-ELE1"
            ], 
            "hugoSymbol": "RET", 
            "name": "ret proto-oncogene", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 1480, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1515512921000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Vandetanib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Truncating Mutations", 
                "consequence": {
                    "description": "A sequence variant that causes the reduction of a genomic feature, with regard to the reference sequence", 
                    "isGenerallyTruncating": true, 
                    "term": "feature_truncation"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000331920", 
                    "curatedRefSeq": "NM_000264.3", 
                    "entrezGeneId": 5727, 
                    "geneAliases": [
                        "NBCCS", 
                        "PTC1", 
                        "BCNS", 
                        "HPE7", 
                        "PTCH11", 
                        "PTCH", 
                        "PTC"
                    ], 
                    "hugoSymbol": "PTCH1", 
                    "name": "patched 1", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Truncating Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Pan S et al", 
                "elocationId": "doi: 10.1021/ml1000307", 
                "issue": "3", 
                "journal": "ACS medicinal chemistry letters", 
                "link": null, 
                "pages": "130-4", 
                "pmid": "24900187", 
                "pubDate": "2010 Jun 10", 
                "reference": "Pan S et al. ACS medicinal chemistry letters. 2010 Jun 10;1(3)130-4.", 
                "title": "Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.", 
                "volume": "1"
            }, 
            {
                "abstract": null, 
                "authors": "Rodon J et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-13-1710", 
                "issue": "7", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1900-9", 
                "pmid": "24523439", 
                "pubDate": "2014 Apr 1", 
                "reference": "Rodon J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1900-9.", 
                "title": "A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.", 
                "volume": "20"
            }
        ], 
        "cancerType": "Skin Cancer, Non-Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000331920", 
            "curatedRefSeq": "NM_000264.3", 
            "entrezGeneId": 5727, 
            "geneAliases": [
                "NBCCS", 
                "PTC1", 
                "BCNS", 
                "HPE7", 
                "PTCH11", 
                "PTCH", 
                "PTC"
            ], 
            "hugoSymbol": "PTCH1", 
            "name": "patched 1", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 1620, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504408000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Skin Cancer, Non-Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sonidegib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Truncating Mutations", 
                "consequence": {
                    "description": "A sequence variant that causes the reduction of a genomic feature, with regard to the reference sequence", 
                    "isGenerallyTruncating": true, 
                    "term": "feature_truncation"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000331920", 
                    "curatedRefSeq": "NM_000264.3", 
                    "entrezGeneId": 5727, 
                    "geneAliases": [
                        "NBCCS", 
                        "PTC1", 
                        "BCNS", 
                        "HPE7", 
                        "PTCH11", 
                        "PTCH", 
                        "PTC"
                    ], 
                    "hugoSymbol": "PTCH1", 
                    "name": "patched 1", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Truncating Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Pan S et al", 
                "elocationId": "doi: 10.1021/ml1000307", 
                "issue": "3", 
                "journal": "ACS medicinal chemistry letters", 
                "link": null, 
                "pages": "130-4", 
                "pmid": "24900187", 
                "pubDate": "2010 Jun 10", 
                "reference": "Pan S et al. ACS medicinal chemistry letters. 2010 Jun 10;1(3)130-4.", 
                "title": "Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.", 
                "volume": "1"
            }, 
            {
                "abstract": null, 
                "authors": "Tang JY et al", 
                "elocationId": "doi: 10.1056/NEJMoa1113538", 
                "issue": "23", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2180-8", 
                "pmid": "22670904", 
                "pubDate": "2012 Jun 7", 
                "reference": "Tang JY et al. The New England journal of medicine. 2012 Jun 7;366(23)2180-8.", 
                "title": "Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.", 
                "volume": "366"
            }, 
            {
                "abstract": null, 
                "authors": "Sekulic A et al", 
                "elocationId": "doi: 10.1056/NEJMoa1113713", 
                "issue": "23", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "2171-9", 
                "pmid": "22670903", 
                "pubDate": "2012 Jun 7", 
                "reference": "Sekulic A et al. The New England journal of medicine. 2012 Jun 7;366(23)2171-9.", 
                "title": "Efficacy and safety of vismodegib in advanced basal-cell carcinoma.", 
                "volume": "366"
            }
        ], 
        "cancerType": "Skin Cancer, Non-Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000331920", 
            "curatedRefSeq": "NM_000264.3", 
            "entrezGeneId": 5727, 
            "geneAliases": [
                "NBCCS", 
                "PTC1", 
                "BCNS", 
                "HPE7", 
                "PTCH11", 
                "PTCH", 
                "PTC"
            ], 
            "hugoSymbol": "PTCH1", 
            "name": "patched 1", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 1621, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504432000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Skin Cancer, Non-Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Vismodegib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Hutchinson KE et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-13-1746", 
                "issue": "24", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "6696-702", 
                "pmid": "24345920", 
                "pubDate": "2013 Dec 15", 
                "reference": "Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.", 
                "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.", 
                "volume": "19"
            }, 
            {
                "abstract": null, 
                "authors": "Botton T et al", 
                "elocationId": "doi: 10.1111/pcmr.12148", 
                "issue": "6", 
                "journal": "Pigment cell &amp; melanoma research", 
                "link": null, 
                "pages": "845-51", 
                "pmid": "23890088", 
                "pubDate": "2013 Nov", 
                "reference": "Botton T et al. Pigment cell &amp; melanoma research. 2013 Nov;26(6)845-51.", 
                "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Grisham RN et al", 
                "elocationId": "doi: 10.1200/JCO.2015.62.4726", 
                "issue": "34", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4099-105", 
                "pmid": "26324360", 
                "pubDate": "2015 Dec 1", 
                "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.", 
                "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.", 
                "volume": "33"
            }
        ], 
        "cancerType": "Ovarian Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4565, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434826000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Ovarian Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cobimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Truncating Mutations", 
                "consequence": {
                    "description": "A sequence variant that causes the reduction of a genomic feature, with regard to the reference sequence", 
                    "isGenerallyTruncating": true, 
                    "term": "feature_truncation"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000331920", 
                    "curatedRefSeq": "NM_000264.3", 
                    "entrezGeneId": 5727, 
                    "geneAliases": [
                        "NBCCS", 
                        "PTC1", 
                        "BCNS", 
                        "HPE7", 
                        "PTCH11", 
                        "PTCH", 
                        "PTC"
                    ], 
                    "hugoSymbol": "PTCH1", 
                    "name": "patched 1", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Truncating Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Pan S et al", 
                "elocationId": "doi: 10.1021/ml1000307", 
                "issue": "3", 
                "journal": "ACS medicinal chemistry letters", 
                "link": null, 
                "pages": "130-4", 
                "pmid": "24900187", 
                "pubDate": "2010 Jun 10", 
                "reference": "Pan S et al. ACS medicinal chemistry letters. 2010 Jun 10;1(3)130-4.", 
                "title": "Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.", 
                "volume": "1"
            }, 
            {
                "abstract": null, 
                "authors": "Rodon J et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-13-1710", 
                "issue": "7", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "1900-9", 
                "pmid": "24523439", 
                "pubDate": "2014 Apr 1", 
                "reference": "Rodon J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1900-9.", 
                "title": "A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.", 
                "volume": "20"
            }
        ], 
        "cancerType": "Embryonal Tumor", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000331920", 
            "curatedRefSeq": "NM_000264.3", 
            "entrezGeneId": 5727, 
            "geneAliases": [
                "NBCCS", 
                "PTC1", 
                "BCNS", 
                "HPE7", 
                "PTCH11", 
                "PTCH", 
                "PTC"
            ], 
            "hugoSymbol": "PTCH1", 
            "name": "patched 1", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 1623, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517504507000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Embryonal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Sonidegib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Menzies AM et al", 
                "elocationId": "doi: 10.1111/pcmr.12388", 
                "issue": "5", 
                "journal": "Pigment cell &amp; melanoma research", 
                "link": null, 
                "pages": "607-10", 
                "pmid": "26072686", 
                "pubDate": "2015 Sep", 
                "reference": "Menzies AM et al. Pigment cell &amp; melanoma research. 2015 Sep;28(5)607-10.", 
                "title": "Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.", 
                "volume": "28"
            }, 
            {
                "abstract": null, 
                "authors": "Hutchinson KE et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-13-1746", 
                "issue": "24", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "6696-702", 
                "pmid": "24345920", 
                "pubDate": "2013 Dec 15", 
                "reference": "Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.", 
                "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.", 
                "volume": "19"
            }, 
            {
                "abstract": null, 
                "authors": "Botton T et al", 
                "elocationId": "doi: 10.1111/pcmr.12148", 
                "issue": "6", 
                "journal": "Pigment cell &amp; melanoma research", 
                "link": null, 
                "pages": "845-51", 
                "pmid": "23890088", 
                "pubDate": "2013 Nov", 
                "reference": "Botton T et al. Pigment cell &amp; melanoma research. 2013 Nov;26(6)845-51.", 
                "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.", 
                "volume": "26"
            }, 
            {
                "abstract": null, 
                "authors": "Ross JS et al", 
                "elocationId": "doi: 10.1002/ijc.29825", 
                "issue": "4", 
                "journal": "International journal of cancer", 
                "link": null, 
                "pages": "881-90", 
                "pmid": "26314551", 
                "pubDate": "2016 Feb 15", 
                "reference": "Ross JS et al. International journal of cancer. 2016 Feb 15;138(4)881-90.", 
                "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.", 
                "volume": "138"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4567, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517434859000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Cobimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "E2014K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000361445", 
                    "curatedRefSeq": "NM_004958.3", 
                    "entrezGeneId": 2475, 
                    "geneAliases": [
                        "FRAP1", 
                        "RAFT1", 
                        "FRAP2", 
                        "FRAP", 
                        "SKS", 
                        "RAPT1"
                    ], 
                    "hugoSymbol": "MTOR", 
                    "name": "mechanistic target of rapamycin", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "E2014K", 
                "proteinEnd": 2014, 
                "proteinStart": 2014, 
                "refResidues": "E", 
                "variantResidues": "K"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Wagle N et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-13-0353", 
                "issue": "5", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "546-53", 
                "pmid": "24625776", 
                "pubDate": "2014 May", 
                "reference": "Wagle N et al. Cancer discovery. 2014 May;4(5)546-53.", 
                "title": "Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.", 
                "volume": "4"
            }, 
            {
                "abstract": null, 
                "authors": "Milowsky MI et al", 
                "elocationId": "doi: 10.1111/j.1464-410X.2012.11720.x", 
                "issue": "4", 
                "journal": "BJU international", 
                "link": null, 
                "pages": "462-70", 
                "pmid": "23551593", 
                "pubDate": "2013 Aug", 
                "reference": "Milowsky MI et al. BJU international. 2013 Aug;112(4)462-70.", 
                "title": "Phase II study of everolimus in metastatic urothelial cancer.", 
                "volume": "112"
            }
        ], 
        "cancerType": "Bladder Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000361445", 
            "curatedRefSeq": "NM_004958.3", 
            "entrezGeneId": 2475, 
            "geneAliases": [
                "FRAP1", 
                "RAFT1", 
                "FRAP2", 
                "FRAP", 
                "SKS", 
                "RAPT1"
            ], 
            "hugoSymbol": "MTOR", 
            "name": "mechanistic target of rapamycin", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2398, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1517503467000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Bladder Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Everolimus", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000311189", 
                    "curatedRefSeq": "NM_001130442.1", 
                    "entrezGeneId": 3265, 
                    "geneAliases": [
                        "C-H-RAS", 
                        "HAMSV", 
                        "p21ras", 
                        "C-BAS/HAS", 
                        "HRAS1", 
                        "CTLO", 
                        "H-RASIDX", 
                        "C-HA-RAS1", 
                        "RASH1"
                    ], 
                    "hugoSymbol": "HRAS", 
                    "name": "HRas proto-oncogene, GTPase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Chen X et al", 
                "elocationId": "doi: 10.1038/onc.2013.489", 
                "issue": "47", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "5442-9", 
                "pmid": "24240680", 
                "pubDate": "2014 Nov 20", 
                "reference": "Chen X et al. Oncogene. 2014 Nov 20;33(47)5442-9.", 
                "title": "Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.", 
                "volume": "33"
            }, 
            {
                "abstract": null, 
                "authors": "Sepp-Lorenzino L et al", 
                "elocationId": "", 
                "issue": "1", 
                "journal": "Prostate cancer and prostatic diseases", 
                "link": null, 
                "pages": "33-43", 
                "pmid": "12497061", 
                "pubDate": "2001", 
                "reference": "Sepp-Lorenzino L et al. Prostate cancer and prostatic diseases. 2001;4(1)33-43.", 
                "title": "Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.", 
                "volume": "4"
            }, 
            {
                "abstract": "Ho et al. Abstract# TPS2618, JCO 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2618", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Head and Neck Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000311189", 
            "curatedRefSeq": "NM_001130442.1", 
            "entrezGeneId": 3265, 
            "geneAliases": [
                "C-H-RAS", 
                "HAMSV", 
                "p21ras", 
                "C-BAS/HAS", 
                "HRAS1", 
                "CTLO", 
                "H-RASIDX", 
                "C-HA-RAS1", 
                "RASH1"
            ], 
            "hugoSymbol": "HRAS", 
            "name": "HRas proto-oncogene, GTPase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 13666, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1513886453000, 
        "levelOfEvidence": "LEVEL_3A", 
        "oncoTreeType": {
            "NCI": [
                "C34447"
            ], 
            "UMLS": [
                "C1168401"
            ], 
            "children": null, 
            "code": "HNSC", 
            "color": "DarkRed", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 2, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Head and Neck Cancer"
            }, 
            "name": "Head and Neck Squamous Cell Carcinoma", 
            "parent": "HEAD_NECK", 
            "tissue": "Head and Neck"
        }, 
        "propagation": "LEVEL_3B", 
        "subtype": "HNSC", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Tipifarnib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000256078", 
                    "curatedRefSeq": "NM_033360.2", 
                    "entrezGeneId": 3845, 
                    "geneAliases": [
                        "KI-RAS", 
                        "RALD", 
                        "NS", 
                        "RASK2", 
                        "CFC2", 
                        "K-RAS2B", 
                        "K-RAS2A", 
                        "K-RAS4B", 
                        "NS3", 
                        "K-RAS4A", 
                        "C-K-RAS", 
                        "KRAS2", 
                        "KRAS1"
                    ], 
                    "hugoSymbol": "KRAS", 
                    "name": "KRAS proto-oncogene, GTPase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Robarge et al. Abstract# DDT02-03, AACR 2014", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/74/19_Supplement/DDT02-03", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Yao Z et al", 
                "elocationId": "doi: 10.1038/nature23291", 
                "issue": "7666", 
                "journal": "Nature", 
                "link": null, 
                "pages": "234-238", 
                "pmid": "28783719", 
                "pubDate": "2017 Aug 10", 
                "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.", 
                "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.", 
                "volume": "548"
            }, 
            {
                "abstract": null, 
                "authors": "Infante JR et al", 
                "elocationId": "doi: 10.1016/S1470-2045(12)70270-X", 
                "issue": "8", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "773-81", 
                "pmid": "22805291", 
                "pubDate": "2012 Aug", 
                "reference": "Infante JR et al. The Lancet. Oncology. 2012 Aug;13(8)773-81.", 
                "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.", 
                "volume": "13"
            }, 
            {
                "abstract": null, 
                "authors": "Rinehart J et al", 
                "elocationId": "", 
                "issue": "22", 
                "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", 
                "link": null, 
                "pages": "4456-62", 
                "pmid": "15483017", 
                "pubDate": "2004 Nov 15", 
                "reference": "Rinehart J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Nov 15;22(22)4456-62.", 
                "title": "Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.", 
                "volume": "22"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000256078", 
            "curatedRefSeq": "NM_033360.2", 
            "entrezGeneId": 3845, 
            "geneAliases": [
                "KI-RAS", 
                "RALD", 
                "NS", 
                "RASK2", 
                "CFC2", 
                "K-RAS2B", 
                "K-RAS2A", 
                "K-RAS4B", 
                "NS3", 
                "K-RAS4A", 
                "C-K-RAS", 
                "KRAS2", 
                "KRAS1"
            ], 
            "hugoSymbol": "KRAS", 
            "name": "KRAS proto-oncogene, GTPase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8675, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507562277000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "GDC-0994", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "KO-947", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "LY3214996", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "R3008C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000278616", 
                    "curatedRefSeq": "NM_000051.3", 
                    "entrezGeneId": 472, 
                    "geneAliases": [
                        "ATC", 
                        "TEL1", 
                        "ATE", 
                        "ATDC", 
                        "TELO1", 
                        "AT1", 
                        "ATA"
                    ], 
                    "hugoSymbol": "ATM", 
                    "name": "ATM serine/threonine kinase", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "R3008C", 
                "proteinEnd": 3008, 
                "proteinStart": 3008, 
                "refResidues": "R", 
                "variantResidues": "C"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Mateo J et al", 
                "elocationId": "doi: 10.1056/NEJMoa1506859", 
                "issue": "18", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1697-708", 
                "pmid": "26510020", 
                "pubDate": "2015 Oct 29", 
                "reference": "Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.", 
                "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.", 
                "volume": "373"
            }
        ], 
        "cancerType": "Prostate Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000278616", 
            "curatedRefSeq": "NM_000051.3", 
            "entrezGeneId": 472, 
            "geneAliases": [
                "ATC", 
                "TEL1", 
                "ATE", 
                "ATDC", 
                "TELO1", 
                "AT1", 
                "ATA"
            ], 
            "hugoSymbol": "ATM", 
            "name": "ATM serine/threonine kinase", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 9508, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1503327870000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Prostate Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Olaparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "E770_K831indel", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 20 insertions/deletions", 
                "proteinEnd": 831, 
                "proteinStart": 770, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "E770_K831ins", 
                "consequence": {
                    "description": "An inframe non synonymous variant that inserts bases into in the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_insertion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000269571", 
                    "curatedRefSeq": "NM_004448.2", 
                    "entrezGeneId": 2064, 
                    "geneAliases": [
                        "CD340", 
                        "MLN 19", 
                        "TKR1", 
                        "NGL", 
                        "HER-2/neu", 
                        "HER2", 
                        "HER-2", 
                        "NEU"
                    ], 
                    "hugoSymbol": "ERBB2", 
                    "name": "erb-b2 receptor tyrosine kinase 2", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 20 insertions", 
                "proteinEnd": 831, 
                "proteinStart": 770, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Gonzalvez, F. et al. Abstract# 2644, AACR Annual Meeting 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/76/14_Supplement/2644", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000269571", 
            "curatedRefSeq": "NM_004448.2", 
            "entrezGeneId": 2064, 
            "geneAliases": [
                "CD340", 
                "MLN 19", 
                "TKR1", 
                "NGL", 
                "HER-2/neu", 
                "HER2", 
                "HER-2", 
                "NEU"
            ], 
            "hugoSymbol": "ERBB2", 
            "name": "erb-b2 receptor tyrosine kinase 2", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 742, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1503348198000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AP32788", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "N2875K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000278616", 
                    "curatedRefSeq": "NM_000051.3", 
                    "entrezGeneId": 472, 
                    "geneAliases": [
                        "ATC", 
                        "TEL1", 
                        "ATE", 
                        "ATDC", 
                        "TELO1", 
                        "AT1", 
                        "ATA"
                    ], 
                    "hugoSymbol": "ATM", 
                    "name": "ATM serine/threonine kinase", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "N2875K", 
                "proteinEnd": 2875, 
                "proteinStart": 2875, 
                "refResidues": "N", 
                "variantResidues": "K"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Mateo J et al", 
                "elocationId": "doi: 10.1056/NEJMoa1506859", 
                "issue": "18", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1697-708", 
                "pmid": "26510020", 
                "pubDate": "2015 Oct 29", 
                "reference": "Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.", 
                "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.", 
                "volume": "373"
            }
        ], 
        "cancerType": "Prostate Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000278616", 
            "curatedRefSeq": "NM_000051.3", 
            "entrezGeneId": 472, 
            "geneAliases": [
                "ATC", 
                "TEL1", 
                "ATE", 
                "ATDC", 
                "TELO1", 
                "AT1", 
                "ATA"
            ], 
            "hugoSymbol": "ATM", 
            "name": "ATM serine/threonine kinase", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 9511, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1503327847000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Prostate Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Olaparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Gain-of-function Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000277541", 
                    "curatedRefSeq": "NM_017617.3", 
                    "entrezGeneId": 4851, 
                    "geneAliases": [
                        "TAN1", 
                        "hN1", 
                        "AOVD1", 
                        "AOS5"
                    ], 
                    "hugoSymbol": "NOTCH1", 
                    "name": "notch 1", 
                    "oncogene": true, 
                    "tsg": true
                }, 
                "name": "Gain-of-function Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Zhang CC et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-12-1379", 
                "issue": "18", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "5008-19", 
                "pmid": "22806875", 
                "pubDate": "2012 Sep 15", 
                "reference": "Zhang CC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Sep 15;18(18)5008-19.", 
                "title": "Biomarker and pharmacologic evaluation of the -secretase inhibitor PF-03084014 in breast cancer models.", 
                "volume": "18"
            }, 
            {
                "abstract": null, 
                "authors": "Zhang CC et al", 
                "elocationId": "doi: 10.5966/sctm.2012-0096", 
                "issue": "3", 
                "journal": "Stem cells translational medicine", 
                "link": null, 
                "pages": "233-42", 
                "pmid": "23408105", 
                "pubDate": "2013 Mar", 
                "reference": "Zhang CC et al. Stem cells translational medicine. 2013 Mar;2(3)233-42.", 
                "title": "Synergistic effect of the -secretase inhibitor PF-03084014 and docetaxel in breast cancer models.", 
                "volume": "2"
            }, 
            {
                "abstract": null, 
                "authors": "Wei P et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-10-0034", 
                "issue": "6", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "1618-28", 
                "pmid": "20530712", 
                "pubDate": "2010 Jun", 
                "reference": "Wei P et al. Molecular cancer therapeutics. 2010 Jun;9(6)1618-28.", 
                "title": "Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.", 
                "volume": "9"
            }, 
            {
                "abstract": null, 
                "authors": "Messersmith WA et al", 
                "elocationId": "doi: 10.1158/1078-0432.CCR-14-0607", 
                "issue": "1", 
                "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", 
                "link": null, 
                "pages": "60-7", 
                "pmid": "25231399", 
                "pubDate": "2015 Jan 1", 
                "reference": "Messersmith WA et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)60-7.", 
                "title": "A Phase I, dose-finding study in patients with advanced solid malignancies of the oral -secretase inhibitor PF-03084014.", 
                "volume": "21"
            }, 
            {
                "abstract": null, 
                "authors": "Arcaroli JJ et al", 
                "elocationId": "doi: 10.1016/j.molonc.2012.03.004", 
                "issue": "3", 
                "journal": "Molecular oncology", 
                "link": null, 
                "pages": "370-81", 
                "pmid": "22521243", 
                "pubDate": "2012 Jun", 
                "reference": "Arcaroli JJ et al. Molecular oncology. 2012 Jun;6(3)370-81.", 
                "title": "ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a -secretase inhibitor and irinotecan in colorectal cancer.", 
                "volume": "6"
            }, 
            {
                "abstract": null, 
                "authors": "Samon JB et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-11-0938", 
                "issue": "7", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "1565-75", 
                "pmid": "22504949", 
                "pubDate": "2012 Jul", 
                "reference": "Samon JB et al. Molecular cancer therapeutics. 2012 Jul;11(7)1565-75.", 
                "title": "Preclinical analysis of the -secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.", 
                "volume": "11"
            }, 
            {
                "abstract": null, 
                "authors": "Yabuuchi S et al", 
                "elocationId": "doi: 10.1016/j.canlet.2013.01.054", 
                "issue": "1", 
                "journal": "Cancer letters", 
                "link": null, 
                "pages": "41-51", 
                "pmid": "23402814", 
                "pubDate": "2013 Jul 10", 
                "reference": "Yabuuchi S et al. Cancer letters. 2013 Jul 10;335(1)41-51.", 
                "title": "Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.", 
                "volume": "335"
            }, 
            {
                "abstract": null, 
                "authors": "Lpez-Guerra M et al", 
                "elocationId": "doi: 10.1038/leu.2014.143", 
                "issue": "1", 
                "journal": "Leukemia", 
                "link": null, 
                "pages": "96-106", 
                "pmid": "24781018", 
                "pubDate": "2015 Jan", 
                "reference": "Lpez-Guerra M et al. Leukemia. 2015 Jan;29(1)96-106.", 
                "title": "The -secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.", 
                "volume": "29"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000277541", 
            "curatedRefSeq": "NM_017617.3", 
            "entrezGeneId": 4851, 
            "geneAliases": [
                "TAN1", 
                "hN1", 
                "AOVD1", 
                "AOS5"
            ], 
            "hugoSymbol": "NOTCH1", 
            "name": "notch 1", 
            "oncogene": true, 
            "tsg": true
        }, 
        "id": 18600, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "PF-03084014", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V169_D380del", 
                "consequence": {
                    "description": "An inframe non synonymous variant that deletes bases from the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_deletion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "p61BRAF-V600E", 
                "proteinEnd": 380, 
                "proteinStart": 169, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Poulikakos PI et al", 
                "elocationId": "doi: 10.1038/nature10662", 
                "issue": "7377", 
                "journal": "Nature", 
                "link": null, 
                "pages": "387-90", 
                "pmid": "22113612", 
                "pubDate": "2011 Nov 23", 
                "reference": "Poulikakos PI et al. Nature. 2011 Nov 23;480(7377)387-90.", 
                "title": "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).", 
                "volume": "480"
            }, 
            {
                "abstract": null, 
                "authors": "Flaherty KT et al", 
                "elocationId": "doi: 10.1056/NEJMoa1203421", 
                "issue": "2", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "107-14", 
                "pmid": "22663011", 
                "pubDate": "2012 Jul 12", 
                "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Jul 12;367(2)107-14.", 
                "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.", 
                "volume": "367"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4778, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "G595R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000524377", 
                    "curatedRefSeq": "NM_002529.3", 
                    "entrezGeneId": 4914, 
                    "geneAliases": [
                        "TRK1", 
                        "TRKA", 
                        "Trk-A", 
                        "TRK", 
                        "p140-TrkA", 
                        "MTC"
                    ], 
                    "hugoSymbol": "NTRK1", 
                    "name": "neurotrophic receptor tyrosine kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G595R", 
                "proteinEnd": 595, 
                "proteinStart": 595, 
                "refResidues": "G", 
                "variantResidues": "R"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-17-0507", 
                "issue": "9", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "963-972", 
                "pmid": "28578312", 
                "pubDate": "2017 Sep", 
                "reference": "Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.", 
                "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.", 
                "volume": "7"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000524377", 
            "curatedRefSeq": "NM_002529.3", 
            "entrezGeneId": 4914, 
            "geneAliases": [
                "TRK1", 
                "TRKA", 
                "Trk-A", 
                "TRK", 
                "p140-TrkA", 
                "MTC"
            ], 
            "hugoSymbol": "NTRK1", 
            "name": "neurotrophic receptor tyrosine kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2223, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507744857000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "LOXO-195", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "G667C", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000524377", 
                    "curatedRefSeq": "NM_002529.3", 
                    "entrezGeneId": 4914, 
                    "geneAliases": [
                        "TRK1", 
                        "TRKA", 
                        "Trk-A", 
                        "TRK", 
                        "p140-TrkA", 
                        "MTC"
                    ], 
                    "hugoSymbol": "NTRK1", 
                    "name": "neurotrophic receptor tyrosine kinase 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G667C", 
                "proteinEnd": 667, 
                "proteinStart": 667, 
                "refResidues": "G", 
                "variantResidues": "C"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-17-0507", 
                "issue": "9", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "963-972", 
                "pmid": "28578312", 
                "pubDate": "2017 Sep", 
                "reference": "Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.", 
                "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.", 
                "volume": "7"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000524377", 
            "curatedRefSeq": "NM_002529.3", 
            "entrezGeneId": 4914, 
            "geneAliases": [
                "TRK1", 
                "TRKA", 
                "Trk-A", 
                "TRK", 
                "p140-TrkA", 
                "MTC"
            ], 
            "hugoSymbol": "NTRK1", 
            "name": "neurotrophic receptor tyrosine kinase 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2226, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507744899000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "LOXO-195", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000358273", 
                    "curatedRefSeq": "NM_001042492.2", 
                    "entrezGeneId": 4763, 
                    "geneAliases": [
                        "WSS", 
                        "NFNS", 
                        "VRNF"
                    ], 
                    "hugoSymbol": "NF1", 
                    "name": "neurofibromin 1", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "de Bruin EC et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-13-0741", 
                "issue": "5", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "606-19", 
                "pmid": "24535670", 
                "pubDate": "2014 May", 
                "reference": "de Bruin EC et al. Cancer discovery. 2014 May;4(5)606-19.", 
                "title": "Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.", 
                "volume": "4"
            }, 
            {
                "abstract": null, 
                "authors": "Nissan MH et al", 
                "elocationId": "doi: 10.1158/0008-5472.CAN-13-2625", 
                "issue": "8", 
                "journal": "Cancer research", 
                "link": null, 
                "pages": "2340-50", 
                "pmid": "24576830", 
                "pubDate": "2014 Apr 15", 
                "reference": "Nissan MH et al. Cancer research. 2014 Apr 15;74(8)2340-50.", 
                "title": "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.", 
                "volume": "74"
            }, 
            {
                "abstract": null, 
                "authors": "Woodfield SE et al", 
                "elocationId": "doi: 10.1186/s12885-016-2199-z", 
                "issue": "", 
                "journal": "BMC cancer", 
                "link": null, 
                "pages": "172", 
                "pmid": "26925841", 
                "pubDate": "2016 Mar 1", 
                "reference": "Woodfield SE et al. BMC cancer. 2016 Mar 1;16()172.", 
                "title": "Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.", 
                "volume": "16"
            }, 
            {
                "abstract": null, 
                "authors": "Ameratunga M et al", 
                "elocationId": "doi: 10.1111/jcpt.12378", 
                "issue": "3", 
                "journal": "Journal of clinical pharmacy and therapeutics", 
                "link": null, 
                "pages": "357-359", 
                "pmid": "26936308", 
                "pubDate": "2016 Jun", 
                "reference": "Ameratunga M et al. Journal of clinical pharmacy and therapeutics. 2016 Jun;41(3)357-359.", 
                "title": "Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.", 
                "volume": "41"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000358273", 
            "curatedRefSeq": "NM_001042492.2", 
            "entrezGeneId": 4763, 
            "geneAliases": [
                "WSS", 
                "NFNS", 
                "VRNF"
            ], 
            "hugoSymbol": "NF1", 
            "name": "neurofibromin 1", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 9078, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Binimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000358273", 
                    "curatedRefSeq": "NM_001042492.2", 
                    "entrezGeneId": 4763, 
                    "geneAliases": [
                        "WSS", 
                        "NFNS", 
                        "VRNF"
                    ], 
                    "hugoSymbol": "NF1", 
                    "name": "neurofibromin 1", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Morris EJ et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-13-0070", 
                "issue": "7", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "742-50", 
                "pmid": "23614898", 
                "pubDate": "2013 Jul", 
                "reference": "Morris EJ et al. Cancer discovery. 2013 Jul;3(7)742-50.", 
                "title": "Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.", 
                "volume": "3"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000358273", 
            "curatedRefSeq": "NM_001042492.2", 
            "entrezGeneId": 4763, 
            "geneAliases": [
                "WSS", 
                "NFNS", 
                "VRNF"
            ], 
            "hugoSymbol": "NF1", 
            "name": "neurofibromin 1", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 9079, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1505496960000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "LTT462", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 4
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "BVD523", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "G469R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G469R", 
                "proteinEnd": 469, 
                "proteinStart": 469, 
                "refResidues": "G", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "G464E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G464E", 
                "proteinEnd": 464, 
                "proteinStart": 464, 
                "refResidues": "G", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "G469A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G469A", 
                "proteinEnd": 469, 
                "proteinStart": 469, 
                "refResidues": "G", 
                "variantResidues": "A"
            }, 
            {
                "alteration": "G464V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G464V", 
                "proteinEnd": 464, 
                "proteinStart": 464, 
                "refResidues": "G", 
                "variantResidues": "V"
            }, 
            {
                "alteration": "G469V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G469V", 
                "proteinEnd": 469, 
                "proteinStart": 469, 
                "refResidues": "G", 
                "variantResidues": "V"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Yao Z et al", 
                "elocationId": "doi: 10.1016/j.ccell.2015.08.001", 
                "issue": "3", 
                "journal": "Cancer cell", 
                "link": null, 
                "pages": "370-83", 
                "pmid": "26343582", 
                "pubDate": "2015 Sep 14", 
                "reference": "Yao Z et al. Cancer cell. 2015 Sep 14;28(3)370-83.", 
                "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.", 
                "volume": "28"
            }, 
            {
                "abstract": null, 
                "authors": "Yao Z et al", 
                "elocationId": "doi: 10.1038/nature23291", 
                "issue": "7666", 
                "journal": "Nature", 
                "link": null, 
                "pages": "234-238", 
                "pmid": "28783719", 
                "pubDate": "2017 Aug 10", 
                "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.", 
                "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.", 
                "volume": "548"
            }
        ], 
        "cancerType": "Melanoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4856, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Melanoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V459L", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V459L", 
                "proteinEnd": 459, 
                "proteinStart": 459, 
                "refResidues": "V", 
                "variantResidues": "L"
            }, 
            {
                "alteration": "F595L", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "F595L", 
                "proteinEnd": 595, 
                "proteinStart": 595, 
                "refResidues": "F", 
                "variantResidues": "L"
            }, 
            {
                "alteration": "G466A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G466A", 
                "proteinEnd": 466, 
                "proteinStart": 466, 
                "refResidues": "G", 
                "variantResidues": "A"
            }, 
            {
                "alteration": "D594N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594N", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "G469E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G469E", 
                "proteinEnd": 469, 
                "proteinStart": 469, 
                "refResidues": "G", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "D594G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594G", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "G596R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G596R", 
                "proteinEnd": 596, 
                "proteinStart": 596, 
                "refResidues": "G", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "S467L", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "S467L", 
                "proteinEnd": 467, 
                "proteinStart": 467, 
                "refResidues": "S", 
                "variantResidues": "L"
            }, 
            {
                "alteration": "N581I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "N581I", 
                "proteinEnd": 581, 
                "proteinStart": 581, 
                "refResidues": "N", 
                "variantResidues": "I"
            }, 
            {
                "alteration": "G466E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G466E", 
                "proteinEnd": 466, 
                "proteinStart": 466, 
                "refResidues": "G", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "N581S", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "N581S", 
                "proteinEnd": 581, 
                "proteinStart": 581, 
                "refResidues": "N", 
                "variantResidues": "S"
            }, 
            {
                "alteration": "G466V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G466V", 
                "proteinEnd": 466, 
                "proteinStart": 466, 
                "refResidues": "G", 
                "variantResidues": "V"
            }, 
            {
                "alteration": "D594H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594H", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "D287H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D287H", 
                "proteinEnd": 287, 
                "proteinStart": 287, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "G596D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G596D", 
                "proteinEnd": 596, 
                "proteinStart": 596, 
                "refResidues": "G", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "D594A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594A", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Yao Z et al", 
                "elocationId": "doi: 10.1038/nature23291", 
                "issue": "7666", 
                "journal": "Nature", 
                "link": null, 
                "pages": "234-238", 
                "pmid": "28783719", 
                "pubDate": "2017 Aug 10", 
                "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.", 
                "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.", 
                "volume": "548"
            }
        ], 
        "cancerType": "Colorectal Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4857, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Colorectal Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 2, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "RTK-Inhibitor", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V459L", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V459L", 
                "proteinEnd": 459, 
                "proteinStart": 459, 
                "refResidues": "V", 
                "variantResidues": "L"
            }, 
            {
                "alteration": "F595L", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "F595L", 
                "proteinEnd": 595, 
                "proteinStart": 595, 
                "refResidues": "F", 
                "variantResidues": "L"
            }, 
            {
                "alteration": "G466A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G466A", 
                "proteinEnd": 466, 
                "proteinStart": 466, 
                "refResidues": "G", 
                "variantResidues": "A"
            }, 
            {
                "alteration": "D594N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594N", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "G469E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G469E", 
                "proteinEnd": 469, 
                "proteinStart": 469, 
                "refResidues": "G", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "D594G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594G", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "G596R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G596R", 
                "proteinEnd": 596, 
                "proteinStart": 596, 
                "refResidues": "G", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "S467L", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "S467L", 
                "proteinEnd": 467, 
                "proteinStart": 467, 
                "refResidues": "S", 
                "variantResidues": "L"
            }, 
            {
                "alteration": "N581I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "N581I", 
                "proteinEnd": 581, 
                "proteinStart": 581, 
                "refResidues": "N", 
                "variantResidues": "I"
            }, 
            {
                "alteration": "G466E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G466E", 
                "proteinEnd": 466, 
                "proteinStart": 466, 
                "refResidues": "G", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "N581S", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "N581S", 
                "proteinEnd": 581, 
                "proteinStart": 581, 
                "refResidues": "N", 
                "variantResidues": "S"
            }, 
            {
                "alteration": "G466V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G466V", 
                "proteinEnd": 466, 
                "proteinStart": 466, 
                "refResidues": "G", 
                "variantResidues": "V"
            }, 
            {
                "alteration": "D594H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594H", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "D287H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D287H", 
                "proteinEnd": 287, 
                "proteinStart": 287, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "G596D", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G596D", 
                "proteinEnd": 596, 
                "proteinStart": 596, 
                "refResidues": "G", 
                "variantResidues": "D"
            }, 
            {
                "alteration": "D594A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D594A", 
                "proteinEnd": 594, 
                "proteinStart": 594, 
                "refResidues": "D", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Yao Z et al", 
                "elocationId": "doi: 10.1038/nature23291", 
                "issue": "7666", 
                "journal": "Nature", 
                "link": null, 
                "pages": "234-238", 
                "pmid": "28783719", 
                "pubDate": "2017 Aug 10", 
                "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.", 
                "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.", 
                "volume": "548"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4858, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "RTK-Inhibitor", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "V600K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600K", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "K"
            }, 
            {
                "alteration": "V600E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "V600E", 
                "proteinEnd": 600, 
                "proteinStart": 600, 
                "refResidues": "V", 
                "variantResidues": "E"
            }
        ], 
        "articles": [
            {
                "abstract": "Sherman, et al. Abstract# 6085, JCO, 2017", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.6085", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Montero-Conde C et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-12-0531", 
                "issue": "5", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "520-33", 
                "pmid": "23365119", 
                "pubDate": "2013 May", 
                "reference": "Montero-Conde C et al. Cancer discovery. 2013 May;3(5)520-33.", 
                "title": "Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.", 
                "volume": "3"
            }, 
            {
                "abstract": null, 
                "authors": "Cheng L et al", 
                "elocationId": "doi: 10.18632/oncotarget.15773", 
                "issue": "12", 
                "journal": "Oncotarget", 
                "link": null, 
                "pages": "19843-19854", 
                "pmid": "28423638", 
                "pubDate": "2017 Mar 21", 
                "reference": "Cheng L et al. Oncotarget. 2017 Mar 21;8(12)19843-19854.", 
                "title": "HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.", 
                "volume": "8"
            }
        ], 
        "cancerType": "Thyroid Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4603, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507561420000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Thyroid Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Lapatinib", 
                        "priority": 2, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "Dabrafenib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "762_823ins", 
                "consequence": {
                    "description": "An inframe non synonymous variant that inserts bases into in the coding sequence", 
                    "isGenerallyTruncating": false, 
                    "term": "inframe_insertion"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Exon 20 insertion", 
                "proteinEnd": 823, 
                "proteinStart": 762, 
                "refResidues": null, 
                "variantResidues": null
            }, 
            {
                "alteration": "L861R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L861R", 
                "proteinEnd": 861, 
                "proteinStart": 861, 
                "refResidues": "L", 
                "variantResidues": "R"
            }, 
            {
                "alteration": "S768I", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "S768I", 
                "proteinEnd": 768, 
                "proteinStart": 768, 
                "refResidues": "S", 
                "variantResidues": "I"
            }, 
            {
                "alteration": "G719A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000275493", 
                    "curatedRefSeq": "NM_005228.3", 
                    "entrezGeneId": 1956, 
                    "geneAliases": [
                        "PIG61", 
                        "ERBB1", 
                        "mENA", 
                        "ERBB", 
                        "HER1", 
                        "NISBD2"
                    ], 
                    "hugoSymbol": "EGFR", 
                    "name": "epidermal growth factor receptor", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G719A", 
                "proteinEnd": 719, 
                "proteinStart": 719, 
                "refResidues": "G", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": "Gonzalvez, F. et al. Abstract# 2644, AACR Annual Meeting 2016", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://cancerres.aacrjournals.org/content/76/14_Supplement/2644", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000275493", 
            "curatedRefSeq": "NM_005228.3", 
            "entrezGeneId": 1956, 
            "geneAliases": [
                "PIG61", 
                "ERBB1", 
                "mENA", 
                "ERBB", 
                "HER1", 
                "NISBD2"
            ], 
            "hugoSymbol": "EGFR", 
            "name": "epidermal growth factor receptor", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 12219, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1493670013000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AP32788", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "D816H", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816H", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "H"
            }, 
            {
                "alteration": "D816G", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816G", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "G"
            }, 
            {
                "alteration": "D816Y", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816Y", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "Y"
            }, 
            {
                "alteration": "D816N", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816N", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "N"
            }, 
            {
                "alteration": "D816E", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816E", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "E"
            }, 
            {
                "alteration": "D816A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816A", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "A"
            }, 
            {
                "alteration": "D816F", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816F", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "F"
            }, 
            {
                "alteration": "D816V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288135", 
                    "curatedRefSeq": "NM_000222.2", 
                    "entrezGeneId": 3815, 
                    "geneAliases": [
                        "PBT", 
                        "C-Kit", 
                        "CD117", 
                        "SCFR"
                    ], 
                    "hugoSymbol": "KIT", 
                    "name": "KIT proto-oncogene receptor tyrosine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "D816V", 
                "proteinEnd": 816, 
                "proteinStart": 816, 
                "refResidues": "D", 
                "variantResidues": "V"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": null, 
                "pages": null, 
                "pmid": "28077435", 
                "pubDate": "2017 Feb", 
                "reference": "null. null. 2017 Feb;.", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "Gastrointestinal Stromal Tumor", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288135", 
            "curatedRefSeq": "NM_000222.2", 
            "entrezGeneId": 3815, 
            "geneAliases": [
                "PBT", 
                "C-Kit", 
                "CD117", 
                "SCFR"
            ], 
            "hugoSymbol": "KIT", 
            "name": "KIT proto-oncogene receptor tyrosine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 321, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1516723953000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Gastrointestinal Stromal Tumor"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "DCC-2618", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Avapritinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "G623R", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000360948", 
                    "curatedRefSeq": "NM_001012338.2", 
                    "entrezGeneId": 4916, 
                    "geneAliases": [
                        "TRKC", 
                        "GP145-TrkC", 
                        "gp145(trkC)"
                    ], 
                    "hugoSymbol": "NTRK3", 
                    "name": "neurotrophic receptor tyrosine kinase 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G623R", 
                "proteinEnd": 623, 
                "proteinStart": 623, 
                "refResidues": "G", 
                "variantResidues": "R"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-17-0507", 
                "issue": "9", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "963-972", 
                "pmid": "28578312", 
                "pubDate": "2017 Sep", 
                "reference": "Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.", 
                "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.", 
                "volume": "7"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000360948", 
            "curatedRefSeq": "NM_001012338.2", 
            "entrezGeneId": 4916, 
            "geneAliases": [
                "TRKC", 
                "GP145-TrkC", 
                "gp145(trkC)"
            ], 
            "hugoSymbol": "NTRK3", 
            "name": "neurotrophic receptor tyrosine kinase 3", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2116, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "LOXO-195", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Fusions", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000397938", 
                    "curatedRefSeq": "NM_005243.3", 
                    "entrezGeneId": 2130, 
                    "geneAliases": [
                        "EWS", 
                        "EWS-FLI1", 
                        "bK984G1.4"
                    ], 
                    "hugoSymbol": "EWSR1", 
                    "name": "EWS RNA binding protein 1", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Fusions", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Erkizan HV et al", 
                "elocationId": "doi: 10.1038/nm.1983", 
                "issue": "7", 
                "journal": "Nature medicine", 
                "link": null, 
                "pages": "750-6", 
                "pmid": "19584866", 
                "pubDate": "2009 Jul", 
                "reference": "Erkizan HV et al. Nature medicine. 2009 Jul;15(7)750-6.", 
                "title": "A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.", 
                "volume": "15"
            }
        ], 
        "cancerType": "Soft Tissue Sarcoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000397938", 
            "curatedRefSeq": "NM_005243.3", 
            "entrezGeneId": 2130, 
            "geneAliases": [
                "EWS", 
                "EWS-FLI1", 
                "bK984G1.4"
            ], 
            "hugoSymbol": "EWSR1", 
            "name": "EWS RNA binding protein 1", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 16455, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Soft Tissue Sarcoma"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "TK216", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "G696A", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000360948", 
                    "curatedRefSeq": "NM_001012338.2", 
                    "entrezGeneId": 4916, 
                    "geneAliases": [
                        "TRKC", 
                        "GP145-TrkC", 
                        "gp145(trkC)"
                    ], 
                    "hugoSymbol": "NTRK3", 
                    "name": "neurotrophic receptor tyrosine kinase 3", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "G696A", 
                "proteinEnd": 696, 
                "proteinStart": 696, 
                "refResidues": "G", 
                "variantResidues": "A"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Drilon A et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-17-0507", 
                "issue": "9", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "963-972", 
                "pmid": "28578312", 
                "pubDate": "2017 Sep", 
                "reference": "Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.", 
                "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.", 
                "volume": "7"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000360948", 
            "curatedRefSeq": "NM_001012338.2", 
            "entrezGeneId": 4916, 
            "geneAliases": [
                "TRKC", 
                "GP145-TrkC", 
                "gp145(trkC)"
            ], 
            "hugoSymbol": "NTRK3", 
            "name": "neurotrophic receptor tyrosine kinase 3", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2121, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507744954000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "LOXO-195", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000261799", 
                    "curatedRefSeq": "NM_002609.3", 
                    "entrezGeneId": 5159, 
                    "geneAliases": [
                        "PDGFR1", 
                        "KOGS", 
                        "PDGFR-1", 
                        "JTK12", 
                        "PDGFR", 
                        "IBGC4", 
                        "IMF1", 
                        "PENTT", 
                        "CD140B"
                    ], 
                    "hugoSymbol": "PDGFRB", 
                    "name": "platelet derived growth factor receptor beta", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Arts FA et al", 
                "elocationId": "doi: 10.1038/onc.2015.383", 
                "issue": "25", 
                "journal": "Oncogene", 
                "link": null, 
                "pages": "3239-48", 
                "pmid": "26455322", 
                "pubDate": "2016 Jun 23", 
                "reference": "Arts FA et al. Oncogene. 2016 Jun 23;35(25)3239-48.", 
                "title": "PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.", 
                "volume": "35"
            }, 
            {
                "abstract": null, 
                "authors": "Heldin CH", 
                "elocationId": "doi: 10.1186/1478-811X-11-97", 
                "issue": "", 
                "journal": "Cell communication and signaling : CCS", 
                "link": null, 
                "pages": "97", 
                "pmid": "24359404", 
                "pubDate": "2013 Dec 20", 
                "reference": "Heldin CH. Cell communication and signaling : CCS. 2013 Dec 20;11()97.", 
                "title": "Targeting the PDGF signaling pathway in tumor treatment.", 
                "volume": "11"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000261799", 
            "curatedRefSeq": "NM_002609.3", 
            "entrezGeneId": 5159, 
            "geneAliases": [
                "PDGFR1", 
                "KOGS", 
                "PDGFR-1", 
                "JTK12", 
                "PDGFR", 
                "IBGC4", 
                "IMF1", 
                "PENTT", 
                "CD140B"
            ], 
            "hugoSymbol": "PDGFRB", 
            "name": "platelet derived growth factor receptor beta", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 13777, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Ponatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Nilotinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Imatinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "C1483F", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000361445", 
                    "curatedRefSeq": "NM_004958.3", 
                    "entrezGeneId": 2475, 
                    "geneAliases": [
                        "FRAP1", 
                        "RAFT1", 
                        "FRAP2", 
                        "FRAP", 
                        "SKS", 
                        "RAPT1"
                    ], 
                    "hugoSymbol": "MTOR", 
                    "name": "mechanistic target of rapamycin", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "C1483F", 
                "proteinEnd": 1483, 
                "proteinStart": 1483, 
                "refResidues": "C", 
                "variantResidues": "F"
            }, 
            {
                "alteration": "L2230V", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000361445", 
                    "curatedRefSeq": "NM_004958.3", 
                    "entrezGeneId": 2475, 
                    "geneAliases": [
                        "FRAP1", 
                        "RAFT1", 
                        "FRAP2", 
                        "FRAP", 
                        "SKS", 
                        "RAPT1"
                    ], 
                    "hugoSymbol": "MTOR", 
                    "name": "mechanistic target of rapamycin", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "L2230V", 
                "proteinEnd": 2230, 
                "proteinStart": 2230, 
                "refResidues": "L", 
                "variantResidues": "V"
            }, 
            {
                "alteration": "F1888L", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000361445", 
                    "curatedRefSeq": "NM_004958.3", 
                    "entrezGeneId": 2475, 
                    "geneAliases": [
                        "FRAP1", 
                        "RAFT1", 
                        "FRAP2", 
                        "FRAP", 
                        "SKS", 
                        "RAPT1"
                    ], 
                    "hugoSymbol": "MTOR", 
                    "name": "mechanistic target of rapamycin", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "F1888L", 
                "proteinEnd": 1888, 
                "proteinStart": 1888, 
                "refResidues": "F", 
                "variantResidues": "L"
            }, 
            {
                "alteration": "S2215F", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000361445", 
                    "curatedRefSeq": "NM_004958.3", 
                    "entrezGeneId": 2475, 
                    "geneAliases": [
                        "FRAP1", 
                        "RAFT1", 
                        "FRAP2", 
                        "FRAP", 
                        "SKS", 
                        "RAPT1"
                    ], 
                    "hugoSymbol": "MTOR", 
                    "name": "mechanistic target of rapamycin", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "S2215F", 
                "proteinEnd": 2215, 
                "proteinStart": 2215, 
                "refResidues": "S", 
                "variantResidues": "F"
            }, 
            {
                "alteration": "T1977K", 
                "consequence": {
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved", 
                    "isGenerallyTruncating": false, 
                    "term": "missense_variant"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000361445", 
                    "curatedRefSeq": "NM_004958.3", 
                    "entrezGeneId": 2475, 
                    "geneAliases": [
                        "FRAP1", 
                        "RAFT1", 
                        "FRAP2", 
                        "FRAP", 
                        "SKS", 
                        "RAPT1"
                    ], 
                    "hugoSymbol": "MTOR", 
                    "name": "mechanistic target of rapamycin", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "T1977K", 
                "proteinEnd": 1977, 
                "proteinStart": 1977, 
                "refResidues": "T", 
                "variantResidues": "K"
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Xu J et al", 
                "elocationId": "doi: 10.1172/JCI86120", 
                "issue": "9", 
                "journal": "The Journal of clinical investigation", 
                "link": null, 
                "pages": "3526-40", 
                "pmid": "27482884", 
                "pubDate": "2016 Sep 1", 
                "reference": "Xu J et al. The Journal of clinical investigation. 2016 Sep 1;126(9)3526-40.", 
                "title": "Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.", 
                "volume": "126"
            }
        ], 
        "cancerType": "Renal Cell Carcinoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000361445", 
            "curatedRefSeq": "NM_004958.3", 
            "entrezGeneId": 2475, 
            "geneAliases": [
                "FRAP1", 
                "RAFT1", 
                "FRAP2", 
                "FRAP", 
                "SKS", 
                "RAPT1"
            ], 
            "hugoSymbol": "MTOR", 
            "name": "mechanistic target of rapamycin", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 2394, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507562378000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [
                "C4033"
            ], 
            "UMLS": [
                "C0279702"
            ], 
            "children": null, 
            "code": "CCRCC", 
            "color": "Orange", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 3, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Renal Cell Carcinoma"
            }, 
            "name": "Renal Clear Cell Carcinoma", 
            "parent": "RCC", 
            "tissue": "Kidney"
        }, 
        "propagation": null, 
        "subtype": "CCRCC", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Temsirolimus", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Everolimus", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000371953", 
                    "curatedRefSeq": "NM_000314.4", 
                    "entrezGeneId": 5728, 
                    "geneAliases": [
                        "DEC", 
                        "MHAM", 
                        "10q23del", 
                        "BZS", 
                        "PTEN1", 
                        "GLM2", 
                        "CWS1", 
                        "MMAC1"
                    ], 
                    "hugoSymbol": "PTEN", 
                    "name": "phosphatase and tensin homolog", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Juric D et al", 
                "elocationId": "doi: 10.1038/nature13948", 
                "issue": "7538", 
                "journal": "Nature", 
                "link": null, 
                "pages": "240-4", 
                "pmid": "25409150", 
                "pubDate": "2015 Feb 12", 
                "reference": "Juric D et al. Nature. 2015 Feb 12;518(7538)240-4.", 
                "title": "Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor.", 
                "volume": "518"
            }
        ], 
        "cancerType": "Breast Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000371953", 
            "curatedRefSeq": "NM_000314.4", 
            "entrezGeneId": 5728, 
            "geneAliases": [
                "DEC", 
                "MHAM", 
                "10q23del", 
                "BZS", 
                "PTEN1", 
                "GLM2", 
                "CWS1", 
                "MMAC1"
            ], 
            "hugoSymbol": "PTEN", 
            "name": "phosphatase and tensin homolog", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 11549, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Breast Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Alpelisib", 
                        "priority": 1, 
                        "synonyms": []
                    }, 
                    {
                        "atcCodes": [], 
                        "drugName": "AZD6482", 
                        "priority": 2, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000320356", 
                    "curatedRefSeq": "NM_004456.4", 
                    "entrezGeneId": 2146, 
                    "geneAliases": [
                        "ENX-1", 
                        "ENX1", 
                        "EZH2b", 
                        "WVS", 
                        "WVS2", 
                        "KMT6", 
                        "KMT6A"
                    ], 
                    "hugoSymbol": "EZH2", 
                    "name": "enhancer of zeste 2 polycomb repressive complex 2 subunit", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Knutson SK et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-13-0773", 
                "issue": "4", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "842-54", 
                "pmid": "24563539", 
                "pubDate": "2014 Apr", 
                "reference": "Knutson SK et al. Molecular cancer therapeutics. 2014 Apr;13(4)842-54.", 
                "title": "Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.", 
                "volume": "13"
            }, 
            {
                "abstract": "Ribrag et al. American Society of Hematology 2015", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://www.bloodjournal.org/content/126/23/473?sso-checked=true", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "McCabe MT et al", 
                "elocationId": "doi: 10.1038/nature11606", 
                "issue": "7427", 
                "journal": "Nature", 
                "link": null, 
                "pages": "108-12", 
                "pmid": "23051747", 
                "pubDate": "2012 Dec 6", 
                "reference": "McCabe MT et al. Nature. 2012 Dec 6;492(7427)108-12.", 
                "title": "EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.", 
                "volume": "492"
            }
        ], 
        "cancerType": "Non-Hodgkin Lymphoma", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000320356", 
            "curatedRefSeq": "NM_004456.4", 
            "entrezGeneId": 2146, 
            "geneAliases": [
                "ENX-1", 
                "ENX1", 
                "EZH2b", 
                "WVS", 
                "WVS2", 
                "KMT6", 
                "KMT6A"
            ], 
            "hugoSymbol": "EZH2", 
            "name": "enhancer of zeste 2 polycomb repressive complex 2 subunit", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 9182, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1505916580000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [
                "C8851"
            ], 
            "UMLS": [
                "C0079744"
            ], 
            "children": null, 
            "code": "DLBCL", 
            "color": "LimeGreen", 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": 4, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Hodgkin Lymphoma"
            }, 
            "name": "Diffuse Large B-Cell Lymphoma", 
            "parent": "BCL", 
            "tissue": "Lymph"
        }, 
        "propagation": null, 
        "subtype": "DLBCL", 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Tazemetostat", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000288602", 
                    "curatedRefSeq": "NM_004333.4", 
                    "entrezGeneId": 673, 
                    "geneAliases": [
                        "NS7", 
                        "B-raf", 
                        "BRAF1", 
                        "RAFB1", 
                        "B-RAF1"
                    ], 
                    "hugoSymbol": "BRAF", 
                    "name": "B-Raf proto-oncogene, serine/threonine kinase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": "Infante et al. Abstract# 2506, ASCO 2015", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://meetinglibrary.asco.org/content/145666-156", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000288602", 
            "curatedRefSeq": "NM_004333.4", 
            "entrezGeneId": 673, 
            "geneAliases": [
                "NS7", 
                "B-raf", 
                "BRAF1", 
                "RAFB1", 
                "B-RAF1"
            ], 
            "hugoSymbol": "BRAF", 
            "name": "B-Raf proto-oncogene, serine/threonine kinase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 4575, 
        "knownEffect": "Sensitive", 
        "lastEdit": null, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "LTT462", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 3
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "KO-947", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "BVD-523", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000256078", 
                    "curatedRefSeq": "NM_033360.2", 
                    "entrezGeneId": 3845, 
                    "geneAliases": [
                        "KI-RAS", 
                        "RALD", 
                        "NS", 
                        "RASK2", 
                        "CFC2", 
                        "K-RAS2B", 
                        "K-RAS2A", 
                        "K-RAS4B", 
                        "NS3", 
                        "K-RAS4A", 
                        "C-K-RAS", 
                        "KRAS2", 
                        "KRAS1"
                    ], 
                    "hugoSymbol": "KRAS", 
                    "name": "KRAS proto-oncogene, GTPase", 
                    "oncogene": true, 
                    "tsg": false
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Hatzivassiliou G et al", 
                "elocationId": "doi: 10.1038/nature12441", 
                "issue": "7466", 
                "journal": "Nature", 
                "link": null, 
                "pages": "232-6", 
                "pmid": "23934108", 
                "pubDate": "2013 Sep 12", 
                "reference": "Hatzivassiliou G et al. Nature. 2013 Sep 12;501(7466)232-6.", 
                "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.", 
                "volume": "501"
            }, 
            {
                "abstract": null, 
                "authors": "Lito P et al", 
                "elocationId": "doi: 10.1016/j.ccr.2014.03.011", 
                "issue": "5", 
                "journal": "Cancer cell", 
                "link": null, 
                "pages": "697-710", 
                "pmid": "24746704", 
                "pubDate": "2014 May 12", 
                "reference": "Lito P et al. Cancer cell. 2014 May 12;25(5)697-710.", 
                "title": "Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.", 
                "volume": "25"
            }, 
            {
                "abstract": null, 
                "authors": "Yao Z et al", 
                "elocationId": "doi: 10.1038/nature23291", 
                "issue": "7666", 
                "journal": "Nature", 
                "link": null, 
                "pages": "234-238", 
                "pmid": "28783719", 
                "pubDate": "2017 Aug 10", 
                "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.", 
                "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.", 
                "volume": "548"
            }, 
            {
                "abstract": null, 
                "authors": "Heigener DF et al", 
                "elocationId": "doi: 10.1016/S2213-2600(15)00026-0", 
                "issue": "4", 
                "journal": "The Lancet. Respiratory medicine", 
                "link": null, 
                "pages": "319-27", 
                "pmid": "25801412", 
                "pubDate": "2015 Apr", 
                "reference": "Heigener DF et al. The Lancet. Respiratory medicine. 2015 Apr;3(4)319-27.", 
                "title": "Targeting of MEK in lung cancer therapeutics.", 
                "volume": "3"
            }, 
            {
                "abstract": null, 
                "authors": "Infante JR et al", 
                "elocationId": "doi: 10.1016/S1470-2045(12)70270-X", 
                "issue": "8", 
                "journal": "The Lancet. Oncology", 
                "link": null, 
                "pages": "773-81", 
                "pmid": "22805291", 
                "pubDate": "2012 Aug", 
                "reference": "Infante JR et al. The Lancet. Oncology. 2012 Aug;13(8)773-81.", 
                "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.", 
                "volume": "13"
            }
        ], 
        "cancerType": "Non-Small Cell Lung Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000256078", 
            "curatedRefSeq": "NM_033360.2", 
            "entrezGeneId": 3845, 
            "geneAliases": [
                "KI-RAS", 
                "RALD", 
                "NS", 
                "RASK2", 
                "CFC2", 
                "K-RAS2B", 
                "K-RAS2A", 
                "K-RAS4B", 
                "NS3", 
                "K-RAS4A", 
                "C-K-RAS", 
                "KRAS2", 
                "KRAS1"
            ], 
            "hugoSymbol": "KRAS", 
            "name": "KRAS proto-oncogene, GTPase", 
            "oncogene": true, 
            "tsg": false
        }, 
        "id": 8671, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1507561923000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Non-Small Cell Lung Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Binimetinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Trametinib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Oncogenic Mutations", 
                "consequence": {
                    "description": "NA", 
                    "isGenerallyTruncating": false, 
                    "term": "NA"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000371953", 
                    "curatedRefSeq": "NM_000314.4", 
                    "entrezGeneId": 5728, 
                    "geneAliases": [
                        "DEC", 
                        "MHAM", 
                        "10q23del", 
                        "BZS", 
                        "PTEN1", 
                        "GLM2", 
                        "CWS1", 
                        "MMAC1"
                    ], 
                    "hugoSymbol": "PTEN", 
                    "name": "phosphatase and tensin homolog", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Oncogenic Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Ni J et al", 
                "elocationId": "doi: 10.1158/2159-8290.CD-12-0003", 
                "issue": "5", 
                "journal": "Cancer discovery", 
                "link": null, 
                "pages": "425-33", 
                "pmid": "22588880", 
                "pubDate": "2012 May", 
                "reference": "Ni J et al. Cancer discovery. 2012 May;2(5)425-33.", 
                "title": "Functional characterization of an isoform-selective inhibitor of PI3K-p110 as a potential anticancer agent.", 
                "volume": "2"
            }, 
            {
                "abstract": "Arkenau et al. Abstract# 2514, ASCO 2014", 
                "authors": null, 
                "elocationId": null, 
                "issue": null, 
                "journal": null, 
                "link": "http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2514", 
                "pages": null, 
                "pmid": null, 
                "pubDate": null, 
                "reference": "null. null. .", 
                "title": null, 
                "volume": null
            }, 
            {
                "abstract": null, 
                "authors": "Knight ZA et al", 
                "elocationId": "", 
                "issue": "4", 
                "journal": "Cell", 
                "link": null, 
                "pages": "733-47", 
                "pmid": "16647110", 
                "pubDate": "2006 May 19", 
                "reference": "Knight ZA et al. Cell. 2006 May 19;125(4)733-47.", 
                "title": "A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.", 
                "volume": "125"
            }, 
            {
                "abstract": null, 
                "authors": "Schwartz S et al", 
                "elocationId": "doi: 10.1016/j.ccell.2014.11.008", 
                "issue": "1", 
                "journal": "Cancer cell", 
                "link": null, 
                "pages": "109-22", 
                "pmid": "25544636", 
                "pubDate": "2015 Jan 12", 
                "reference": "Schwartz S et al. Cancer cell. 2015 Jan 12;27(1)109-22.", 
                "title": "Feedback suppression of PI3K signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K.", 
                "volume": "27"
            }, 
            {
                "abstract": null, 
                "authors": "Jia S et al", 
                "elocationId": "doi: 10.1038/nature07091", 
                "issue": "7205", 
                "journal": "Nature", 
                "link": null, 
                "pages": "776-9", 
                "pmid": "18594509", 
                "pubDate": "2008 Aug 7", 
                "reference": "Jia S et al. Nature. 2008 Aug 7;454(7205)776-9.", 
                "title": "Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.", 
                "volume": "454"
            }, 
            {
                "abstract": null, 
                "authors": "Hancox U et al", 
                "elocationId": "doi: 10.1158/1535-7163.MCT-14-0406", 
                "issue": "1", 
                "journal": "Molecular cancer therapeutics", 
                "link": null, 
                "pages": "48-58", 
                "pmid": "25398829", 
                "pubDate": "2015 Jan", 
                "reference": "Hancox U et al. Molecular cancer therapeutics. 2015 Jan;14(1)48-58.", 
                "title": "Inhibition of PI3K signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.", 
                "volume": "14"
            }
        ], 
        "cancerType": "All Tumors", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000371953", 
            "curatedRefSeq": "NM_000314.4", 
            "entrezGeneId": 5728, 
            "geneAliases": [
                "DEC", 
                "MHAM", 
                "10q23del", 
                "BZS", 
                "PTEN1", 
                "GLM2", 
                "CWS1", 
                "MMAC1"
            ], 
            "hugoSymbol": "PTEN", 
            "name": "phosphatase and tensin homolog", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 11551, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1505502173000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "All Tumors"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "AZD8186", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 2
            }, 
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "GSK2636771", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }, 
    {
        "additionalInfo": null, 
        "alterations": [
            {
                "alteration": "Truncating Mutations", 
                "consequence": {
                    "description": "A sequence variant that causes the reduction of a genomic feature, with regard to the reference sequence", 
                    "isGenerallyTruncating": true, 
                    "term": "feature_truncation"
                }, 
                "gene": {
                    "curatedIsoform": "ENST00000278616", 
                    "curatedRefSeq": "NM_000051.3", 
                    "entrezGeneId": 472, 
                    "geneAliases": [
                        "ATC", 
                        "TEL1", 
                        "ATE", 
                        "ATDC", 
                        "TELO1", 
                        "AT1", 
                        "ATA"
                    ], 
                    "hugoSymbol": "ATM", 
                    "name": "ATM serine/threonine kinase", 
                    "oncogene": false, 
                    "tsg": true
                }, 
                "name": "Truncating Mutations", 
                "proteinEnd": 100000, 
                "proteinStart": -1, 
                "refResidues": null, 
                "variantResidues": null
            }
        ], 
        "articles": [
            {
                "abstract": null, 
                "authors": "Mateo J et al", 
                "elocationId": "doi: 10.1056/NEJMoa1506859", 
                "issue": "18", 
                "journal": "The New England journal of medicine", 
                "link": null, 
                "pages": "1697-708", 
                "pmid": "26510020", 
                "pubDate": "2015 Oct 29", 
                "reference": "Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.", 
                "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.", 
                "volume": "373"
            }
        ], 
        "cancerType": "Prostate Cancer", 
        "description": "", 
        "evidenceType": "INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY", 
        "gene": {
            "curatedIsoform": "ENST00000278616", 
            "curatedRefSeq": "NM_000051.3", 
            "entrezGeneId": 472, 
            "geneAliases": [
                "ATC", 
                "TEL1", 
                "ATE", 
                "ATDC", 
                "TELO1", 
                "AT1", 
                "ATA"
            ], 
            "hugoSymbol": "ATM", 
            "name": "ATM serine/threonine kinase", 
            "oncogene": false, 
            "tsg": true
        }, 
        "id": 9504, 
        "knownEffect": "Sensitive", 
        "lastEdit": 1503327906000, 
        "levelOfEvidence": "LEVEL_4", 
        "oncoTreeType": {
            "NCI": [], 
            "UMLS": [], 
            "children": {}, 
            "code": null, 
            "color": null, 
            "deprecated": false, 
            "history": [], 
            "id": null, 
            "level": null, 
            "links": null, 
            "mainType": {
                "id": null, 
                "name": "Prostate Cancer"
            }, 
            "name": null, 
            "parent": null, 
            "tissue": null
        }, 
        "propagation": null, 
        "subtype": null, 
        "treatments": [
            {
                "approvedIndications": [], 
                "drugs": [
                    {
                        "atcCodes": [], 
                        "drugName": "Olaparib", 
                        "priority": 1, 
                        "synonyms": []
                    }
                ], 
                "priority": 1
            }
        ]
    }
]